

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies: protocol of field studies of the Dengue Vaccine Initiative

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017673
Article Type:	Protocol
Date Submitted by the Author:	10-May-2017
Complete List of Authors:	Lim, Jacqueline; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Carabali, Mabel; International Vaccine Institute Lee, Jung-Seok; International Vaccine Institute Lee, Kang Sung ; International Vaccine Institute Namkung, Suk; International Vaccine Institute Lim, Si-Ki; International Vaccine Institute Ridde, Valéry; Université de Montréal, Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM); Université de Montréal, Département de médecine sociale et préventive Fernandes, Jose; Hopital Albert Schweitzer, Lambaréné,, Centre de Recherches Médicales de Lambaréné Lell, Bertrand; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Matendechero, Sultani ; Ministry of Health, Kenya, Dept. of Neglected Tropical Diseases Esen, Meral; University of Tübingen, Institute of Tropical Medicine Andia, Esther; Kenya Medical Research Institute Oyembo, Noah; Kenya Medical Research Institute Barro, Ahmed; Action-Gouvernance-Integration-Reinforcement, Program Equité Bonnet, Emmanuel ; Institut de recherche pour le developpement Njenga, Sammy; Kenya Medical Research Institute, Eastern & Southern Africa Centre of International Parasite Control Agnandji, Selidji ; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Yaro, Seydou; Centre MURAZ Alexander, Neal; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Yoon, In Kyu; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases
Keywords:	dengue, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, Tropical medicine < INFECTIOUS DISEASES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies: protocol of field studies of the Dengue Vaccine Initiative

Jacqueline K. Lim^{1*}, Mabel Carabali¹, Jung-Seok Lee¹, Kang Sung Lee¹, Suk Namkung¹, SI-Ki Lim¹, Valery Ridde², Jose Fernandes³, Bertrand Lell³, Sultani Hadley Matendecheo⁴, Meral Esen⁵, Esther Andia⁶, Noah Oyembo⁶, Ahmed Barro⁷, Emmanuel Bonnet⁸, Sammy M. Njenga⁶, Selidji Todagbe Agnandji³, Seydou Yaro⁹, Neal Alexander¹⁰, In-Kyu Yoon¹

¹International Vaccine Institute, Seoul, Korea, Republic of; ²Montreal School of Public Health (ESPUM), Montreal, QC, Canada; ³Centre de Recherches Médicales de Lambaréné, Hopital Albert Schweitzer, B.P. 118, Lambaréné, Gabon; ⁴Communicable Disease Prevention and Control, Ministry of Health, Nairobi, Kenya; ⁵Institute of Tropical Medicine, University of Tübingen, Germany; ⁶Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; ⁷AGIR, Ouagadougou, Burkina Faso; ⁸Institut de Recherche pour le Développement (IRD), Paris, France; ⁹Centre Muraz, Bobo-Dioulasso, Burkina Faso; ¹⁰Epidemiology and Public Health Department, London School of Hygiene and Tropical Medicine

*Corresponding author

Jacqueline K. Lim^{1*}, MPH

Research Scientist

Global Dengue and Aedes-transmitted Diseases Consortium (GDAC)

International Vaccine Institute (IVI)

SNU Research Park, Gwankak-ro 1

Gwanak-gu, Seoul, Korea 151-191

T: +82-2-881-1340 (Dir) / +82-2-872-2801 (ext. 340)

Email: kalim@ivi.int

Author information

Dr. Mabel Carabali, MD, MSc Local medical epidemiologist Dengue Vaccine Initiative International Vaccine Institute (IVI) Seoul, Korea Email: mabel.carabali@gmail.com	Jung-Seok Lee, MSc, MPA Health economist International Vaccine Institute (IVI) Seoul, Korea Email: jslee@ivi.int
Kang Sung Lee, MSc Researcher International Vaccine Institute (IVI) Seoul, Korea Email: KangSungLee@ivi.int	Suk Namkung BSc Program Research Assistant International Vaccine Institute (IVI) Seoul, Korea Email: Suk.Namkung@ivi.int
SI-Ki Lim, MPH Researcher International Vaccine Institute (IVI) Seoul, Korea Email: slkilim@ivi.int	Dr. Valery Ridde, PhD Principal Scientist Associate Professor, Department of Social and Preventive Medicine, École de santé publique, Université de Montréal Email: valery.ridde@umontreal.ca

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p>	<p>Jose Fernandes, MD Physician Investigator Centre de Recherches Médicales de Lambaréné, Hopital Albert Schweitzer, Lambaréné, Gabon Email: jose.fernandes@lambarene.org</p> <p>Sultani Hadley Matendehero, MD Head of Neglected Tropical Diseases Ministry of Health Nairobi, Kenya Email: hadleysultani@gmail.com</p> <p>Esther Andia, BSc Study coordinator Kenya Medical Research Institute (KEMRI) Nairobi, KENYA Email: astar812@gmail.com</p> <p>Ahmed Barro, BSc Research Coordinator Program Equité AGIR Ouagadougou, Burkina Faso Email: siebarro@gmail.com</p> <p>Sammy M. Njenga, PhD Director, Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) Kenya Medical Research Institute (KEMRI) Nairobi, KENYA Email: SNjenga@kemri.org</p> <p>Seydou Yaro, MD Medical Doctor and Epidemiologist Head of the Research Unit of Potential Epidemic Diseases Centre MURAZ, Bobo-Dioulasso, Burkina Faso Email: yaro_seydou@yahoo.com</p> <p>In-Kyu Yoon, MD Deputy Director General of Science Director, Global Dengue and Aedes- transmitted Diseases Consortium (GDAC) International Vaccine Institute (IVI) Seoul, Korea 151-191 Email: InKyu.Yoon@ivi.int</p>	<p>Bertrand Lell, MD, MSc Co-director Centre de Recherches Médicales de Lambaréné, Hopital Albert Schweitzer, Lambaréné, Gabon Email: Bertrand.lell@lambarene.org</p> <p>Meral Esen, MD Group leader Institute of Tropical Medicine University of Tübingen Germany, Email: meral.esen@uni-tuebingen.de</p> <p>Noah Oyembo, BSc Study coordinator Kenya Medical Research Institute (KEMRI) Nairobi, KENYA Email: unouah@gmail.com</p> <p>Emmanuel Bonnet, PhD Chargé de recherche Institut de Recherche pour le Développement (IRD), Paris, France Email: emmanuel.bonnet@ird.fr</p> <p>Selidji Todagbe Agnandji, MD, PhD Co-director Centre de Recherches Médicales de Lambaréné, Hopital Albert Schweitzer, Lambaréné, Gabon Email: agnandjis@cermel.org</p> <p>Neal Alexander, PhD Reader in Medical Statistics and Epidemiology Epidemiology and Public Health Department London School of Hygiene and Tropical Medicine Email: Neal.Alexander@lshtm.ac.uk</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abstract

Introduction.

Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control.

Methods and Analysis.

In 2014-17, the Dengue Vaccine Initiative initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; to obtain comparable incidence data on dengue and assess its burden through standardized hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through passive facility-based fever surveillance, cost-of-illness surveys, serological surveys, and healthcare utilization surveys. All three sites conducted case detection using standardized procedures with uniform laboratory assays to diagnose dengue. Healthcare utilization surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between dengue and non-dengue patients using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of 3,000 randomly selected residents at each site at 6 month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted in a target sample size of 120-150 dengue-confirmed patients with acute dengue by Rapid Diagnostic patients.

Ethics and Dissemination.

The protocol for each study obtained ethical approvals from the Institutional Review Boards of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions. By standardizing methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals by the end of 2017.

Strengths of this study

- No study has been conducted with multi-disciplinary population-based approach to measure burden of dengue in multisites in Africa.
- This study will provide incidence of dengue in Africa from the surveillance and also provide prevalence and force of infection from the serological surveys.
- The manuscript provides details on how the studies were conducted in a standardized fashion across three sites with inherent site-specific differences.

Limitations of this study

- This was not a cohort study, so may under-estimate dengue disease burden by measuring incidence by conducting passive, facility-based, surveillance.
- There may be limited generalizability as this study is conducted in only 3 locations in Africa.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word counts: 298 (abstract) and 6,557 (text)

Keywords: dengue; Africa; seroepidemiologic Studies; incidence

Running head: Evaluating dengue burden in Africa: DVI field studies

For peer review only

Background

Dengue fever, a mosquito-borne flavivirus infection caused by four related but antigenically distinct dengue viruses (DENVs, serotypes 1–4), is a major and rapidly increasing global public health problem. Recent studies have estimated an annual incidence of 50–100 million symptomatic infections globally [1]. Dengue is a high burden disease that disproportionately affects countries in the tropics and subtropics, many of which have limited health care resources [2]. Although one dengue vaccine has been recently licensed in several endemic countries, the vaccine has restricted age and epidemiological indications. Other prevention and control measures such as vector control are suboptimal as standalone interventions [3, 4], and no drugs for treatment are currently available.

The presence of *Aedes* mosquitoes and reports of dengue cases have been documented as early as 1823 in Africa [5]. However, most of these reports are limited to a few countries, and many cases have been from travellers, with a small number of reported autochthonous cases [6]. Amarasinghe et al. indicated that dengue cases have been reported in 34 countries in Africa, with most of these countries also having *Aedes* mosquitoes [6]. However, prior studies which suggested the presence of dengue were limited by their retrospective design or sample collection (blood donors or sample collected from surveys of other diseases) to demonstrate the true, population-based, burden of dengue. Also, while many dengue endemic countries in Asia and Latin America have mandatory reporting of dengue cases to public health authorities, and national surveillance systems in place to monitor incidence patterns [7], most African countries lack such established reporting mechanisms, and only sporadic outbreaks and individual case reports have been documented. In addition, the frequently non-specific clinical presentation of dengue may be difficult to distinguish from the myriad other infectious diseases present in Africa, since dengue diagnostic assays are not widely available.

1
2
3
4 Thus, the burden of dengue remains largely unknown in Africa [6, 8]. Without such dengue
5
6 burden data, informed decision-making about prevention and control measures, including
7
8 dengue vaccine introduction, in Africa are not possible.
9

10
11 To improve estimates of population-based dengue disease burden in Africa, the
12
13 Dengue Vaccine Initiative (DVI) initiated field studies at three sites in West, West-Central,
14
15 and East Africa in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya;
16
17 respectively. In each of the three sites, a standardized package of study components,
18
19 including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-
20
21 illness surveys, and serological surveys (Fig 1), was initiated between December, 2014 and
22
23 March, 2016.
24
25
26
27

28 **Methods**

29 *Site selection*

30
31
32 Study sites were selected, in part, based on their likelihood of supporting DENV
33
34 transmission. Dengue outbreaks and cases reported in the literature, available seroprevalence
35
36 studies, and country-specific dengue risk maps of the probability of DENV transmission and
37
38 the level of evidence of dengue burden from modelling were considered in site selection. [5]
39
40 [9]. In addition, adequate research infrastructure to implement the studies was taken into
41
42 account. Finally, inclusion of different regions of Africa was also a factor in site selection.
43
44 Thus, Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; were selected,
45
46 respectively, to measure the true burden of dengue in West, (West-) Central, and East Africa.
47
48
49
50

51
52 In Burkina Faso, the first reported dengue outbreak occurred in Ouagadougou in
53
54 1982 due to DENV-2 [6]. Serological prevalence of dengue was found to be 26.3% in a rural
55
56 setting (Nouna village) and 36.5% in an urban setting (Ouagadougou) in 2006 [10]. More
57
58
59
60

1
2
3
4 recently, an observational study conducted by Ridde et al. among febrile patients consulting
5 at selected study facilities in 2013-14 showed 8.7 % (33/379) to be positive by dengue RDT;
6 and 15 of 60 samples tested by RT-PCR to be dengue positive [11]. With evidence for the
7 presence of dengue, along with a strong health and demographic surveillance system (Ouaga-
8 HDSS) which could be used to describe the demographic characteristics of the catchment
9 area, a field study was initiated in Ouagadougou, Burkina Faso in December 2014.

10
11
12
13
14
15
16
17
18 In Gabon, cases of dengue hemorrhagic fever (DHF) caused by up to three different
19 DENV serotypes have been reported, and dengue seroprevalence has been found to be
20 between 5 and 20% [12-14]. A recently published study results demonstrated seroprevalence
21 of 12.3% among toddlers approximately 30 months of age in semi-rural Lambaréné between
22 2007 and 2010 [15]. However, a different study in 2005-2008 suggested minimal DENV
23 transmission in rural areas of Gabon [16]. This latter study examined antibodies against
24 dengue in individuals from randomly selected villages representing about 10% of all
25 Gabonese villages. Blood samples were tested by anti-DENV IgG and IgM capture ELISA
26 and found to have only minimal IgG (0.5%) and IgM (0.5%) seroprevalence. Based on these
27 low prevalences, authors concluded that there was no active circulation of DENV in rural
28 Gabon. However, the low seroprevalence may have been affected by low sensitivities of the
29 tests used leading to a high rate of false negative, and/or selection bias in the blood sample
30 pool among the selected villagers [17]. Seroprevalence estimates may have also been
31 impacted by the possibility of false-positive results due to IgG cross-reactivity among
32 flaviviruses [16]. Nevertheless, given the possibility of DENV circulation in Gabon, a field
33 study was initiated in Lambaréné in March 2015 in a community with a catchment population
34 of about 77,000 residents, using the clinical research infrastructure of the Centre de
35 Recherches Medicales de Lambaréné (CERMEL), benefiting from experienced research staff
36 who conducted a large Phase 3 malaria vaccine trial [18, 19].

1
2
3
4 In Kenya, more evidence is available for the presence of dengue based on local data.
5
6 Dengue was the most common viral pathogen in retrospectively tested blood specimens from
7
8 HIV-negative survey samples from the 2007 Kenya AIDS Indicator Survey. Antibody testing
9
10 for dengue as well as chikungunya and Rift Valley fever was performed by IgG ELISA using
11
12 either commercial kits or CDC assays; 12.5% were found to be dengue positive [20].
13
14 Similarly, a household survey found 13% of individuals from 701 households in Mombasa
15
16 had serological evidence of either past or current DENV infection [21]. These data suggest
17
18 that there is more dengue in Kenya than indicated by public health reporting, possibly due to
19
20 misdiagnosis [20, 21]. A field study was initiated in Mombasa, Kenya in March 2016.
21
22
23

24 25 *Study participants*

26
27 For the passive facility-based fever surveillance, individuals who met the following criteria
28
29 were eligible for study enrollment:
30
31

- 32 1. Age 1- 55 years old;
- 33 34 2. Resident of the catchment area covered by healthcare facilities participating in the
35 study, without plans to move out of the catchment area within 12 months;
- 36 37 3. Signed informed consent, and assent for those aged between 7 and 18 years; and
- 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 60 4. Patients presenting with current fever (axillary temperature $\geq 37.5^{\circ}$ C) or history of
fever for ≤ 7 days duration without localizing signs (fever caused by a localized
infection as well as fever with a known and confirmed etiology other than dengue,
such as malaria confirmed by malaria RDT- listed in the patient identification SOP).

53 For the serological survey, criteria 1-3 were applied. For the healthcare utilization
54 survey, household interviews were conducted among the heads or representatives of the
55 household invited from each family participating in the serosurvey.
56
57
58
59
60

Study area and population

Burkina Faso, located in West Africa, has a population of 14,017,462 with 22.7% living in urban areas. The country is mainly rural with about 29% of the population reported to be living in urban areas in 2014. However, Burkina Faso is urbanizing rapidly and is positioned at the 4th country with the fastest urbanization in the last 25 years [22, 23]. The capital, Ouagadougou, has a population of 2,741,128. The majority of the population live in urban settings. About 45% of the population are under 15 years of age [24]. The city is divided into 12 districts and 52 sectors. Ouagadougou is the country's largest city and the cultural and economic center. The city is part of the Soudano-Sahelian area, with a rainfall of about 800 mm per year. The rainy season is from May to October, with a mean temperature of 28 °C (82 °F). The cold season runs from December to January, with a minimum average temperature of 16 °C (61 °F). During the hot season, which runs from March to May, the temperature can reach as high as 43 °C (109 °F).

The Health and Demographic Surveillance System is in place in Ouagadougou. Ouaga HDSS monitors a population of 81,717 residents; according to this surveillance system, the city population is very stable with a rate of migration of 4.1% and more than 80% of the inhabitants with ownership of their houses [20]. A map of the city and distribution of the population is shown in Figure 2.

Gabon, located on the west coast of Central Africa, has an area of nearly 270,000 square kilometres (100,000 sq. mi) with a population estimated at 1.5 million. Its capital and largest city is Libreville. In 2014, it is reported that 87% of the Gabonese population lived in urban areas [23]. The sixth largest city, Lambaréné, the capital of Moyen-Ogooué, is located 75 kilometers south of the equator, with a population of 25,257 in 2009. The majority of

1
2
3
4 Lambaréné residents live in semi-rural areas. About 42% of the Gabonese population is under
5
6 15 years of age [24]. Similarly, Lambaréné's population is relatively young with about 50%
7
8 under 20 years of age.
9

10
11 The health services of Gabon are mostly public, but there are some private
12
13 institutions as well. With one of the best medical infrastructure in the region, almost 90% of
14
15 the population have access to health care services. Albert Schweitzer Hospital (ASH) is a
16
17 private institution which served as a study site for the passive fever surveillance study [25,
18
19 26].
20

21
22 Kenya, located in East Africa, lies on the equator, covering 581,309 km²
23
24 (224,445 sq. mi), with a population of approximately 45 million people in 2014 [2]. Kenya
25
26 generally has a warm and humid tropical climate, but is diverse ranging from the cooler
27
28 climate around the capital city, Nairobi, to a hot and dry climate inland, as well as a desert-
29
30 like climate in the north-eastern regions along the border with Somalia and Ethiopia [27]. The
31
32 capital, Nairobi, is a regional commercial hub. The main industries include agriculture,
33
34 exporting tea and coffee, as well as the service industry.
35
36

37
38 Kenya is divided into 47 semi-autonomous counties. Mombasa is the country's
39
40 second largest city after Nairobi, and is located on the east coast of the country [2].
41
42 Administratively, Mombasa is the capital of Mombasa County, what was formerly called
43
44 Coast Province. This overall Coast region covers over 80,000 km² in the south-eastern part of
45
46 Kenya, constituting about 15% of the country's land area, with a population of 3,325,307
47
48 residents.
49

50
51 The main driver of economy of Mombasa is tourism and trading industry. Mombasa
52
53 itself has a population of about 1.3 million with almost 50% of the population under 15 years
54
55 of age [24]. Increasingly, the population of the province lives in urban areas; at present about
56
57 45% live in Mombasa and other urban centers. The long rains begins around April and the
58
59
60

1
2
3
4 short rains begins in October [27]. Mean annual temperature ranges from 24°C to 27°C, but
5
6 maximum temperature averages over 30°C during the hottest months, January to April.
7

8
9 Figure 3 shows the area of Mvita subcounty of Mombasa, which was the catchment
10 area for the study in Kenya, with a catchment population of 74,735 residents. The map
11 indicates the three facilities involved in the study.
12
13

14 15 *Sample size*

16
17 Given the paucity of available age-specific dengue incidence data in the study
18 countries or nearby countries, it was difficult to obtain population-based incidence to make
19 assumptions when calculating sample sizes. The required catchment population for the
20 passive facility-based fever surveillance was roughly estimated based on the limited data
21 available in the literature. Annual incidence estimates were calculated based on available
22 prevalence estimates with the assumption that the outcome of interest has zero prevalence at
23 age zero, and that force of infection is constant. It was assumed that prevalence estimates
24 found for one particular age group would be adjusted as the annual incidence and used across
25 all ages.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Wichmann et al. calculated an expansion factor for children by comparing data from
41 three cohort studies to national surveillance data in Southeast Asia [28]. For children in
42 Thailand, the age-specific expansion factors calculated were 11.85 for <5 years, 8.76 for 5-9
43 years, and 7.81 for 10-14 years [28]. The estimates used in our calculation were not from
44 population-based studies and the degree of under-reporting of dengue in Africa is unknown.
45 While it would have been ideal to adjust the incidence further for likely underestimation, the
46 annual incidence used in sample size calculations could not be adjusted for possible under-
47 reporting due to the lack of data. The sample sizes were calculated with 95% confidence
48 levels and a margin of error at a fixed significance level within 25% of the true proportion of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 incidence. This gives relative precision of 75%, considering the gap in evidence for dengue
5
6 incidence in the study areas. The final sample sizes were calculated by assuming 20% non-
7
8 response rate or loss to follow-up. The required catchment population size for the fever
9
10 surveillance study in Burkina Faso was estimated to be 100,000, Gabon to be 77,000, and
11
12 Kenya to be 70,000. In these catchment populations, the number of enrolled subjects depends
13
14 on the number of eligible patients who seek care at the study facilities. How many eligible
15
16 febrile episodes would actually present at our study facilities was difficult to predict; but after
17
18 assessment of the volume of febrile patients at the facilities, a realistic upper limit for
19
20 enrollment for a study period of approximately 1.5 years was set at 3,000 subjects to offer
21
22 enrollment to all consenting eligible patients.
23
24

25
26 For the serological survey, the sample size was calculated similarly using the
27
28 prevalence proportion based on published literature. Seroprevalence of 0.304 for Burkina
29
30 Faso [10], 0.123 for Gabon [16], and 0.144 for Kenya [29] were used. With the same
31
32 confidence levels and allowed margin of error, and assuming 5-15% non-response rate
33
34 (variable by site), the sample size was calculated to be 3,000 participants at each site. Again,
35
36 with the scarcity of data from the selected countries, there were no other prevalence estimates
37
38 reported or estimates from different age groups. As prevalence is expected to increase with
39
40 age, and higher prevalence would give a smaller sample size, our calculations are likely to be
41
42 conservative.
43
44
45

46 47 48 *Study components*

49 50 51 Fever surveillance – design and methods

52
53
54
55 To determine burden due to symptomatic dengue in each of the three sites in Burkina
56
57 Faso, Gabon, and Kenya, passive facility-based fever surveillance was implemented in a
58
59
60

1
2
3
4 well-defined catchment area population. In Burkina Faso, the surveillance study was initiated
5
6 in December 2014 in five selected primary health care centres, locally called “Centre de
7
8 Santé et de Promotion Sociale” (CSPS), in the municipality of Ouagadougou, with a
9
10 catchment population of 105,000 residents. This project was implemented in collaboration
11
12 with Centre Muraz in Bobo-Dioulasso, EQUITE sante program (a collaborative program
13
14 between University of Montreal and Action-Gouvernance-Integration-Reinforcement, AGIR,
15
16 based in Ouagadougou, funded by Canadian Institute of Health Research), and DVI. In
17
18 Gabon, the surveillance study was initiated in the Albert Schweitzer Hospital serving a
19
20 catchment population of 130,000 residents in the Moyen-Ogooué and surroundings within
21
22 Lambaréné, in collaboration with CERMEL and Institute of Tropical Medicine in Tübingen,
23
24 Germany. In Kenya, the surveillance study was implemented at Ganjoni dispensary, Tudor
25
26 sub-county Hospital, and Coast Provincial General Hospital, serving a catchment population
27
28 of 70,000 residents in Mombasa, in collaboration with Kenya Medical Research Institute
29
30 (KEMRI) and Ministry of Health of Kenya.
31
32
33
34

35 As described in Fig. 2, both outpatients and inpatients at the designated study
36
37 facilities, who meet inclusion criteria as mentioned earlier are tested for dengue, first with SD
38
39 Dengue Duo® RDT. Dengue confirmation is done by detection of dengue virus in serum
40
41 samples using PCR, as well as anti-dengue IgM and IgG antibodies in acute and convalescent
42
43 serum by ELISA (SD Dengue IgM & IgG capture ELISA® tests, Standard Diagnostics,
44
45 Yongin-Si, Korea) [30, 31]. Every consecutive patient meeting inclusion criteria is eligible
46
47 for enrolment during the study period. Infants < 1 year old were not included due to
48
49 operational limitations, such as difficulty of infantile bleeding.
50
51
52
53
54

55
56 In Ouagadougou, Burkina Faso, the fever surveillance initiated in December 2014
57
58
59
60

1
2
3
4 continued until February 2017 (approximately 2 years). In Lambaréné, Gabon, the fever
5
6 surveillance initiated in April 2015 continued until January, 2017 (approximately 1.5 years).
7
8
9 In Mombasa, Kenya, the fever surveillance initiated in March 2016 will continue until May
10
11 2017.

12
13 Among subjects enrolled in the fever surveillance, those who are positive by dengue
14
15 rapid diagnostic test are offered further enrolment in the cost-of-illness survey, consisting of
16
17 interviews on the day of acute illness visit, day 10-14 from the first visit, and day 28, if
18
19 illness continues. The cost-of-illness survey questionnaire was designed to estimate the direct
20
21 medical, direct non-medical, and indirect costs associated with dengue-positive patients
22
23 identified at study facilities. This survey also estimates the cost of treating dengue at the
24
25 facility level. Data are gathered by linking patients' medical records concerning outpatient
26
27 visits, inpatient visits, and service consumption (e.g., diagnostic tests, medication, and other
28
29 services provided to patients). The cost-of-illness portion of the study will be described
30
31 separately.
32
33
34
35
36

37 Fever surveillance – laboratory testing

38
39
40 In all three sites, acute samples are tested using a commercial RDT for dengue NS1
41
42 and IgM/IgG (Dengue Duo[®], Standard Diagnostics, Yongin-Si, Korea). Dengue Duo RDT is
43
44 used on the day of acute illness visit at the site of patient presentation (day 1). The acute and
45
46 convalescent samples are subsequently tested at a local laboratory using dengue IgM/IgG
47
48 ELISA (SD Dengue IgM & IgG Capture ELISA[®], Standard Diagnostics, Yongin-Si, Korea).
49
50
51
52 The serum is separated and stored in 4 aliquots of about 500 µL for various lab tests, as
53
54 indicated in consent documents.
55
56

57 Samples with positive results by RDT or ELISA undergo further testing by RT-PCR.
58
59
60

Four DENV serotype-specific real-time RT-PCR assays are used for laboratory confirmation of dengue and serotyping [32]. The DENV 1-4 RT-PCR assays are carried out in 25µL reaction mixtures containing 5µL template RNA, TagMan® Fast Virus 1-step mastermix (Applied Biosystems®), 0.9 µM of each primer, and 0.2 µM probe [32]. Amplification and detection are performed in a StepOne Plus real-time PCR system and the baseline and threshold are determined using the auto-baseline and threshold feature in StepOne Software v2.2.2 (Applied Biosystems®). Thermocycling parameters are as follows: reverse transcription at 50 °C for 5 min, inactivation at 95 °C for 20 s, followed by 45 cycles of fluorescence detection at 95 °C for 3 s, and annealing at 60 °C for 30 s [32]. A specimen is considered positive if target amplification was recorded within 40 cycles.

Serological survey – design and methods

While the facility-based fever surveillance studies provide estimates of the burden of medically-attended dengue disease, evaluation of all DENV infections in a population – including subclinical and mildly symptomatic infections, which impact immune status – is needed to capture the overall impact of dengue. As part of the study package, population-based serological surveys were conducted in the same catchment population used for the fever surveillance. At each of the three sites in Africa, the serosurvey was conducted on a cohort of approximately 3,000 randomly selected residents of urban and semi-urban parts of Ouagadougou, Lambaréné, and Mombasa. Without individual-level census information on all residents of Lambaréné and Mombasa, with help of community/village health workers, randomization was done based on neighbourhoods (or defined areas for which the health workers/volunteers are responsible) as cluster units. As the community/village health workers

1
2
3
4 are familiar with the villages and their residents, they are good entry points into the
5
6 communities. With these health workers, the field team screened houses in the selected
7
8 villages by knocking on doors of every 5~7 houses, depending on the household density per
9
10 neighbourhood. Also, demographic information collected in previous research projects
11
12 conducted in the same area was used as a guide, if available. In the case of the site in
13
14 Ouagadougou, HDSS data were available and the EQUITE CIHR research program of
15
16 University of Montreal had set up a geographic information system (GIS) database system of
17
18 houses in the study area. Using these data, households of potential enrollees of the serosurvey
19
20 were pre-selected randomly and household visits were made. In the three sites, about 45% of
21
22 the serosurvey samples were targeted to be collected from children 1 - 14 years-of-age, and
23
24 55% were targeted to be collected from adults between 15 and 55 years of age to reflect the
25
26 age distribution of the general population of the area. Household-based enrollment was
27
28 offered to the head of the household until the specific cap for the age-group was reached in
29
30 Lambaréné and Mombasa.
31
32
33

34
35 Randomly-selected subjects 1-55 years of age underwent phlebotomy (5ml for
36
37 children and 7ml for adults) twice — during pre-transmission (before the rainy season) and
38
39 post-transmission (after the rainy season) at 6 month intervals. The sera were evaluated using
40
41 IgG indirect ELISA at baseline and after 6 months. The presence of dengue IgG antibodies at
42
43 6 month intervals will be used to estimate the level of occurrence of inapparent DENV
44
45 infection and to calculate the rate of infection in the catchment population. Flow cytometry-
46
47 based DENV neutralization assays will be applied to a subset of samples to assess for
48
49 presence of dengue neutralizing antibodies and seroconversion over the 6 month interval. In
50
51 addition to overall seroconversion, age-specific seroconversion estimates in the catchment
52
53 population as well as the proportion of inapparent infections are determined.
54
55
56
57
58
59
60

Serological survey – laboratory testing

From the samples collected in the serosurvey, about 200 μ L of serum are used and tested at a local laboratory using dengue IgG ELISA (Panbio Dengue IgG Indirect ELISA[®], Alere North America, LLC, Florida, United States). Given potential serological cross-reactivity among flaviviruses [33], flow cytometry-based neutralization assays will be performed against selected flaviviruses to include yellow fever virus, West Nile virus, Zika virus, and Japanese Encephalitis virus at the International Vaccine Institute, Seoul, Korea [34, 35].

About 1,000 μ L of serum is kept aside for this procedure. The flow cytometry-based neutralization assays are performed in duplicate in 96-well cell culture plates with flat-bottom wells, each containing DC-SIGN-expressing U937 cells [34]. The amount of virus used in the assay infects between 7 and 15% of the cells. Human immune sera are serially diluted and the virus is pre-incubated with the sera for 1 h at 37°C [34]. The cells are washed, and the virus and serum mixture is added to the cells for 1 h at 37°C, and the cells are further incubated for 24 to 48 h at 37°C in 5% CO₂. The cells are fixed, permeabilized, and stained with fluorescein-conjugated monoclonal antibody 4G2, which recognizes the flavivirus E protein [36]. FACSscan flow cytometer (Becton Dickinson, San Diego, CA) is used to analyze the cells [34]. The serum dilution that neutralized 50% of the viruses is calculated by nonlinear, dose-response regression analysis with Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).

In addition, a Luminex-based multiplex immunoassay will be performed on a randomly selected sub-sample to assess for IgG to different flaviviruses [37]. Detection of IgG against ZIKV and each the four DENV serotypes was performed on patient serum

1
2
3
4 samples using an in-house microsphere-based multiplex immuno-assay (arbo-MIA) [38, 39].
5
6 The arbo-MIA is based on a mixture of microspheres covalently coupled with either DENV-1,
7
8 -2, -3, -4 or ZIKV recombinant antigens (E protein domain III) produced in Drosophila S2
9
10 expression system. Briefly, microsphere mixtures were sequentially incubated in the dark
11
12 under constant shaking with a 1:400 dilution of patient serum samples, with 2 µg/mL anti-
13
14 human IgG biotin-conjugated antibody (Jackson ImmunoResearch, West Grove, PA) and with
15
16 2 µg/mL streptavidin-R-phycoerythrin conjugate (Life technologies). After the final
17
18 incubation, the median fluorescence intensity (MFI) of each microsphere set was quantified
19
20 using a BioPlex 200 instrument (Bio-Rad Laboratories, Hercules, CA). Samples were
21
22 considered seropositive if the ratio of MFI values obtained for the viral antigen to the control
23
24 antigen was superior to the defined cut-off. The cut-off of the MIA was determined for each
25
26 viral antigen by ROC curve analysis using well characterized sera.
27
28
29

30
31 In Lambaréné, the enrolment bleed, took place in November -December 2015 with
32
33 2nd blood collection in May 2016. In Ouagadougou, the enrolment bleed took place in May-
34
35 June 2015 with follow-up blood collections in December 2015, June 2016, and January 2017.
36
37 In Mombasa, enrolment bleed took place in May 2016 with the 2nd blood collection in
38
39 November 2016 – February 2017.
40
41
42

43 44 Healthcare Utilization Survey 45

46
47 As the passive fever surveillance is conducted at the study facilities, potential dengue
48
49 patients could be missed if they seek care elsewhere. To identify the proportion of fever and
50
51 dengue cases potentially missed by the passive surveillance system due to patients living in
52
53 the study area but seeking care outside of study facilities, a population-based healthcare
54
55 utilization survey was conducted in 400 randomly selected households from the study
56
57
58
59
60

1
2
3
4 catchment area to characterize their healthcare utilization patterns of the households when
5 they have (self-reported) febrile episodes among the family members. In addition to assessing
6 health-seeking behaviours of the residents, preferences in terms of health-seeking behavior
7 and respective reasons for their preferences were investigated. The questionnaire was
8 administered to 400 heads of households. Among 3,000 residents who participated in the
9 serosurvey, there were about 600 households. From these households, 400 heads of
10 households were randomly selected and offered enrolment in the health utilization survey.
11 Heads of households or a senior representative within the household were asked questions on
12 health seeking patterns of their family members. The surveys provide data to determine the
13 proportion of these cases missed by our passive fever surveillance system. Also, the surveys
14 document health seeking patterns, who would seek care at which facilities, who would make
15 health-seeking related decisions, and the reasons for their preferences.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 *Study questionnaires*

34
35 For the fever surveillance study, questionnaires are administered at the acute illness visit and
36 the convalescent visit. The convalescent visit may take place at the health care facility (10-14
37 days later) or at the patient's home (15-21 days after the acute visit), according to patient
38 preference and availability. The questionnaires are completed by medical staff of the study
39 facilities, including demographic and clinical information (e.g., signs, symptoms, past
40 medical history, treatments prescribed, and diagnoses). The same staff also complete the
41 follow-up questionnaire at the convalescent visit within 21 days from the acute visit. Study
42 nurses complete surveillance enrolment log. Lab technicians complete the lab section (mostly
43 dengue-related diagnostics) and the forms are compiled by the study coordinator on site.
44
45
46
47
48
49
50
51
52

53 For the serosurvey component, questionnaires are administered at the household by trained
54 field team staff at each serosurvey visit. Study nurses complete the questionnaire after a brief
55
56
57
58
59
60

physical and medical examination. There are (a) follow-up visit(s) in about 6 months and the same staff make the household visits to complete the follow-up questionnaire. Enrolment log is maintained by our study coordinator on site.

Variables of the surveillance questionnaires

The variables collected are listed in table 1.

Table 1. List of variables collected in the passive fever surveillance data collection form

Topic	Description	Items
Basic information	Demographic and basic information about the patient and the treatment received	Type of treatment where patient is enrolled (IPD vs. OPD) Date of fever onset, duration of fever Current temperature Tourniquet test results Patient's address (district and village-level) Date of visit, date of birth, age, and sex Weight and height
General health condition	Current condition of the patient (self-report) and underlying diseases of the patient	How well the patient could handle daily activities Pre-existing conditions
Signs and symptoms during this illness	A set of sign and symptoms that may be related to fever and dengue (DF and DHF)	Rash, fatigue, headache, retro-orbital pain, neck/ear pain, sore throat, breathing difficulty, cough, expectoration, gastrointestinal signs (Nausea/vomiting, diarrhea, abdominal pain, etc.), hemorrhagic signs (nose/gum bleeding, ecchymosis, petechiae, etc.), signs of shock (cyanosis, capillary refill), arthralgia, myalgia, loss of appetite, jaundice, etc.
Medical History:	Previous dengue-related or other flavivirus infection as well as vaccination history (self-report)	Previous dengue infection and related hospitalization Previous infection to other commonly circulating arboviral infection in the area Yellow fever vaccination history
Laboratory findings	Records from the routine laboratory tests widely used in	Platelet count, hematocrit, haemoglobin, leukocytes, neutrophils,

	clinical fever/dengue patient management, as part of the hospital care procedure	protein level, AST, ALT, urine test results, etc.
Clinical Diagnosis	Clinician's diagnosis with or without referring to the RDT	Diagnosis given by the physician based on clinical presentation after physical examination of the patient.
Dengue testing results	Results from the dengue tests, mainly RDTs for dengue as well as other commonly circulating arbovirus in the area	Dates of blood draw Test results of the RDT IgM/IgG capture ELISA results PCR results (if available)
Treatment	Medicine(s) prescribed and the starting and end dates	Antibiotics, paracetamol, ibuprofen, aspirin, and others that may be site-specifically prescribed
Outcome	Outcome of this particular visit	Hospitalized, returned home, or referral
Hospitalization	Information collected only among hospitalized patients in the surveillance to record other severe signs and progression of illness	Admission and discharge diagnoses Presence of haemorrhagic signs or shock syndrome
Hospital Charges	Expenses and hospital charges incurred by patient on the visit 1	Amount of the out of pocket payment by the patient or the family/or guardian Breakdown of the hospital charges (laboratory, medication, admission-related charges)
Final outcome	Outcome of the patient's illness at the 2 nd visit	Final diagnosis given for the patient outcome of illness Completion of study participation (early termination and the reason, etc.)

Planned statistical analysis

From the fever surveillance data, incidence of symptomatic dengue among patients that seek health care at the study facilities will be calculated. Age-specific incidence rates in all the children and adults will be determined by referring to the size and distribution of the general population of the study area at the time of surveillance as the denominator in calculation of the incidence of symptomatic dengue cases. Each person residing in the study area is assumed to contribute 12 months of person time to the denominator. Although the

1
2
3
4 study areas all report a low migration rate, the in-migration is assumed to balance the out-
5
6 migration of the population during the study period. Age-specific incidence of symptomatic
7
8 dengue will be calculated by using age-specific denominators and the number of symptomatic
9
10 dengue cases in eligible individuals as the numerator.
11

12
13 Using the data collected in the Healthcare Utilization Survey, the proportion of
14
15 febrile cases missed by the passive surveillance system will be determined. Then using the
16
17 proportion, the numerator will be further adjusted in recognition of those missed fever cases
18
19 from the study area, which could have been dengue. Also, comparison will be made between
20
21 those that agreed to participate and those that declined participation so that our sample of
22
23 febrile cases is representative of febrile patients of the general population of the catchment
24
25 area.
26
27

28
29 SPSS software will be used for analysis of the fever surveillance data. Multivariable
30
31 logistic regression will be used to compare confirmed dengue patients versus non-dengue
32
33 febrile patients in terms of symptomatic presentation, based on signs and symptoms collected
34
35 from all patients with laboratory-confirmed dengue by serology and RT-PCR, adjusting for
36
37 possible confounders, such as age, days since onset of fever, primary vs. secondary infection,
38
39 inpatient vs. outpatient, etc. Differences in symptomatic complex of DF (and DHF, if data
40
41 allows) by age and serotype will be also determined using multivariable logistic regression.
42
43

44
45 As outpatient disease accounts for the greater part of dengue disease burden, clinical
46
47 profile of individuals with DENV infection will be characterized by the type of treatment
48
49 (hospitalized and outpatients), as well as by severity of the disease (severe vs. non-severe by
50
51 the 2009 WHO criteria) [40]. Classification is determined after the course of illness is
52
53 completed (typically during the convalescent visit). Symptomatic dengue is classified as
54
55 outpatient or hospitalized. Progression of dengue is recorded in the CRF as DF, DHF I, DHF
56
57 II, DHF III or DHF IV and clinical patterns will be compared by the severity grade [40, 41].
58
59
60

1
2
3
4 These will be compared to results obtained from other DVI studies in Latin America
5 (Colombia) and Asia (Thailand, Vietnam, and Cambodia). Overall, comparisons will be made
6
7
8 across Burkina Faso, Gabon and Kenya.
9

10
11 With the age-stratified sera that reflect age distribution of the general population of
12 the country, the serological survey sampling strategy ensures sufficient subjects to obtain
13 precise age-specific estimates of sero-positivity and sero-conversion of the catchment area
14 population. The sero-conversion rate and change in the immune status will be determined by
15 age group during the study period. The age-stratified serosurvey data will also allow
16
17 calculation of the force of infection of dengue in the study population. Comparisons will be
18
19 made among Burkina Faso, Gabon and Kenya.
20
21
22
23
24
25

26 27 *Ethical considerations* 28

29
30 To minimize inconvenience of the study to patients, clinicians and nurses were
31 sensitized and trained regarding the study requirements and procedures in order for data
32 collection to be integrated into routine patient care. The clinicians and nurses selected for the
33 study receive coordinated support from study field staff throughout the study process. Written
34 informed consent, and assent for participants 7 (13 for Kenya) -17 years of age, was obtained
35 from patients by study staff. Study staff go through consent and assent documents for short
36 summary of the disease, detailed description of study procedure, and information on
37 reimbursement. Patient data are documented in the study designated office and only the study
38 staff have access to the data that had been de-identified without any personal identifiable
39 information. Data are exclusively handled in the study office and stored safely in a protected
40 database in the study office as well as the DVI main server.
41
42
43
44
45
46
47
48
49
50
51
52

53
54 The protocol for each study obtained ethical approvals from the Institutional Review
55 Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and
56
57
58
59
60

1
2
3
4 Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI
5
6 Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and
7
8 Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB
9
10 of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and
11
12 the National Health Ethical Committee of Burkina Faso.
13

14 15 16 17 **Results and discussion** 18

19
20 Despite the fact that dengue cases and *Aedes* mosquitoes have been reported in
21
22 Africa as early as 1823 [5], very few dengue studies have been conducted in Africa. Also,
23
24 little evidence is from population-based studies [6]. Compared to the volume of evidence
25
26 from SE Asia and the Americas, there is critical data scarcity on dengue in Africa. Suspicion
27
28 of substantial dengue burden in Africa is based on limited reports of outbreaks and a handful
29
30 of sero-prevalence studies testing different viruses among samples that likely do not represent
31
32 the general population. In the three countries selected for our field studies, somewhat more
33
34 data is available but is also very limited. In Burkina Faso, recent reported incidence was 8.7%
35
36 based on dengue RDT from an observational study conducted in 2013 [11]. In Gabon, one
37
38 study suggested minimal DENV circulation in rural areas [16], while a recent study reported
39
40 12.3% seroprevalence among toddlers 30 months of age in semi-rural parts of Lambaréné
41
42 [15]. In Kenya, about 13% of the individuals in Mombasa have been reported evidence of
43
44 past or current DENV infection [21]. Despite the limited scope and generalizability of these
45
46 studies, they suggest that there may be more dengue than previously appreciated due to
47
48 underestimation and misdiagnosis [20, 21].
49
50
51
52

53
54 These studies all indicate presence of dengue and some level of underlying sero-
55
56 prevalence in the countries of our field studies. However, often these studies are limited by
57
58 their retrospective design or sample collection (blood donors or sample collected from
59
60

1
2
3
4 surveys of other diseases) in terms of assessing the true, population-based, burden of dengue.
5
6 We proposed to address this gap by population-based dengue surveillance and sero-
7
8 prevalence studies in West, (West-) Central, and East Africa.
9

10
11 The present studies at three sites in Africa will provide important information on
12
13 undocumented DENV circulation in Africa. Such data will help to strengthen the evidence
14
15 base for dengue burden in Africa. Better defined disease burden data based on our studies
16
17 could be used to assess the relative need for dengue prevention and control measures, such as
18
19 whether a dengue vaccine would be a cost-effective public health intervention for countries in
20
21 Africa. Clinical findings from our studies could also be used as a guide for dengue case
22
23 detection and case management.
24

25
26 The studies have some important limitations. One potential source of bias in
27
28 estimating the incidence of symptomatic dengue is under-ascertainment due to the
29
30 community residents with relevant symptoms seeking care from other healthcare providers
31
32 and facilities than the facility under surveillance. As the study design remains passive
33
34 surveillance, cases are ascertained only at study facilities. By estimating the proportion of
35
36 febrile patients seeking care elsewhere, the degree of fever patients missed by the study
37
38 facility will be determined. Also, depending on the transmission volume of dengue or other
39
40 co-circulating diseases with onset of fever there may be patients that are diagnosed with other
41
42 diseases, and ruled out of dengue. These factors may increase the likelihood of under-
43
44 reporting or over-reporting.
45
46
47

48
49 In addition, the sero-survey and healthcare utilization survey are conducted on a
50
51 randomized sub-sample of the catchment area population and there may be limited
52
53 generalizability of the data collected from these surveys. With unknown differences among
54
55 those that agree to participate and those that do not agree, the data may not be representative
56
57 of the general population of the study countries.
58
59
60

Conclusions

Data collection continues and study closure is planned in all three sites in April – May, 2017. Although not described in this paper, preliminary results indicate a substantial level of dengue incidence and prevalence in each site. The data collected from our studies will provide a more accurate assessment of the unknown dengue disease burden in Burkina Faso, Gabon, and Kenya. These data can fill a gap in undocumented burden of dengue in the region and, collectively, may be used to infer dengue burden in other areas of Western, Central, and Eastern Africa. Countries in Africa may not consider introduction of a dengue vaccine as the foremost priority in the near future due to many other competing public health problems and limited resources as a major challenge. For cost-effective implementation of public health interventions, accurate data on dengue burden from epidemiological studies would be needed for policy makers to make evidence-based decisions on control and prevention of dengue. Our studies will provide some much needed information based on population-based research to assess dengue burden in Africa.

1
2
3
4 List of abbreviations
5

6 GDAC - Global Dengue and *Aedes*-transmitted Diseases Consortium

7 IVI - International Vaccine Institute

8 DENV- dengue viruses

9 DVI - Dengue Vaccine Initiative

10 Ouaga-HDSS - health and demographic surveillance system

11 DHF - dengue hemorrhagic fever

12 CERMEL - Centre de Recherches Médicales de Lambaréné

13 ASH – Albert Schweitzer Hospital

14 CSPS - Centre de Santé et de Promotion Sociale

15 KEMRI - Kenya Medical Research Institute

16 SD – Standard Diagnostics

17 GIS - geographic information system

18 MFI - median fluorescence intensity

19 CRCHUM - Centre Hospitalier de l'Université de Montréal
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Declarations

- Ethics approval and consent to participate

The protocol for each study obtained ethical approvals from the Institutional Review Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and the National Health Ethical Committee of Burkina Faso.

- Consent for publication

Not applicable

- Availability of data and material

Data sharing is not applicable to this article as no datasets were analyzed during the current study.

This manuscript does not include data from the studies described here in. This is a protocol paper. The datasets that are being generated for analysis as described in the current study are not yet publicly available as the studies are currently ongoing at the time of submission. They will be available from the corresponding author on reasonable request.

- Competing interests

The authors declare that they have no competing interests.

- Funding

The current study was supported by funds from the Bill and Melinda Gates Foundation (OPP 1053432). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

1
2
3
4 • Authors' contributions

5
6 JKL designed the study, is overseeing data collection, and was a major contributor in writing
7 the manuscript. MC co-designed the study, oversaw some parts of data collection, and
8 supported in writing of the manuscript. JSL was a contributor in designing of the study and
9 oversight of parts of data collection. KSL was a contributor in oversight of data collection.
10 SN supported in data collection. SKL supported in data collection. VR supported in designing
11 of the study and was a major contributor in finalization of the manuscript. JF was a
12 contributor in data collection. BL was a contributor in designing of the study and data
13 collection. SHM was a contributor in designing of the study and site establishment. ME was a
14 contributor in designing of the study. EA supported in data collection. NO supported in data
15 collection. AB supported in data collection. EB supported in data generation. SMN was a
16 contributor in designing of the study and site establishment. STA was a contributor in
17 designing of the study and site establishment. SY was a contributor in designing of the study
18 and site establishment. NA was a major contributor in providing oversight of the data
19 collection and finalization of the manuscript. IKY was a major contributor in designing of the
20 study and finalization of the manuscript.
21 All authors read and approved the final manuscript.
22
23
24

25
26
27 • Acknowledgements

28
29 We thank the doctors and laboratory staff of CSPS of Ouagadougou, ASH, Ganjoni
30 dispensary, Tudor sub-county Hospital, and Coast Provincial General Hospital, as well as at
31 Centre Muraz, CERMEL, and KEMRI. We thank collaborators at AGIR, IRD France, and
32 University of Montreal, and University of Tubingen. Lastly, we would like to thank the DVI
33 team and statisticians and administrative staff at the International Vaccine Institute for their
34 helpful comments during the preparation of this manuscript and support during the studies.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O *et al*: **The global distribution and burden of dengue.** *Nature* 2013, **496**(7446):504-507.
2. Murray NE, Quam MB, Wilder-Smith A: **Epidemiology of dengue: past, present and future prospects.** *Clin Epidemiol* 2013, **5**:299-309.
3. Chang M, Christophel E, Gopinath D, Abdur R, on behalf of Malaria OVaPD, World Health Organization Regional Office for the Western Pacific: **Challenges and future perspective for dengue vector control in the Western Pacific Region, Regional Analysis.** *Western Pacific Surveillance and Response Journal* 2011, **2**(2):9-16.
4. Eisen L, Beaty B, Morrison A, Scott T: **Proactive Vector control strategies and improved monitoring and evaluation practices for dengue prevention.** *J Med Entomol* 2009, **46**(6):1245-1255.
5. Messina JP BO, Scott TW, Zou C, Pigott DM, Duda KA, Bhatt S, Katzelnick L, Howes RE, Battle KE, Simmons CP, Hay SI.: **Global spread of dengue virus types: mapping the 70 year history.** *Trends Microbiol* 2014, **22**(3):138-146.
6. Amarasinghe A KJ, Letson GW, Margolis HS.: **Dengue virus infection in Africa.** *Emerg Infect Dis* 2011, **17**(8):1349-1354. .
7. Beatty ME SA, Fitzsimons DW, Hanna JN, Lam SK, Vong S, Guzman MG, Mendez-Galvan JF, Halstead SB, Letson GW, Kuritsky J, Mahoney R, Margolis HS; Asia-Pacific and Americas Dengue Prevention Boards Surveillance Working Group.: **Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards.** *PLoS Negl Trop Dis* 2010, **4**(11):e890.
8. Were F: **The dengue situation in Africa.** *Paediatrics and Internatinoal Child Health* 2012, **32**(S1):18-21.
9. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI: **Refining the global spatial limits of dengue virus transmission by evidence-based consensus.** *PLoS neglected tropical diseases* 2012, **6**(8):e1760.
10. Collenberg E, Ouedraogo T, Ganame J, Fickenscher H, Kynast-Wolf G, Becher H, Kouyate B, Krausslich HG, Sangare L, Tebit DM: **Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis.** *J Med Virol* 2006, **78**(5):683-692.
11. Ridde V, Agier I, Bonnet E, Carabali M, Dabiré K, Fournet F, Ly A, Meda I, Parra B: **Presence of three dengue serotypes in Ouagadougou (Burkina Faso): research and public health implications.** *Infect Dis Poverty* 2016, **5**(23).
12. Caron M, Grard G, Paupy C, Mombo IM, Bikie Bi Nso B, Kassa Kassa FR, Nkoghe D, Leroy EM: **First evidence of simultaneous circulation of three different dengue virus serotypes in Africa.** *PloS one* 2013, **8**(10):e78030.
13. Leroy EM, Nkoghe D, Ollomo B, Nze-Nkoghe C, Becquart P, Grard G, Pourrut X, Charrel R, Moureau G, Ndjoyi-Mbiguino A *et al*: **Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007.** *Emerging infectious diseases* 2009, **15**(4):591-593.
14. Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, Kassa Kassa F, Nkoghe D, Leroy EM: **Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012, **55**(6):e45-53.

15. Gabor J, Schwarz N, Esen M, Kremsner P, Grobusch M: **Dengue and chikungunya seroprevalence in Gabonese infants prior to major outbreaks in 2007 and 2010: A sero-epidemiological study.** *Travel Med Infect Dis* 2016.
16. Pourrut X, Nkoghe D, Gonzalez JP, Leroy E: **No evidence of dengue virus circulation in rural Gabon.** *Emerging infectious diseases* 2011, **17**(8):1568-1569.
17. Andries A, Duong V, Ngan C, Ong S, Huy R, Sroin K, Te V, Bunthin Y, Try P, P B: **Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG.** *PLoS Negl Trop Dis* 2012, **6**(12):e1993.
18. Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, Issifou S, Vekemans J, Leach A, Lievens M, Dubois MC *et al*: **A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.** *PLoS One* 2009, **4**(10):e7611. .
19. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B *et al*: **First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.** *N Engl J Med* 2011, **365**(20):1863-1875. .
20. Ochieng C AP, Vittor AY, Nyoka R, Gikunju S, Wachira C, Waiboci L, Umuro M, Kim AA, Nderitu L, Juma B, Montgomery JM, Breiman RF, Fields B.: **Seroprevalence of Infections with Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya, 2007.** *PLoS One* 2015, **10**(7).
21. Ellis EM, Neatherlin JC, Delorey M, Ochieng M, Mohamed AH, Mogeni DO, Hunsperger E, Patta S, Gikunju S, Waiboic L *et al*: **A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013.** *PLoS Negl Trop Dis* 2015, **9**(4):e0003733.
22. United Nations Development Programme: **Population, urban (% of population).** In: Edited by Reports HD, vol. 2016: UNDP; 2013.
23. United Nations: **World Urbanization Prospects: The 2014 Revision, Highlights.** In: Edited by Department of Economic and Social Affairs PD. United Nations: United Nations; 2014.
24. Central Intelligence Agency: **Age structure.** In: *The world factbook* vol. 2016: Central Intelligence Agency.
25. Ramharter M, Adegnika AA, Agnandji ST, Matsiegui PB, Grobusch MP, Winkler S, Graninger W, Krishna S, Yazdanbakhsh M, Mordmüller B *et al*: **History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon.** *The Middle European Journal of Medicine, WIENER KLINISCHE WOCHENSCHRIFT* 2007, **119**(Suppl 3):8–12.
26. Schwarz NG, Gysels M, Pell C, Gabor J, Schlie M, Issifou S, Lell B, Kremsner PG, Grobusch MP, Pool R: **Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon.** *Vaccine* 2009, **27**(2009):5371-5375.
27. **Kenya** [<https://en.wikipedia.org/w/index.php?title=Kenya&oldid=737329303>]
28. Wichmann O YI, Vong S, Limkittikul K, Gibbons R, Mammen MP, *et al*.: **Dengue in Thailand and Cambodia: An assessment of the degree of underestimated disease burden based on reported cases.** . *PLoS NTD* 2010, **Accepted in Feb. 2010**.
29. Mease L, Coldren R, Musila L, Prosser T, Ogolla F, Ofula V, Schoepp R, Rossi C, Adungo N: **Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study.** *Virol J* 2011, **8**(371).
30. Beatty ME, Stone A, Fitzsimons D, Hanna JN, Lam SK, Vong S, Guzman MG, Mendez-Galvan J, Halstead S, Letson GW *et al*: **Best Practices in Dengue**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards.** *PLoS NTD* 2010, *Submitted*.
31. World Health Organization: **Guidelines for the clinical evaluation of dengue vaccines in endemic areas.** In. Geneva: World Health Organization; 2008.
32. Alm E, Lindegren G, Falk K, Lagerqvist N: **One-step real-time RT-PCR assays for serotyping dengue virus in clinical samples.** *BMC Infect Dis* 2015, **15**(493).
33. Peeling R, Artsob H, Pelegrino J, Buchy P, Cardoso M, Devi S, Enria D, Farrar J, Gubler D, Guzman M *et al*: **Evaluation of diagnostic tests: dengue.** *Nature Reviews Microbiology* 2010:S30-S37
34. Kraus A, Messer W, Haymore L, de Silva A: **Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.** *J Clin Microbiol* 2007, **45**(11):3777-3780.
35. de Alwis R, de Silva A: **Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique.** *Methods Mol Biol* 2014, **1138**:27-39.
36. Lambeth C, White L, Johnston R, de Silva A: **Flow cytometry-based assay for titrating dengue virus.** *J Clin Microbiol* 2005, **43**(7):3267-3272.
37. Cabral-Castroa M, Saramago Peraltab R, Cavalcantia M, Puccioni-Sohlerd M, Carvalhoe V, da Costa Vasconcelose P, Peraltaa J: **A Luminex-based single DNA fragment amplification assay as a practical tool for detecting and serotyping dengue virus.** *Journal of virological methods* 2016, **236**:18-24.
38. Balasuriya U, Shi P, Wong S, Demarest V, Gardner I, Hullinger P, Ferraro G, Boone J, De Cino C, Glaser A *et al*: **Detection of antibodies to West Nile virus in equine sera using microsphere immunoassay.** *J Vet Diagn Invest* 2006, **18**(4):392-395.
39. Beck C, Desprès P, Paulous S, Vanhomwegen J, Lowenski S, Nowotny N, Durand B, Garnier A, Blaise-Boisseau S, Guitton E *et al*: **A High-Performance Multiplex Immunoassay for Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses.** *Biomed Res Int* 2015, **2015**(678084).
40. Hadinegoro SRS: **The revised WHO dengue case classification: does the system need to be modified?** *Paediatr Int Child Health* 2012, **32**(S1):33-38.
41. Guilarde AO, Turchi MD, Siqueira Jr JB, Feres VCR, Rocha B, Levi JE, Souza VAUF, Boas LSV, Pannuti CS, Martelli CMT: **Dengue and Dengue Hemorrhagic Fever among Adults: Clinical Outcomes Related to Viremia, Serotypes, and Antibody Response.** *The Journal of Infectious Diseases*, **197**(6): 817-824. .

1
2
3
4 Fig. 1 Description of the study components, including passive facility-based fever
5 surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys
6
7
8

9
10
11 There are two arms in the study package, composed of four parts. In the health facility-based
12 arm of the study package, there are the passive facility-based fever surveillance and cost-of-
13 illness survey embedded within the surveillance. In the community arm of the study, there are
14 serological survey and healthcare utilization survey.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Fig. 2 A map of the city and distribution of the population in Ouagadougou, Burkina Faso

5
6 Fig. 3 A map of the city and distribution of the population in Lambaréné, Gabon

7
8 Fig. 4 A map of the city and distribution of the population in Mombasa, Kenya

9
10
11
12
13 Figures 2 – 4 show the map of the study area at each site in Burkina Faso, Gabon, and Kenya.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Fig. 5 Patient flow in the fever surveillance
5
6
7


8
9 Eligible febrile patients identified and enrolled as study subjects will follow these steps to
10
11 complete participation in the passive fever surveillance.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 6 Laboratory testing algorithm for dengue
5
6
7

8 Samples from subjects of the passive fever surveillance would follow these steps of the
9
10 testing algorithm for confirmation of dengue.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only



Review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open: first published as 10.1136/bmjopen-2017-017673 on 21 January 2018. Downloaded from <http://bmjopen.bmj.com/> on May 7, 2023 by guest. Protected by copyright.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




only

BMJ Open: first published as 10.1136/bmjopen-2017-017673 on 21 January 2018. Downloaded from <http://bmjopen.bmj.com/> on May 7, 2023 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open: first published as 10.1136/bmjopen-2017-017673 on 21 January 2018. Downloaded from <http://bmjopen.bmj.com/> on May 7, 2023 by guest. Protected by copyright.



* A small number of those samples that are negative on ELISA or NS1 are tested with PCR to exclude false negative results of the ELISA.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 6 Laboratory testing algorithm for dengue

* Dengue Duo® test is performed on enrolled febrile patients to identify dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey.

**Selected samples, including those that were found positive by IgM and NS1 on Dengue Duo®, as well as those positive by IgM and IgG capture ELISA, will be tested with RT-PCR.

BMJ Open

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies: protocol of field studies of the Dengue Vaccine Initiative

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017673.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Aug-2017
Complete List of Authors:	Lim, Jacqueline; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Carabali, Mabel; International Vaccine Institute Lee, Jung-Seok; International Vaccine Institute Lee, Kang Sung ; International Vaccine Institute Namkung, Suk; International Vaccine Institute Lim, Si-Ki; International Vaccine Institute Ridde, Valéry; Université de Montréal, Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM); Université de Montréal, Département de médecine sociale et préventive Fernandes, Jose; Hopital Albert Schweitzer, Lambaréné,, Centre de Recherches Médicales de Lambaréné Lell, Bertrand; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Matendechero, Sultani ; Ministry of Health, Kenya, Dept. of Neglected Tropical Diseases Esen, Meral; University of Tübingen, Institute of Tropical Medicine Andia, Esther; Kenya Medical Research Institute Oyembo, Noah; Kenya Medical Research Institute Barro, Ahmed; Action-Gouvernance-Integration-Reinforcement, Program Equité Bonnet, Emmanuel ; Institut de recherche pour le developpement Njenga, Sammy; Kenya Medical Research Institute, Eastern & Southern Africa Centre of International Parasite Control Agnandji, Selidji ; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Yaro, Seydou; Centre MURAZ Alexander, Neal; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Yoon, In Kyu; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Epidemiology, Global health, Public health
Keywords:	dengue, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, Tropical medicine < INFECTIOUS DISEASES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

1
2
3
4 igfEvaluating dengue burden in Africa in passive fever surveillance and sero-prevalence
5 studies: protocol of field studies of the Dengue Vaccine Initiative
6
7

8 Jacqueline K. Lim^{1*}, Mabel Carabali¹, Jung-Seok Lee¹, Kang Sung Lee¹, Suk Namkung¹, Si-
9 Ki Lim¹, Valery Ridde², Jose Fernandes³, Bertrand Lell³, Sultani Hadley Matendecheo⁴,
10 Meral Esen⁵, Esther Andia⁶, Noah Oyembo⁶, Ahmed Barro⁷, Emmanuel Bonnet⁸, Sammy M.
11 Njenga⁶, Selidji Todagbe Agnandji³, Seydou Yaro⁹, Neal Alexander¹⁰, In Kyu Yoon¹
12
13

14 ¹International Vaccine Institute, Seoul, Korea, Republic of; ²Montreal School of Public
15 Health (ESPUM), Montreal, QC, Canada; ³Centre de Recherches Médicales de Lambaréné,
16 Hôpital Albert Schweitzer, B.P. 118, Lambaréné, Gabon; ⁴Communicable Disease Prevention
17 and Control, Ministry of Health, Nairobi, Kenya; ⁵Institute of Tropical Medicine, University
18 of Tübingen, Germany; ⁶Eastern and Southern Africa Centre of International Parasite Control
19 (ESACIPAC), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; ⁷AGIR,
20 Ouagadougou, Burkina Faso; ⁸Institut de Recherche pour le Développement (IRD), Paris,
21 France; ⁹Centre Muraz, Bobo-Dioulasso, Burkina Faso; ¹⁰Epidemiology and Public Health
22 Department, London School of Hygiene and Tropical Medicine
23
24

25 *Corresponding author

26 Jacqueline K. Lim^{1*}, MPH

27 Research Scientist

28 Global Dengue and Aedes-transmitted Diseases Consortium (GDAC)

29 International Vaccine Institute (IVI)

30 SNU Research Park, Gwankak-ro 1

31 Gwanak-gu, Seoul, Korea 151-191

32 T: +82-2-881-1340 (Dir) / +82-2-872-2801 (ext. 340)

33 Email: kalim@ivi.int
34
35

36 36 pages

37 Word count of the text: 6,422 (not counting the Abstract)

38 Word count of the abstract: 320

39 Figures and tables: 6 figures and 1 table
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction.

Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardized methods were launched in three locations in Africa.

Methods and Analysis.

In 2014-17, the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; to obtain comparable incidence data on dengue and assess its burden through standardized hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys, and healthcare utilization surveys. All three sites conducted case detection using standardized procedures with uniform laboratory assays to diagnose dengue. Healthcare utilization surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between dengue and non-dengue patients using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3,000 randomly selected residents at each site at 6 month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test.

Ethics and Dissemination.

The protocol for each study obtained ethical approvals from the Institutional Review Boards of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions. By standardizing methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals by the end of 2017.

Strengths of this study

- There have not been population-based studies conducted with a multi-disciplinary approach (i.e. surveillance, healthcare utilization, and sero-survey in one catchment area population). Data from the passive surveillance will be used to calculate annual incidences of dengue and data from the serosurvey will estimate force of infection and prevalence.
- The studies were conducted in three locations in Africa, based on standardized methods and laboratory algorithm. Thus, comparison by site would be possible.

Limitations of this study

- 1
2
3
4 - This is not a cohort study. The passive facility-based surveillance may lead to under-
5 estimation of the burden of dengue fever by measuring incidence based on only those
6 that sought care at our study facilities.
7
8 - There may be limited generalizability of our study results to other dengue-endemic
9 parts of Africa.
10

11
12 Keywords: dengue; Africa; seroepidemiologic Studies; incidence
13

14 Running head: Evaluating dengue burden in Africa: DVI field studies
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Dengue fever, a mosquito-borne flavivirus infection caused by four related but antigenically distinct dengue viruses (DENVs, serotypes 1–4), is a major and rapidly increasing global public health problem. Recent studies have estimated an annual incidence of 50–100 million symptomatic infections globally¹. Dengue is a high burden disease that disproportionately affects countries in the tropics and subtropics, many of which have limited health care resources². Although one dengue vaccine has been recently licensed in several endemic countries, the vaccine has restricted age and epidemiological indications. Other prevention and control measures such as vector control are suboptimal as stand-alone interventions^{3,4}, and no drugs for treatment are currently available.

Like in Asia and the Americas, there were reports of multiple epidemics of dengue in Africa in 1779-1780⁵. Specifically for Africa, there are records of multiple dengue case reports between 1964 and 1968 with DENV 2 in Nigeria⁶. Data from several studies conducted in the 1960-70s in Nigeria supported a substantially high level of immunity in adults as well as children^{7,8}. In 2011, Amarasinghe et al. conducted a comprehensive review of literature on dengue in Africa and described that dengue cases have been reported in 34 countries in Africa, with most of these countries also having *Aedes* mosquitoes⁹. However, prior studies which suggested the presence of dengue in Africa were limited by their retrospective design or sample collection (blood donors or sample collected from surveys of other diseases), and often from travellers, with a small number of reported autochthonous cases, to demonstrate the true, population-based, burden of dengue. Also, while many dengue endemic countries in Asia and Latin America have mandatory reporting of dengue cases to public health authorities, and national surveillance systems in place to monitor incidence patterns¹⁰, most African countries lack such established reporting mechanisms and only

1
2
3
4 sporadic outbreaks and individual case reports have been documented. In addition, the
5 frequently non-specific clinical presentation of dengue may be difficult to distinguish from
6 the myriad other infectious diseases present in Africa, since dengue diagnostic assays are not
7 widely available. Thus, the burden of dengue remains largely unknown in Africa^{9 11}. Without
8 such dengue burden data, informed decision-making about prevention and control measures,
9 including dengue vaccine introduction, in Africa are not possible.

10
11
12
13
14
15
16
17
18 Limited by surveillance capacity hindering continuous reporting in the region, there
19 had not been frequent and systematic reporting of dengue in Africa. African ancestry is
20 known to be protective against severe dengue and the candidate genes were recently
21 identified in Cuban patient^{12 13}. Bhatt et al.'s modelling of global dengue burden suggests
22 high burden of dengue in Africa in terms of equal numbers of, both apparent and inapparent,
23 infections as that of Latin America¹. There are new findings about dengue in Africa, but there
24 is still much unknown about the magnitude of dengue problem in the continent. To improve
25 estimates of population-based dengue disease burden in Africa and validate whether the
26 undocumented burden of dengue is as high in Africa as in the Americas with empirical data,
27 the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in West, West-
28 Central, and East Africa in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa,
29 Kenya; respectively. In each of the three sites, a standardized package of study components,
30 including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-
31 illness surveys, and serological surveys (Fig 1), was initiated between December 2014 and
32 March 2016.

33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Methods

Site selection

1
2
3
4 Study sites were selected, in part, based on their likelihood of supporting DENV
5 transmission. In site selection, we considered dengue outbreaks and cases reports in the
6 literature, available seroprevalence studies, as well as country-specific dengue risk maps of
7 the probability of DENV transmission and the level of evidence of dengue presence reporting
8 the uncertainty of the consensus estimates of dengue in Africa ^{6 14}. In addition, adequate
9 research infrastructure to implement the studies was taken into account. Finally, inclusion of
10 different regions of Africa was also a factor in site selection. Thus, Ouagadougou, Burkina
11 Faso; Lambaréné, Gabon; and Mombasa, Kenya; were selected, respectively, to measure the
12 true burden of dengue in selected sites from West, (West-) Central, and East Africa.
13
14

15
16 In Burkina Faso, the first reported dengue outbreak occurred in Ouagadougou in
17 1982 due to DENV-2 ⁹. Serological prevalence of dengue was found to be 26.3% in a rural
18 setting (Nouna village) and 36.5% in an urban setting (Ouagadougou) in 2006 ¹⁵. More
19 recently, an observational study conducted by Ridde et al. among febrile patients consulting
20 at selected study facilities in 2013-14 showed 8.7 % (33/379) to be positive by dengue RDT;
21 and 15 of 60 samples tested by RT-PCR to be dengue positive ¹⁶. With evidence for the
22 presence of dengue, along with a strong health and demographic surveillance system (Ouaga-
23 HDSS) which could be used to describe the demographic characteristics of the catchment
24 area, a field study was initiated in Ouagadougou, Burkina Faso in December 2014.
25
26

27
28 In Gabon, cases of dengue hemorrhagic fever (DHF) caused by up to three different
29 DENV serotypes have been reported, and dengue seroprevalence has been found to be
30 between 5 and 20% ¹⁷⁻¹⁹. Results of a recently published study demonstrated seroprevalence
31 of 12.3% among toddlers approximately 30 months of age in semi-rural Lambaréné between
32 2007 and 2010 ²⁰. However, a different study in 2005-2008 suggested minimal DENV
33 transmission in rural areas of Gabon ²¹. This latter study examined antibodies against dengue
34 in individuals from randomly selected villages representing about 10% of all Gabonese
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

villages. Blood samples were tested by anti-DENV IgG and IgM capture ELISA and found to have only minimal IgG (0.5%) and IgM (0.5%) seroprevalence. Based on these low prevalences, authors concluded that there was no active circulation of DENV in rural Gabon. However, the low seroprevalence may have been affected by low sensitivities of the tests used leading to a high rate of false negative, and/or selection bias in the blood sample pool among the selected villagers²². Seroprevalence estimates may have also been impacted by the possibility of false-positive results due to IgG cross-reactivity among flaviviruses²¹. Nevertheless, given the possibility of DENV circulation in Gabon, a field study was initiated in Lambaréné in March 2015 in a community with a catchment population of about 77,000 residents, using the clinical research infrastructure of the Centre de Recherches Medicales de Lambaréné (CERMEL), benefiting from experienced research staff who conducted a large Phase 3 malaria vaccine trial^{23 24}.

In Kenya, more evidence is available for the presence of dengue based on local data. Dengue was the most common viral pathogen in retrospectively tested blood specimens from HIV-negative survey samples from the 2007 Kenya AIDS Indicator Survey. Antibody testing for dengue as well as chikungunya and Rift Valley fever was performed by IgG ELISA using either commercial kits or CDC assays; 12.5% were found to be dengue positive²⁵. Similarly, a household survey found 13% of individuals from 701 households in Mombasa had serological evidence of either past or current DENV infection²⁶. These data suggest that there is more dengue in Kenya than indicated by public health reporting, possibly due to misdiagnosis^{25 26}. A field study was initiated in Mombasa, Kenya in March 2016.

Study participants

For the passive facility-based fever surveillance, individuals who met the following criteria were eligible for study enrollment:

- 1
- 2
- 3
- 4 1. Age 1- 55 years old;
- 5
- 6 2. Resident of the catchment area covered by healthcare facilities participating in the
- 7 study, without plans to move out of the catchment area within 12 months;
- 8
- 9
- 10 3. Signed informed consent, and assent for those aged between 7 and 18 years; and
- 11
- 12 4. Patients presenting with current fever (axillary temperature $\geq 37.5^{\circ}$ C) or history of
- 13 fever for ≤ 7 days duration without localizing signs (fever caused by a localized
- 14 infection as well as fever with a known and confirmed etiology other than dengue,
- 15 such as malaria confirmed by malaria RDT- listed in the patient identification SOP).
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24

25 For the serological survey, criteria 1-3 were applied. For the healthcare utilization
26 survey, household interviews were conducted among the heads or representatives of the
27 household invited from each family participating in the serosurvey.
28
29
30
31

32 *Study area and population*

33
34
35
36 Burkina Faso, located in West Africa, has a population of 14,017,462 with 22.7%
37 living in urban areas. The country is mainly rural with about 29% of the population reported
38 to be living in urban areas in 2014. However, Burkina Faso is urbanizing rapidly and is
39 positioned as the country with the fourth fastest urbanization in the last 25 years^{27 28}. The
40 capital, Ouagadougou, has a population of 2,741,128. The majority of the population live in
41 urban settings. About 45% of the population are under 15 years of age²⁹. The city is divided
42 into 12 districts and 52 sectors. Ouagadougou is the country's largest city and the cultural and
43 economic center. The city is part of the Soudano-Sahelian area, with a rainfall of about 800
44 mm per year. The rainy season is from May to October, with a mean temperature of 28 °C
45 (82 °F). The cold season runs from December to January, with a minimum average
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 temperature of 16 °C (61 °F). During the hot season, which runs from March to May, the
5
6 temperature can reach as high as 43 °C (109 °F).
7

8
9 The Health and Demographic Surveillance System is in place in Ouagadougou.
10
11 Ouaga HDSS monitors a population of 81,717 residents; according to this surveillance
12
13 system, the city population is very stable with a rate of migration of 4.1% and more than 80%
14
15 of the inhabitants with ownership of their houses [20]. A map of the city and distribution of
16
17 the population is shown in Figure 2.
18
19

20
21 Gabon, located on the west coast of Central Africa, has an area of nearly 270,000
22
23 square kilometres (100,000 sq. mi) with a population estimated at 1.5 million. Its capital and
24
25 largest city is Libreville. In 2014, it is reported that 87% of the Gabonese population lived in
26
27 urban areas²⁸. The sixth largest city, Lambaréné, the capital of Moyen-Ogooué, is located 75
28
29 kilometers south of the equator, with a population of 25,257 in 2009. The majority of
30
31 Lambaréné residents live in semi-rural areas. About 42% of the Gabonese population is under
32
33 15 years of age²⁹. Similarly, Lambaréné's population is relatively young with about 50%
34
35 under 20 years of age.
36
37

38
39 The health services of Gabon are mostly public, but there are some private
40
41 institutions as well. With one of the best medical infrastructure in the region, almost 90% of
42
43 the population have access to health care services. Albert Schweitzer Hospital (ASH) is a
44
45 private institution which served as a study site for the passive fever surveillance study^{30 31}.
46
47 The study area in Lambaréné is shown in Figure 3.
48

49
50 Kenya, located in East Africa, lies on the equator, covering 581,309 km²
51
52 (224,445 sq. mi), with a population of approximately 45 million people in 2014 [2]. Kenya
53
54 generally has a warm and humid tropical climate, but is diverse ranging from the cooler
55
56 climate around the capital city, Nairobi, to a hot and dry climate inland, as well as a desert-
57
58
59
60

1
2
3
4 like climate in the north-eastern regions along the border with Somalia and Ethiopia ³². The
5
6 capital, Nairobi, is a regional commercial hub. The main industries include agriculture,
7
8 exporting tea and coffee, as well as the service industry.
9

10
11 Kenya is divided into 47 semi-autonomous counties. Mombasa is the country's
12
13 second largest city after Nairobi and is located on the east coast of the country [2].
14
15 Administratively, Mombasa is the capital of Mombasa County, what was formerly called
16
17 Coast Province. This overall Coast region covers over 80,000 km² in the south-eastern part of
18
19 Kenya, constituting about 15% of the country's land area, with a population of 3,325,307
20
21 residents.
22

23
24 The main driver of economy of Mombasa is tourism and trading industry. Mombasa
25
26 itself has a population of about 1.3 million with almost 50% of the population under 15 years
27
28 of age ²⁹. Increasingly, the population of the province lives in urban areas; at present about 45%
29
30 live in Mombasa and other urban centers. The long rains begins around April and the short
31
32 rains begins in October ³². Mean annual temperature ranges from 24°C to 27°C, but
33
34 maximum temperature averages over 30°C during the hottest months, January to April.
35

36
37 Figure 4 shows the area of Mvita subcounty of Mombasa, which was the catchment
38
39 area for the study in Kenya, with a catchment population of 74,735 residents. The map
40
41 indicates the three facilities involved in the study.
42

43 44 45 46 *Sample size*

47
48 Given the paucity of available age-specific dengue incidence data in the study
49
50 countries or nearby countries, it was difficult to obtain population-based incidence to make
51
52 assumptions when calculating sample sizes. The required catchment population for the
53
54 passive facility-based fever surveillance was roughly estimated based on the limited data
55
56 available in the literature. Annual incidence estimates were calculated based on available
57
58
59
60

1
2
3
4 prevalence estimates with the assumption that the outcome of interest has zero prevalence at
5
6 age zero, and that force of infection is constant. It was assumed that prevalence estimates
7
8 found for one particular age group would be adjusted as the annual incidence and used across
9
10 all ages.

11
12 Wichmann et al. calculated an expansion factor for children by comparing data from
13
14 three cohort studies to national surveillance data in Southeast Asia³³. For children in
15
16 Thailand, the age-specific expansion factors calculated were 11.85 for <5 years, 8.76 for 5-9
17
18 years, and 7.81 for 10-14 years³³. The results show that, even for Asia where better reporting
19
20 and surveillance systems are available, there is a considerable degree of underreporting. For
21
22 Africa, such information on extent of under-reporting of dengue was not available. Also, the
23
24 estimates used in our sample size calculations were not from population-based studies. While
25
26 it would have been ideal to adjust the incidence further for likely underestimation, the annual
27
28 incidence used in sample size calculations could not be adjusted for possible under-reporting
29
30 due to the lack of data. The sample sizes were calculated with 95% confidence levels and a
31
32 margin of error at a fixed significance level within 25% of the true proportion of incidence.
33
34 This gives relative precision of 75%, considering the gap in evidence for dengue incidence in
35
36 the study areas. The final sample sizes were calculated by assuming 20% non-response rate
37
38 or loss to follow-up. The required catchment population size for the fever surveillance study
39
40 in Burkina Faso was estimated to be 100,000, Gabon to be 77,000, and Kenya to be 70,000.
41
42 In these catchment populations, the number of enrolled subjects depends on the number of
43
44 eligible patients who seek care at the study facilities. How many eligible febrile episodes
45
46 would actually present at our study facilities was difficult to predict; but after assessment of
47
48 the volume of febrile patients at the facilities, a realistic upper limit for enrollment for a study
49
50 period of approximately 1.5 years was set at 3,000 subjects to offer enrollment to all
51
52 consenting eligible patients.
53
54
55
56
57
58
59
60

1
2
3
4 For the serological survey, the sample size was calculated similarly using the
5 prevalence proportion based on published literature. Seroprevalence of 0.304 for Burkina
6 Faso ¹⁵, 0.123 for Gabon ²¹, and 0.144 for Kenya ³⁴ were used. With the same confidence
7 levels and allowed margin of error, and assuming 10-30% (variable by site) non-response rate,
8 the sample size was calculated to be 3,000 participants at each site. Again, with the scarcity
9 of data from the selected countries, there were no other prevalence estimates reported or
10 estimates from different age groups. As prevalence is expected to increase with age, and
11 higher prevalence would give a smaller sample size, our calculations are likely to be
12 conservative.
13
14
15
16
17
18
19
20
21
22
23

24 *Study components*

25 Fever surveillance – design and methods

26
27
28
29 To determine burden due to symptomatic dengue in each of the three sites in Burkina
30 Faso, Gabon, and Kenya, passive facility-based fever surveillance was implemented in a
31 well-defined catchment area population. In Burkina Faso, the surveillance study was initiated
32 in December 2014 in five selected primary health care centres, locally called “Centre de
33 Santé et de Promotion Sociale” (CSPS), in the municipality of Ouagadougou, with a
34 catchment population of 105,000 residents. This project was implemented in collaboration
35 with Centre Muraz in Bobo-Dioulasso, EQUITE sante program (a collaborative program
36 between University of Montreal and Action-Gouvernance-Integration-Reinforcement, AGIR,
37 based in Ouagadougou, funded by Canadian Institute of Health Research), and DVI. In
38 Gabon, the surveillance study was initiated in the Albert Schweitzer Hospital serving a
39 catchment population of 130,000 residents in the Moyen-Ogooué and surroundings within
40 Lambaréné, in collaboration with CERMEL and Institute of Tropical Medicine in Tubingen,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Germany. In Kenya, the surveillance study was implemented at Ganjoni dispensary, Tudor
5 sub-county Hospital, and Coast Provincial General Hospital, serving a catchment population
6 of 70,000 residents in Mombasa, in collaboration with Kenya Medical Research Institute
7 (KEMRI) and Ministry of Health of Kenya.
8
9

10
11
12 As described in Figure 5, both outpatients and inpatients at the designated study
13 facilities, who meet inclusion criteria as mentioned earlier are tested for dengue, first with SD
14 Dengue Duo[®] RDT. Dengue confirmation is done by detection of dengue virus in serum
15 samples using PCR, as well as anti-dengue IgM and IgG antibodies in acute and convalescent
16 serum by ELISA (SD Dengue IgM & IgG capture ELISA[®] tests, Standard Diagnostics,
17 Yongin-Si, Korea)^{35 36}. Every consecutive patient meeting inclusion criteria is eligible for
18 enrolment during the study period. Infants < 1 year old were not included due to operational
19 limitations, such as difficulty of infantile bleeding.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 In Ouagadougou, Burkina Faso, the fever surveillance initiated in December 2014
35 continued until February 2017 (approximately 2 years). In Lambaréné, Gabon, the fever
36 surveillance initiated in April 2015 continued until January 2017 (approximately 1.5 years).
37 In Mombasa, Kenya, the fever surveillance initiated in March 2016 will continue until June
38 2017.
39
40
41
42
43
44

45 Among subjects enrolled in the fever surveillance, those who are positive by dengue
46 rapid diagnostic test are offered further enrolment in the cost-of-illness survey, consisting of
47 interviews on the day of acute illness visit, day 10-14 from the first visit, and day 28, if
48 illness continues. The cost-of-illness survey questionnaire was designed to estimate the direct
49 medical, direct non-medical, and indirect costs associated with dengue-positive patients
50 identified at study facilities. This survey also estimates the cost of treating dengue at the
51
52
53
54
55
56
57
58
59
60

1
2
3
4 facility level. Data are gathered by linking patients' medical records concerning outpatient
5 visits, inpatient visits, and service consumption (e.g., diagnostic tests, medication, and other
6 services provided to patients). The cost-of-illness portion of the study will be described
7 separately.
8
9
10
11

12 Fever surveillance – laboratory testing

13
14
15
16
17
18 As shown in Figure. 6, in all three sites, acute samples are tested using a commercial
19 RDT for dengue NS1 and IgM/IgG (Dengue Duo[®], Standard Diagnostics, Yongin-Si, Korea).
20 Dengue Duo RDT is used on the day of acute illness visit at the site of patient presentation
21 (day 1). The acute and convalescent samples are subsequently tested at a local laboratory
22 using dengue IgM/IgG ELISA (SD Dengue IgM & IgG Capture ELISA[®], Standard
23 Diagnostics, Yongin-Si, Korea). The serum is separated and stored in 4 aliquots of about 500
24 μ L for various lab tests, as indicated in consent documents.
25
26
27
28
29
30
31
32
33

34
35 After ELISA testing, samples will be shipped to IVI in Korea. Samples with positive
36 results by RDT or ELISA undergo further testing by RT-PCR at the Clinical Immunology
37 Laboratory of IVI. Four DENV serotype-specific real-time RT-PCR assays are used for
38 laboratory confirmation of dengue and serotyping³⁷. The DENV 1-4 RT-PCR assays are
39 carried out in 25 μ L reaction mixtures containing 5 μ L template RNA, TagMan[®] Fast Virus 1-
40 step mastermix (Applied Biosystems[®]), 0.9 μ M of each primer, and 0.2 μ M probe³⁷.
41
42
43
44
45
46
47
48
49

50 Amplification and detection are performed in a StepOne Plus real-time PCR system and the
51 baseline and threshold are determined using the auto-baseline and threshold feature in
52 StepOne Software v2.2.2 (Applied Biosystems[®]). Thermocycling parameters are as follows:
53 reverse transcription at 50 °C for 5 min, inactivation at 95 °C for 20 s, followed by 45 cycles
54
55
56
57
58
59
60

1
2
3
4 of fluorescence detection at 95 °C for 3 s, and annealing at 60 °C for 30 s³⁷. A specimen is
5
6 considered positive if target amplification was recorded within 40 cycles.
7
8
9

10 Serological survey – design and methods

11
12
13
14 While the facility-based fever surveillance studies provide estimates of the burden of
15 medically-attended dengue disease, evaluation of all DENV infections in a population –
16 including subclinical and mildly symptomatic infections, which impact immune status – is
17 needed to capture the overall impact of dengue. As part of the study package, population-
18 based serological surveys were conducted in the same catchment population used for the
19 fever surveillance. At each of the three sites in Africa, the serosurvey was conducted on a
20 cohort of approximately 3,000 randomly selected residents of urban and semi-urban parts of
21 Ouagadougou, Lambaréné, and Mombasa. Without individual-level census information on all
22 residents of Lambaréné and Mombasa, with help of community/village health workers,
23 randomization was done based on neighbourhoods (or defined areas for which the health
24 workers/volunteers are responsible) as cluster units. As the community/village health workers
25 are familiar with the villages and their residents, they are good entry points into the
26 communities. With these health workers, the field team screened houses in the selected
27 villages by knocking on doors of every 5~7 houses, depending on the household density per
28 neighbourhood. Also, demographic information collected in previous research projects
29 conducted in the same area was used as a guide, if available. In the case of the site in
30 Ouagadougou, HDSS data were available and the EQUITE SANTE, a CIHR funded research
31 program of University of Montreal had set up a geographic information system (GIS)
32 database system of houses in the study area. Using these data, households of potential
33 enrollees of the serosurvey were pre-selected randomly and household visits were made in
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Ouagadougou. In the three sites, about 45% of the serosurvey samples were targeted to be
5
6 collected from children 1 - 14 years-of-age, and 55% were targeted to be collected from
7
8 adults between 15 and 55 years of age to reflect the age distribution of the general population
9
10 of the area. Household-based enrollment was offered to the head of the household until the
11
12 specific cap for the age-group was reached in Lambaréné and Mombasa.

13
14
15 Randomly-selected subjects 1-55 years of age underwent phlebotomy (5ml for
16
17 children and 7ml for adults) twice — during pre-transmission (before the rainy season) and
18
19 post-transmission (after the rainy season) at 6 month intervals. The sera were evaluated using
20
21 IgG indirect ELISA at baseline and after 6 months. The presence of dengue IgG antibodies at
22
23 6 month intervals will be used to estimate the level of occurrence of inapparent DENV
24
25 infection and to calculate the rate of infection in the catchment population. Flow cytometry-
26
27 based DENV neutralization assays will be applied to a subset of samples to assess for
28
29 presence of dengue neutralizing antibodies and seroconversion over the 6 month interval. In
30
31 addition to overall seroconversion, age-specific seroconversion estimates in the catchment
32
33 population, as well as the proportion of inapparent infections, are determined.
34
35
36
37
38
39

40 Serological survey – laboratory testing

41
42 From the samples collected in the serosurvey, about 200 µL of serum are used and
43
44 tested at a local laboratory using dengue IgG ELISA (Panbio Dengue IgG Indirect ELISA[®],
45
46 Alere North America, LLC, Florida, United States). After ELISA testing for dengue IgG at
47
48 the local labs, samples will be shipped to IVI. Given potential serological cross-reactivity
49
50 among flaviviruses³⁸, flow cytometry-based neutralization assays will be performed against
51
52 selected flaviviruses to include yellow fever virus, West Nile virus, Zika virus, and Japanese
53
54 Encephalitis virus at the Clinical Immunology Lab of the International Vaccine Institute (IVI),
55
56
57
58
59
60

1
2
3
4 Seoul, Korea ^{39 40}. About 50 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in
5
6 Gabon and Kenya will be tested.
7

8
9 About 1,000 μ L of serum is kept aside for this procedure. The flow cytometry-based
10 neutralization assays are performed in duplicate in 96-well cell culture plates with flat-bottom
11 wells, each containing DC-SIGN-expressing U937 cells ³⁹. The amount of virus used in the
12 assay infects between 7 and 15% of the cells. Human immune sera are serially diluted and the
13 virus is pre-incubated with the sera for 1 h at 37°C ³⁹. The cells are washed, and the virus and
14 serum mixture is added to the cells for 1 h at 37°C, and the cells are further incubated for 24
15 to 48 h at 37°C in 5% CO₂. The cells are fixed, permeabilized, and stained with fluoresce-
16 conjugated monoclonal antibody 4G2, which recognizes the flavivirus E protein ⁴¹. FACScan
17 flow cytometer (Becton Dickinson, San Diego, CA) is used to analyze the cells ³⁹. The serum
18 dilution that neutralized 50% of the viruses is calculated by nonlinear, dose-response
19 regression analysis with Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).
20
21
22
23
24
25
26
27
28
29
30
31
32

33 In addition, a Luminex-based multiplex immunoassay will be performed on a
34 randomly selected sub-sample to assess for IgG to different flaviviruses ⁴². About 200
35 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in Gabon will be tested.
36
37 Detection of IgG against ZIKV and each the four DENV serotypes was performed on patient
38 serum samples using an in-house microsphere-based multiplex immuno-assay (arbo-MIA) at
39 the Clinical Immunology Lab of IVI ^{43 44}. The arbo-MIA is based on a mixture of
40 microspheres covalently coupled with either DENV-1, -2, -3, -4 or ZIKV recombinant
41 antigens (E protein domain III) produced in Drosophila S2 expression system. Briefly,
42 microsphere mixtures were sequentially incubated in the dark under constant shaking with a
43 1:400 dilution of patient serum samples, with 2 μ g/mL anti-human IgG biotin-conjugated
44 antibody (Jackson ImmunoResearch, West Grove, PA) and with 2 μ g/mL streptavidin-R-
45 phycoerythrin conjugate (Life technologies). After the final incubation, the median
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 fluorescence intensity (MFI) of each microsphere set was quantified using a BioPlex 200
5
6 instrument (Bio-Rad Laboratories, Hercules, CA). Samples were considered seropositive if
7
8 the ratio of MFI values obtained for the viral antigen to the control antigen was superior to
9
10 the defined cut-off. The cut-off of the MIA was determined for each viral antigen by ROC
11
12 curve analysis using well characterized sera.
13

14
15 In Lambaréné, the enrolment bleed, took place in November -December 2015 with
16
17 2nd blood collection in May 2016. In Ouagadougou, the enrolment bleed took place in May-
18
19 June 2015 with follow-up blood collections in December 2015, June 2016, and January 2017.
20
21 In Mombasa, enrolment bleed took place in May 2016 with the 2nd blood collection in
22
23 November 2016 – February 2017.
24
25

26 27 28 Healthcare Utilization Survey 29

30
31 As the passive fever surveillance is conducted at the study facilities, potential dengue
32
33 patients could be missed if they seek care elsewhere. To identify the proportion of fever and
34
35 dengue cases potentially missed by the passive surveillance system due to patients living in
36
37 the study area but seeking care outside of study facilities, a population-based healthcare
38
39 utilization survey was conducted in 400 randomly selected households from the study
40
41 catchment area to characterize their healthcare utilization patterns of the households when
42
43 they have (self-reported) febrile episodes among the family members. In addition to assessing
44
45 health-seeking behaviours of the residents, preferences in terms of health-seeking behavior
46
47 and respective reasons for their preferences were investigated. The questionnaire was
48
49 administered to 400 heads of households. Among 3,000 residents who participated in the
50
51 serosurvey, there were about 600 households. From these households, 400 heads of
52
53 households were randomly selected and offered enrolment in the health utilization survey.
54
55
56
57
58
59
60

1
2
3
4 Heads of households or a senior representative within the household were asked questions on
5
6 health seeking patterns of their family members. The surveys provide data to determine the
7
8 proportion of these cases missed by our passive fever surveillance system. Also, the surveys
9
10 document health seeking patterns, who would seek care at which facilities, who would make
11
12 health-seeking related decisions, and the reasons for their preferences.
13

14 15 16 17 *Study questionnaires*

18
19 For the fever surveillance study, questionnaires are administered at the acute illness visit and
20
21 the convalescent visit. The convalescent visit may take place at the health care facility (10-14
22
23 days later) or at the patient's home (15-21 days after the acute visit), according to patient
24
25 preference and availability. The questionnaires are completed by medical staff of the study
26
27 facilities, including demographic and clinical information (e.g., signs, symptoms, past
28
29 medical history, treatments prescribed, and diagnoses). The same staff also complete the
30
31 follow-up questionnaire at the convalescent visit within 21 days from the acute visit. Study
32
33 nurses complete surveillance enrolment log. Lab technicians complete the lab section (mostly
34
35 dengue-related diagnostics) and the forms are compiled by the study coordinator on site.
36
37

38
39 For the serosurvey component, questionnaires are administered at the household by trained
40
41 field team staff at each serosurvey visit. Study nurses complete the questionnaire after a brief
42
43 physical and medical examination. There are (a) follow-up visit(s) in about 6 months and the
44
45 same staff make the household visits to complete the follow-up questionnaire. Enrolment log
46
47 is maintained by our study coordinator on site.
48
49

50 51 52 53 *Variables of the surveillance questionnaires*

54
55
56
57 The variables collected are listed in table 1.
58
59
60

Table 1. List of variables collected in the passive fever surveillance data collection form

Topic	Description	Items
Basic information	Demographic and basic information about the patient and the treatment received	Type of treatment where patient is enrolled (IPD vs. OPD) Date of fever onset, duration of fever Current temperature Tourniquet test results Patient's address (district and village-level) Date of visit, date of birth, age, and sex Weight and height
General health condition	Current condition of the patient (self-report) and underlying diseases of the patient	How well the patient could handle daily activities Pre-existing conditions
Signs and symptoms during this illness	A set of sign and symptoms that may be related to fever and dengue (DF and DHF)	Rash, fatigue, headache, retro-orbital pain, neck/ear pain, sore throat, breathing difficulty, cough, expectoration, gastrointestinal signs (Nausea/vomiting, diarrhea, abdominal pain, etc.), hemorrhagic signs (nose/gum bleeding, ecchymosis, petechiae, etc.), signs of shock (cyanosis, capillary refill), arthralgia, myalgia, loss of appetite, jaundice, etc.
Medical History:	Previous dengue-related or other flavivirus infection as well as vaccination history (self-report)	Previous dengue infection and related hospitalization Previous infection to other commonly circulating arboviral infection in the area Yellow fever vaccination history
Laboratory findings	Records from the routine laboratory tests widely used in clinical fever/dengue patient management, as part of the hospital care procedure	Platelet count, hematocrit, haemoglobin, leukocytes, neutrophils, protein level, AST, ALT, urine test results, etc.
Clinical Diagnosis	Clinician's diagnosis with or without referring to the RDT	Diagnosis given by the physician based on clinical presentation after physical examination of the patient.
Dengue testing results	Results from the dengue tests, mainly RDTs for dengue as well as other commonly circulating arbovirus in the area	Dates of blood draw Test results of the RDT IgM/IgG capture ELISA results PCR results (if available)
Treatment	Medicine(s) prescribed and the starting and end dates	Antibiotics, paracetamol, ibuprofen, aspirin, and others that may be site-specifically prescribed
Outcome	Outcome of this particular visit	Hospitalized, returned home, or

		referral
Hospitalization	Information collected only among hospitalized patients in the surveillance to record other severe signs and progression of illness	Admission and discharge diagnoses Presence of haemorrhagic signs or shock syndrome
Hospital Charges	Expenses and hospital charges incurred by patient on the visit 1	Amount of the out of pocket payment by the patient or the family/or guardian Breakdown of the hospital charges (laboratory, medication, admission-related charges)
Final outcome	Outcome of the patient's illness at the 2 nd visit	Final diagnosis given for the patient outcome of illness Completion of study participation (early termination and the reason, etc.)

Planned statistical analysis

From the fever surveillance data, incidence of symptomatic dengue among patients that seek health care at the study facilities will be calculated. Age-specific incidence rates in all the children and adults will be determined by referring to the size and distribution of the general population of the study area at the time of surveillance as the denominator in calculation of the incidence of symptomatic dengue cases. Each person residing in the study area is assumed to contribute 12 months of person time to the denominator. Although the study areas all report a low migration rate, the in-migration is assumed to balance the out-migration of the population during the study period. Age-specific incidence of symptomatic dengue will be calculated by using age-specific denominators and the number of symptomatic dengue cases in eligible individuals as the numerator.

Using the data collected in the Healthcare Utilization Survey, the proportion of febrile cases missed by the passive surveillance system will be determined. Then using the proportion, the numerator will be further adjusted in recognition of those missed fever cases

1
2
3
4 from the study area, which could have been dengue. Also, comparison will be made between
5
6 those that agreed to participate and those that declined participation among the eligible
7
8 potential enrollees. The enrollment log, which recorded basic information obtained during the
9
10 screening process of potential enrollees, will be reviewed. In addition to checking that our
11
12 sample of febrile cases is representative of febrile patients of the general population in the
13
14 catchment area, refusal rates will be determined based on information in the log. Then, the
15
16 refusal rates will be used to adjust the numerator.
17
18

19
20 SPSS software will be used for analysis of the fever surveillance data. Multivariable
21
22 logistic regression will be used to compare confirmed dengue patients versus non-dengue
23
24 febrile patients in terms of symptomatic presentation, based on signs and symptoms collected
25
26 from all patients with laboratory-confirmed dengue by serology and RT-PCR, adjusting for
27
28 possible confounders, such as age, days since onset of fever, primary vs. secondary infection,
29
30 inpatient vs. outpatient, etc. Differences in symptomatic complex of DF (and DHF, if data
31
32 allows) by age and serotype will be also determined using multivariable logistic regression.
33
34

35
36 As outpatient disease accounts for the greater part of dengue disease burden, clinical
37
38 profile of individuals with DENV infection will be characterized by the type of treatment
39
40 (hospitalized and outpatients), as well as by severity of the disease (severe vs. non-severe by
41
42 the 2009 WHO criteria)⁴⁵. Classification is determined after the course of illness is
43
44 completed (typically during the convalescent visit). Symptomatic dengue is classified as
45
46 outpatient or hospitalized. Progression of dengue is recorded in the CRF as DF, DHF I, DHF
47
48 II, DHF III or DHF IV and clinical patterns will be compared by the severity grade^{45 46}.
49
50 These will be compared to results obtained from other DVI studies in Latin America
51
52 (Colombia) and Asia (Thailand, Vietnam, and Cambodia). Overall, comparisons will be made
53
54 across Burkina Faso, Gabon, and Kenya.
55
56

57
58 With the age-stratified sera that reflect the age distribution of the general population
59
60

1
2
3
4 of the country, the serological survey sampling strategy ensures sufficient subjects to obtain
5
6 precise age-specific estimates of sero-positivity and sero-conversion of the catchment area
7
8 population. The sero-conversion rate and change in the immune status will be determined by
9
10 age group during the study period. The age-stratified serosurvey data will also allow
11
12 calculation of the force of infection of dengue in the study population. After enrolment, there
13
14 were subjects who drop out in the follow-up bleeds about 6 months later. Basic demographic
15
16 information will be compared between those that completed participation and those with
17
18 incomplete participation to check whether our sample represents the catchment area
19
20 population. Comparisons will be made among Burkina Faso, Gabon and Kenya.
21
22
23
24
25
26

27 *Ethical considerations*

28
29 To minimize inconvenience of the study to patients, clinicians and nurses were
30
31 sensitized and trained regarding the study requirements and procedures in order for data
32
33 collection to be integrated into routine patient care. The clinicians and nurses selected for the
34
35 study receive coordinated support from study field staff throughout the study process. Written
36
37 informed consent, and assent for participants 7 (13 for Kenya) -17 years of age, were
38
39 obtained from patients by study staff. Study staff go through consent and assent documents
40
41 for short summary of the disease, detailed description of study procedure, and information on
42
43 reimbursement. Patient data are documented in the study designated office and only the study
44
45 staff have access to the data that had been de-identified without any personal identifiable
46
47 information. Data are exclusively handled in the study office and stored safely in a protected
48
49 database in the study office as well as the DVI main server.
50
51
52
53

54 The protocol for each study obtained ethical approvals from the Institutional Review
55
56 Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and
57
58
59
60

1
2
3
4 Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI
5 Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and
6 Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB
7 of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and
8 the National Health Ethical Committee of Burkina Faso.
9
10
11
12
13
14

15 Discussion

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dengue cases have been detected since 1960's in Africa and there has been continued presence of the *Aedes* vectors in the continent^{5 6}. However, very few dengue studies have been conducted in Africa. Also, little evidence is from population-based studies⁹. Compared to the volume of evidence from SE Asia and the Americas, there is critical data scarcity on dengue in Africa. Suspicion of substantial dengue burden in Africa is based on limited reports of outbreaks and a handful of sero-prevalence studies testing different viruses among samples that likely do not represent the general population. In the three countries selected for our field studies, somewhat more data were available but were still very limited. In Burkina Faso, a recent observational study conducted in 2013 reported that 8.7% of the febrile patients showed positive results on dengue RDT¹⁶. In Gabon, one study suggested minimal DENV circulation in rural areas²¹, while a recent study reported 12.3% seroprevalence, by IgG antibodies against dengue, among toddlers 30 months of age in semi-rural parts of Lambaréné²⁰. In Kenya, about 13% of the individuals in Mombasa have been reported evidence of past or current DENV infection by RT-PCR and IgM anti-dengue ELISA after the 2013 outbreak²⁶. Despite the limited scope and generalizability of these studies, they suggest that there may be more dengue than previously appreciated due to underestimation and misdiagnosis^{25 26}.

These studies all indicate presence of dengue and some level of underlying sero-

1
2
3
4 prevalence in the countries of our field studies. However, often these studies are limited by
5
6 their retrospective design or sample collection (blood donors or sample collected from
7
8 surveys of other diseases) in terms of assessing the true, population-based, burden of dengue.
9
10 We proposed to address this gap by population-based dengue surveillance and sero-
11
12 prevalence studies in West, (West-) Central, and East Africa.
13
14

15 The present studies at three sites in Africa will provide important information on
16
17 undocumented DENV circulation in Africa. Such data will help to strengthen the evidence
18
19 base for dengue burden in Africa. Better defined disease burden data based on our studies
20
21 could be used to assess the relative need for dengue prevention and control measures, such as
22
23 whether a dengue vaccine would be a cost-effective public health intervention for countries in
24
25 Africa. Clinical findings from our studies could also be used as a guide for dengue case
26
27 detection and case management.
28
29

30 The studies have some important limitations. One potential source of bias in
31
32 estimating the incidence of symptomatic dengue is under-ascertainment due to the
33
34 community residents with relevant symptoms seeking care from other healthcare providers
35
36 and facilities than the facility under surveillance. As the study design remains passive
37
38 surveillance, cases are ascertained only at our study facilities. By estimating the proportion of
39
40 febrile patients seeking care elsewhere, as well as refusal rates among the potential enrollees
41
42 that were screened for eligibility criteria, the degree of fever patients missed by the study
43
44 facility will be determined. Inverse probability weighting will be used to account for these
45
46 potential subjects missed by the surveillance as adjustments in incidence calculation. Also,
47
48 depending on the transmission volume of dengue or other co-circulating diseases with onset
49
50 of fever there may be patients that are diagnosed with other diseases and ruled out of dengue.
51
52 These factors may increase the likelihood of under-reporting or over-reporting.
53
54
55
56
57
58
59
60

1
2
3
4 In addition, the sero-survey and healthcare utilization survey are conducted on a
5
6 randomized sub-sample of the catchment area population and there may be limited
7
8 generalizability of the data collected from these surveys. With unknown differences among
9
10 those that agree to participate and those that do not agree, the data may not be representative
11
12 of the general population of the study countries.
13
14

15 16 17 Conclusions

18
19 Data collection continues and study closure is planned in all three sites in April –
20
21 June 2017. Although not described in this paper, preliminary results indicate a substantial
22
23 level of dengue incidence and prevalence in each site. The data collected from our studies
24
25 will provide a more accurate assessment of the unknown dengue disease burden in Burkina
26
27 Faso, Gabon, and Kenya. These data can fill a gap in undocumented burden of dengue in the
28
29 region and, collectively, may be used to infer dengue burden in other areas of Western,
30
31 Central, and Eastern Africa. Countries in Africa may not consider introduction of a dengue
32
33 vaccine as the foremost priority in the near future due to many other competing public health
34
35 problems and limited resources as a major challenge. For cost-effective implementation of
36
37 public health interventions, accurate data on dengue burden from epidemiological studies
38
39 would be needed for policy makers to make evidence-based decisions on control and
40
41 prevention of dengue. Our studies will provide some much needed information based on
42
43 population-based research to assess dengue burden in Africa.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

List of abbreviations

GDAC - Global Dengue and *Aedes*-transmitted Diseases Consortium

IVI - International Vaccine Institute

DENV- dengue viruses

DVI - Dengue Vaccine Initiative

Ouaga-HDSS - health and demographic surveillance system

DHF - dengue hemorrhagic fever

CERMEL - Centre de Recherches Médicales de Lambaréné

ASH – Albert Schweitzer Hospital

CSPS - Centre de Santé et de Promotion Sociale

KEMRI - Kenya Medical Research Institute

SD – Standard Diagnostics

GIS = geographic information system

MFI - median fluorescence intensity

CRCHUM - Centre Hospitalier de l'Université de Montréal

Declarations

- Ethics approval and consent to participate

The protocol for each study obtained ethical approvals from the Institutional Review Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and the National Health Ethical Committee of Burkina Faso.

- Consent for publication

Not applicable

- Availability of data and material

Data sharing is not applicable to this article as no datasets were analyzed during the current study.

This manuscript does not include data from the studies described here in. This is a protocol paper. The datasets that are being generated for analysis as described in the current study are not yet publicly available as the studies are currently ongoing at the time of submission. They will be available from the corresponding author on reasonable request.

- Competing interests

The authors declare that they have no competing interests.

- Funding

The current study was supported by funds from the Bill and Melinda Gates Foundation (OPP 1053432). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

1
2
3
4 • Authors' contributions

5
6 JKL designed the study, is overseeing data collection, and was a major contributor in writing
7 the manuscript. MC co-designed the study, oversaw some parts of data collection, and
8 supported in writing of the manuscript. JSL was a contributor in designing of the study and
9 oversight of parts of data collection. KSL was a contributor in oversight of data collection.
10 SN supported in data collection. SKL supported in data collection. VR supported in designing
11 of the study and was a major contributor in finalization of the manuscript. JF was a
12 contributor in data collection. BL was a contributor in designing of the study and data
13 collection. SHM was a contributor in designing of the study and site establishment. ME was a
14 contributor in designing of the study. EA supported in data collection. NO supported in data
15 collection. AB supported in data collection. EB supported in data generation. SMN was a
16 contributor in designing of the study and site establishment. STA was a contributor in
17 designing of the study and site establishment. SY was a contributor in designing of the study
18 and site establishment. NA was a major contributor in providing oversight of the data
19 collection and finalization of the manuscript. IKY was a major contributor in designing of the
20 study and finalization of the manuscript.
21 All authors read and approved the final manuscript.
22
23
24

25
26
27 • Acknowledgements

28
29 We thank the doctors and laboratory staff of CSPS of Ouagadougou, ASH, Ganjoni
30 dispensary, Tudor sub-county Hospital, and Coast Provincial General Hospital, as well as at
31 Centre Muraz, CERMEL, and KEMRI. We thank collaborators at AGIR, IRD France, and
32 University of Montreal, and University of Tubingen. Lastly, we would like to thank the DVI
33 team and statisticians and administrative staff at the International Vaccine Institute for their
34 helpful comments during the preparation of this manuscript and support during the studies.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013;**496**(7446):504-7.
2. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. *Clin Epidemiol* 2013;**5**:299-309.
3. Chang M, Christophel E, Gopinath D, et al. Challenges and future perspective for dengue vector control in the Western Pacific Region, Regional Analysis. *Western Pacific Surveillance and Response Journal* 2011;**2**(2):9-16.
4. Eisen L, Beaty B, Morrison A, et al. Proactive Vector control strategies and improved monitoring and evaluation practices for dengue prevention. *J Med Entomol* 2009;**46**(6):1245-55.
5. Gubler D, Clark G. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* 1995;**1**(2):55-57. .
6. Messina JP BO, Scott TW, Zou C, Pigott DM, Duda KA, Bhatt S, Katzelnick L, Howes RE, Battle KE, Simmons CP, Hay SI. Global spread of dengue virus types: mapping the 70 year history. *Trends Microbiol* 2014;**22**(3):138-46.
7. Fagbami A, Monath T, Fabiyi A. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. *Trans R Soc Trop Med Hyg* 1977;**71**(1):60-5.
8. Carey D, Causey O, Reddy S, et al. Dengue viruses from febrile patients in Nigeria, 1964-68. *Lancet* 1971;**1**(7690):105-6.
9. Amarasinghe A KJ, Letson GW, Margolis HS. Dengue virus infection in Africa. *Emerg Infect Dis* 2011;**17**(8):1349-54. .
10. Beatty ME SA, Fitzsimons DW, Hanna JN, Lam SK, Vong S, Guzman MG, Mendez-Galvan JF, Halstead SB, Letson GW, Kuritsky J, Mahoney R, Margolis HS; Asia-Pacific and Americas Dengue Prevention Boards Surveillance Working Group. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. *PLoS Negl Trop Dis* 2010;**4**(11):e890.
11. Were F. The dengue situation in Africa. *Paediatrics and Internatinoal Child Health* 2012;**32**(S1):18-21.
12. Sierra B, Triska P, Soares P, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. *PLoS Pathog* 2017;**13**(2):e1006220. .
13. Chacón-Duque J, Adhikari K, Avendaño E, et al. African genetic ancestry is associated with a protective effect on Dengue severity in colombian populations. *Infect Genet Evol* 2014;**27**:89-95. .
14. Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS neglected tropical diseases* 2012;**6**(8):e1760.
15. Collenberg E, Ouedraogo T, Ganame J, et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. *J Med Virol* 2006;**78**(5):683-92.
16. Ridde V, Agier I, Bonnet E, et al. Presence of three dengue serotypes in Ouagadougou (Burkina Faso): research and public health implications. *Infect Dis Poverty* 2016;**5**(23).
17. Caron M, Grard G, Paupy C, et al. First evidence of simultaneous circulation of three different dengue virus serotypes in Africa. *PloS one* 2013;**8**(10):e78030.

18. Leroy EM, Nkoghe D, Ollomo B, et al. Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007. *Emerging infectious diseases* 2009;**15**(4):591-3.
19. Caron M, Paupy C, Grard G, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012;**55**(6):e45-53.
20. Gabor J, Schwarz N, Esen M, et al. Dengue and chikungunya seroprevalence in Gabonese infants prior to major outbreaks in 2007 and 2010: A sero-epidemiological study. *Travel Med Infect Dis* 2016.
21. Pourrut X, Nkoghe D, Gonzalez JP, et al. No evidence of dengue virus circulation in rural Gabon. *Emerging infectious diseases* 2011;**17**(8):1568-9.
22. Andries A, Duong V, Ngan C, et al. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. *PLoS Negl Trop Dis* 2012;**6**(12):e1993.
23. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. *PLoS One* 2009;**4**(10):e7611. .
24. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med* 2011;**365**(20):1863-75. .
25. Ochieng C AP, Vittor AY, Nyoka R, Gikunju S, Wachira C, Waiboci L, Umuro M, Kim AA, Nderitu L, Juma B, Montgomery JM, Breiman RF, Fields B. Seroprevalence of Infections with Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya, 2007. *PLoS One* 2015;**10**(7).
26. Ellis EM, Neatherlin JC, Delorey M, et al. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. *PLoS Negl Trop Dis* 2015;**9**(4):e0003733.
27. United Nations Development Programme. Population, urban (% of population). In: *Reports HD*, ed.: UNDP, 2013.
28. United Nations. World Urbanization Prospects: The 2014 Revision, Highlights. In: *Department of Economic and Social Affairs PD*, ed. United Nations: United Nations, 2014.
29. Central Intelligence Agency. Age structure. *The world factbook* Central Intelligence Agency.
30. Ramharter M, Adegnika AA, Agnandji ST, et al. History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. *The Middle European Journal of Medicine, WIENER KLINISCHE WOCHENSCHRIFT* 2007;**119**(Suppl 3):8-12.
31. Schwarz NG, Gysels M, Pell C, et al. Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon. *Vaccine* 2009;**27**(2009):5371-75.
32. Kenya. Secondary Kenya. <https://en.wikipedia.org/w/index.php?title=Kenya&oldid=737329303>
33. Wichmann O YI, Vong S, Limkittikul K, Gibbons R, Mammen MP, et al. Dengue in Thailand and Cambodia: An assessment of the degree of underestimated disease burden based on reported cases. . *PLoS NTD* 2010;**Accepted in Feb. 2010**.
34. Mease L, Coldren R, Musila L, et al. Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study. *Virology* 2011;**8**(371).

- 1
- 2
- 3
- 4 35. Beatty ME, Stone A, Fitzsimons D, et al. Best Practices in Dengue Surveillance: A
- 5 Report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS NTD
- 6 2010;*Submitted*.
- 7
- 8 36. World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in
- 9 endemic areas. Geneva: World Health Organization, 2008.
- 10 37. Alm E, Lindegren G, Falk K, et al. One-step real-time RT-PCR assays for serotyping
- 11 dengue virus in clinical samples. BMC Infect Dis 2015;**15**(493).
- 12 38. Peeling R, Artsob H, Pelegriano J, et al. Evaluation of diagnostic tests: dengue. Nature
- 13 Reviews Microbiology 2010:S30-S37
- 14 39. Kraus A, Messer W, Haymore L, et al. Comparison of plaque- and flow cytometry-based
- 15 methods for measuring dengue virus neutralization. J Clin Microbiol
- 16 2007;**45**(11):3777-80.
- 17 40. de Alwis R, de Silva A. Measuring antibody neutralization of dengue virus (DENV) using
- 18 a flow cytometry-based technique. Methods Mol Biol 2014;**1138**:27-39.
- 19 41. Lambeth C, White L, Johnston R, et al. Flow cytometry-based assay for titrating dengue
- 20 virus. J Clin Microbiol 2005;**43**(7):3267-72.
- 21 42. Cabral-Castroa M, Saramago Peraltab R, Cavalcantia M, et al. A Luminex-based single
- 22 DNA fragment amplification assay as a practical tool for detecting and serotyping
- 23 dengue virus. Journal of virological methods 2016;**236**:18-24.
- 24 43. Balasuriya U, Shi P, Wong S, et al. Detection of antibodies to West Nile virus in equine
- 25 sera using microsphere immunoassay. J Vet Diagn Invest 2006;**18**(4):392-5.
- 26 44. Beck C, Desprès P, Paulous S, et al. A High-Performance Multiplex Immunoassay for
- 27 Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses. Biomed Res
- 28 Int 2015;**2015**(678084).
- 29 45. Hadinegoro SRS. The revised WHO dengue case classification: does the system need to
- 30 be modified? Paediatr Int Child Health 2012;**32**(S1):33-38.
- 31 46. Guilarde AO, Turchi MD, Siqueira Jr JB, et al. Dengue and Dengue Hemorrhagic Fever
- 32 among Adults: Clinical Outcomes Related to Viremia, Serotypes, and Antibody
- 33 Response. The Journal of Infectious Diseases;**197**(6): 817-24. .
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4 Fig. 1 Description of the study components, including passive facility-based fever
5 surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys
6
7
8

9
10
11 There are two arms in the study package, composed of four parts. In the health facility-based
12 arm of the study package, there are the passive facility-based fever surveillance and cost-of-
13 illness survey embedded within the surveillance. In the community arm of the study, there are
14 serological survey and healthcare utilization survey.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig. 2 Map of the study area in Ouagadougou, Burkina Faso

Fig. 3 Map of the study area in Lambaréné, Gabon

Fig. 4 Map of the study area in Mombasa, Kenya

Figures 2 – 4 show the map of the study area at each site in Burkina Faso, Gabon, and Kenya.

For peer review only

1
2
3
4 Fig. 5 Patient flow in the fever surveillance
5
6
7

8
9 Eligible febrile patients identified and enrolled as study subjects will follow these steps to
10
11 complete participation in the passive fever surveillance.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 6 Laboratory testing algorithm for dengue
5
6
7

8 Samples from subjects of the passive fever surveillance would follow these steps of the
9
10 testing algorithm for confirmation of dengue.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Fig. 1 Description of study components, including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Fig. 2 Map of the study area in Ouagadougou, Burkina Faso

A map of the city and distribution of the population in Ouagadougou, Burkina Faso

140x198mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A map of the city and distribution of the population in Lambaréné, Gabon


140x198mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A map of the city and distribution of the population in Mombasa, Kenya

140x198mm (300 x 300 DPI)



* A small number of those samples that are negative on ELISA or NS1 are tested with PCR to exclude false negative results of the ELISA.

Patient flow in the fever surveillance - Eligible febrile patients identified and enrolled as study subjects will follow these steps to complete participation in the passive fever surveillance.

140x198mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 6 Laboratory testing algorithm for dengue

* Dengue Duo® test is performed on enrolled febrile patients to identify dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey.

**Selected samples, including those that were found positive by IgM and NS1 on Dengue Duo® as well as those positive by IgM and IgG capture ELISA, will be tested with RT-PCR.

Laboratory testing algorithm for dengue: Samples from subjects of the passive fever surveillance would follow these steps of the testing algorithm for confirmation of dengue.

140x198mm (300 x 300 DPI)

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies: protocol of field studies of the Dengue Vaccine Initiative

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017673.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Sep-2017
Complete List of Authors:	Lim, Jacqueline; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Carabali, Mabel; International Vaccine Institute Lee, Jung-Seok; International Vaccine Institute Lee, Kang Sung ; International Vaccine Institute Namkung, Suk; International Vaccine Institute Lim, Si-Ki; International Vaccine Institute Ridde, Valéry; Université de Montréal, Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM); Université de Montréal, Département de médecine sociale et préventive Fernandes, Jose; Hopital Albert Schweitzer, Lambaréné,, Centre de Recherches Médicales de Lambaréné Lell, Bertrand; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Matendechero, Sultani ; Ministry of Health, Kenya, Dept. of Neglected Tropical Diseases Esen, Meral; University of Tübingen, Institute of Tropical Medicine Andia, Esther; Kenya Medical Research Institute Oyembo, Noah; Kenya Medical Research Institute Barro, Ahmed; Action-Gouvernance-Integration-Reinforcement, Program Equité Bonnet, Emmanuel ; Institut de recherche pour le developpement Njenga, Sammy; Kenya Medical Research Institute, Eastern & Southern Africa Centre of International Parasite Control Agnandji, Selidji ; Hopital Albert Schweitzer, Lambaréné, Centre de Recherches Médicales de Lambaréné Yaro, Seydou; Centre MURAZ Alexander, Neal; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health Yoon, In Kyu; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Infectious diseases, Epidemiology, Global health, Public health
Keywords:	dengue, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, Tropical medicine < INFECTIOUS DISEASES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies:
protocol of field studies of the Dengue Vaccine Initiative

Jacqueline K. Lim^{1*}, Mabel Carabali¹, Jung-Seok Lee¹, Kang Sung Lee¹, Suk Namkung¹, Si-Ki Lim¹, Valery Ridde², Jose Fernandes³, Bertrand Lell³, Sultani Hadley Matendecheo⁴, Meral Esen⁵, Esther Andia⁶, Noah Oyembo⁶, Ahmed Barro⁷, Emmanuel Bonnet⁸, Sammy M. Njenga⁶, Selidji Todagbe Agnandji³, Seydou Yaro⁹, Neal Alexander¹⁰, In Kyu Yoon¹

¹International Vaccine Institute, Seoul, Korea, Republic of; ²Montreal School of Public Health (ESPUM), Montreal, QC, Canada; ³Centre de Recherches Médicales de Lambaréné, Hôpital Albert Schweitzer, B.P. 118, Lambaréné, Gabon; ⁴Communicable Disease Prevention and Control, Ministry of Health, Nairobi, Kenya; ⁵Institute of Tropical Medicine, University of Tübingen, Germany; ⁶Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; ⁷AGIR, Ouagadougou, Burkina Faso; ⁸Institut de Recherche pour le Développement (IRD), Paris, France; ⁹Centre Muraz, Bobo-Dioulasso, Burkina Faso; ¹⁰Epidemiology and Public Health Department, London School of Hygiene and Tropical Medicine

*Corresponding author

Jacqueline K. Lim^{1*}, MPH

Research Scientist

Global Dengue and Aedes-transmitted Diseases Consortium (GDAC)

International Vaccine Institute (IVI)

SNU Research Park, Gwankak-ro 1

Gwanak-gu, Seoul, Korea 151-191

T: +82-2-881-1340 (Dir) / +82-2-872-2801 (ext. 340)

Email: kalim@ivi.int

37 pages

Word count of the text: 6,619 (not counting the Abstract and table 1)

Word count of the abstract: 320

Figures and tables: 6 figures and 1 table

Abstract

Introduction.

Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardized methods were launched in three locations in Africa.

Methods and Analysis.

In 2014-17, the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; to obtain comparable incidence data on dengue and assess its burden through standardized hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys, and healthcare utilization surveys. All three sites conducted case detection using standardized procedures with uniform laboratory assays to diagnose dengue. Healthcare utilization surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between dengue and non-dengue patients using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3,000 randomly selected residents at each site at 6 month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test.

Ethics and Dissemination.

The protocol for each study obtained ethical approvals from the Institutional Review Boards of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions. By standardizing methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals by the end of 2017.

Strengths of this study

- There have not been population-based studies conducted with a multi-disciplinary approach (i.e. surveillance, healthcare utilization, and sero-survey in one catchment area population). Data from the passive surveillance will be used to calculate annual incidences of dengue and data from the serosurvey will estimate force of infection and prevalence.
- The studies were conducted in three locations in Africa, based on standardized methods and laboratory algorithm. Thus, comparison by site would be possible.

Limitations of this study

- 1
2
3
4 - This is not a cohort study. The passive facility-based surveillance may lead to under-
5 estimation of the burden of dengue fever by measuring incidence based on only those
6 that sought care at our study facilities.
7
8 - There may be limited generalizability of our study results to other dengue-endemic
9 parts of Africa.
10

11
12 Keywords: dengue; Africa; seroepidemiologic Studies; incidence
13

14 Running head: Evaluating dengue burden in Africa: DVI field studies
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Dengue fever, a mosquito-borne flavivirus infection caused by four related but antigenically distinct dengue viruses (DENVs, serotypes 1–4), is a major and rapidly increasing global public health problem. Recent studies have estimated an annual incidence of 50–100 million symptomatic infections globally¹. Dengue is a high burden disease that disproportionately affects countries in the tropics and subtropics, many of which have limited health care resources². Although one dengue vaccine has been recently licensed in several endemic countries, the vaccine has restricted age and epidemiological indications. Other prevention and control measures such as vector control are suboptimal as stand-alone interventions^{3,4}, and no drugs for treatment are currently available.

Like in Asia and the Americas, epidemics of dengue were reported from Africa in the late 19th and early 20th centuries^{5,6}. Specifically for Africa, there are records of multiple dengue case reports between 1964 and 1968 with DENV 2 in Nigeria⁷. Data from several studies conducted in the 1960–70s in Nigeria supported a substantially high level of immunity in adults as well as children^{8,9}. In 2011, Amarasinghe et al. conducted a comprehensive review of literature on dengue in Africa and described that dengue cases have been reported in 34 countries in Africa, with most of these countries also having *Aedes* mosquitoes⁶. However, prior studies which suggested the presence of dengue in Africa were limited by their retrospective design or sample collection (blood donors or sample collected from surveys of other diseases), and often from travellers, with a small number of reported autochthonous cases, to demonstrate the true, population-based, burden of dengue. Also, while many dengue endemic countries in Asia and Latin America have mandatory reporting of dengue cases to public health authorities, and national surveillance systems in place to monitor incidence patterns¹⁰, most African countries lack such established reporting

1
2
3
4 mechanisms and only sporadic outbreaks and individual case reports have been documented.
5
6 In addition, the frequently non-specific clinical presentation of dengue may be difficult to
7
8 distinguish from the myriad other infectious diseases present in Africa, since dengue
9
10 diagnostic assays are not widely available. Thus, the burden of dengue remains largely
11
12 unknown in Africa^{6 11}. Without such dengue burden data, informed decision-making about
13
14 prevention and control measures, including dengue vaccine introduction, in Africa are not
15
16 possible.
17
18

19
20 Limited by surveillance capacity hindering continuous reporting in the region, there
21
22 had not been frequent and systematic reporting of dengue in Africa. African ancestry is
23
24 known to be protective against severe dengue and the candidate genes were recently
25
26 identified in Cuban patient^{12 13}. Bhatt et al.'s modelling of global dengue burden suggests
27
28 high burden of dengue in Africa in terms of equal numbers of, both apparent and inapparent,
29
30 infections as that of Latin America¹. There are new findings about dengue in Africa, but there
31
32 is still much unknown about the magnitude of dengue problem in the continent. To improve
33
34 estimates of population-based dengue disease burden in Africa and validate whether the
35
36 undocumented burden of dengue is as high in Africa as in the Americas with empirical data,
37
38 the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in West, West-
39
40 Central, and East Africa in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa,
41
42 Kenya; respectively. In each of the three sites, a standardized package of study components,
43
44 including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-
45
46 illness surveys, and serological surveys (Fig 1), was initiated between December 2014 and
47
48 March 2016.
49
50
51

52
53
54
55 Methods
56
57
58
59
60

Site selection

Study sites were selected, in part, based on their likelihood of supporting DENV transmission. In site selection, we considered dengue outbreaks and cases reports in the literature, available seroprevalence studies, as well as country-specific dengue risk maps of the probability of DENV transmission and the level of evidence of dengue presence reporting the uncertainty of the consensus estimates of dengue in Africa^{7 14}. In addition, adequate research infrastructure to implement the studies was taken into account. Finally, inclusion of different regions of Africa was also a factor in site selection. Thus, Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; were selected, respectively, to measure the burden of dengue in selected sites from West, (West-) Central, and East Africa.

In Burkina Faso, the first reported dengue outbreak occurred in Ouagadougou in 1982 due to DENV-2⁶. Serological prevalence of dengue was found to be 26.3% in a rural setting (Nouna village) and 36.5% in an urban setting (Ouagadougou) in 2006¹⁵. More recently, an observational study conducted by Ridde et al. among febrile patients consulting at selected study facilities in 2013-14 showed 8.7 % (33/379) to be positive by dengue RDT; and 15 of 60 samples tested by RT-PCR to be dengue positive¹⁶. With evidence for the presence of dengue, along with a strong health and demographic surveillance system (Ouaga-HDSS) which could be used to describe the demographic characteristics of the catchment area, a field study was initiated in Ouagadougou, Burkina Faso in December 2014.

In Gabon, cases of dengue hemorrhagic fever (DHF) caused by up to three different DENV serotypes have been reported, and dengue seroprevalence has been found to be between 5 and 20%¹⁷⁻¹⁹. Results of a recently published study demonstrated seroprevalence of 12.3% among toddlers approximately 30 months of age in semi-rural Lambaréné between 2007 and 2010²⁰. However, a different study in 2005-2008 suggested minimal DENV transmission in rural areas of Gabon²¹. This latter study examined antibodies against dengue

1
2
3
4 in individuals from randomly selected villages representing about 10% of all Gabonese
5
6 villages. Blood samples were tested by anti-DENV IgG and IgM capture ELISA and found to
7
8 have only minimal IgG (0.5%) and IgM (0.5%) seroprevalence. Based on these low
9
10 prevalences, authors concluded that there was no active circulation of DENV in rural Gabon.
11
12 However, the low seroprevalence may have been affected by low sensitivities of the tests
13
14 used leading to a high rate of false negative, and/or selection bias in the blood sample pool
15
16 among the selected villagers²². Seroprevalence estimates may have also been impacted by
17
18 the possibility of false-positive results due to IgG cross-reactivity among flaviviruses²¹.
19
20 Nevertheless, given the possibility of DENV circulation in Gabon, a field study was initiated
21
22 in Lambaréné in March 2015 in a community with a catchment population of about 77,000
23
24 residents, using the clinical research infrastructure of the Centre de Recherches Medicales de
25
26 Lambaréné (CERMEL), benefiting from experienced research staff who conducted a large
27
28 Phase 3 malaria vaccine trial^{23,24}.
29
30
31
32

33 In Kenya, more evidence is available for the presence of dengue based on local data.
34
35 Dengue was the most common viral pathogen in retrospectively tested blood specimens from
36
37 HIV-negative survey samples from the 2007 Kenya AIDS Indicator Survey. Antibody testing
38
39 for dengue as well as chikungunya and Rift Valley fever was performed by IgG ELISA using
40
41 either commercial kits or CDC assays; 12.5% were found to be dengue positive²⁵. Similarly,
42
43 a household survey found 13% of individuals from 701 households in Mombasa had
44
45 serological evidence of either past or current DENV infection²⁶. These data suggest that
46
47 there is more dengue in Kenya than indicated by public health reporting, possibly due to
48
49 misdiagnosis^{25,26}. A field study was initiated in Mombasa, Kenya in March 2016.
50
51
52

53 *Study participants*

54
55
56
57
58
59
60

1
2
3
4 For the passive facility-based fever surveillance, individuals who met the following criteria
5
6 were eligible for study enrollment:
7

- 8 1. Age 1- 55 years old;
- 9
- 10 2. Resident of the catchment area covered by healthcare facilities participating in the
11 study, without plans to move out of the catchment area within 12 months;
- 12
- 13 3. Signed informed consent, and assent for those aged between 7 and 18 years; and
- 14
- 15 4. Patients presenting with current fever (axillary temperature $\geq 37.5^{\circ}$ C) or history of
16 fever for ≤ 7 days duration without localizing signs (fever caused by a localized
17 infection as well as fever with a known and confirmed etiology other than dengue,
18 such as malaria confirmed by malaria RDT- listed in the patient identification SOP).
19
20
21
22
23
24
25
26
27
28

29 For the serological survey, criteria 1-3 were applied. For the healthcare utilization
30 survey, household interviews were conducted among the heads or representatives of the
31 household invited from each family participating in the serosurvey.
32
33
34
35
36
37
38

39 *Study area and population*

40 Burkina Faso, located in West Africa, has a population of 14,017,462 with 22.7%
41 living in urban areas. The country is mainly rural with about 29% of the population reported
42 to be living in urban areas in 2014. However, Burkina Faso is urbanizing rapidly and is
43 positioned as the country with the fourth fastest urbanization in the last 25 years^{27 28}. The
44 capital, Ouagadougou, has a population of 2,741,128. The majority of the population live in
45 urban settings. About 45% of the population are under 15 years of age²⁹. The city is divided
46 into 12 districts and 52 sectors. Ouagadougou is the country's largest city and the cultural and
47 economic center. The city is part of the Soudano-Sahelian area, with a rainfall of about 800
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 mm per year. The rainy season is from May to October, with a mean temperature of 28 °C
5
6 (82 °F). The cold season runs from December to January, with a minimum average
7
8 temperature of 16 °C (61 °F). During the hot season, which runs from March to May, the
9
10 temperature can reach as high as 43 °C (109 °F).
11

12
13 The Health and Demographic Surveillance System is in place in Ouagadougou.
14
15 Ouaga HDSS monitors a population of 81,717 residents; according to this surveillance
16
17 system, the city population is very stable with a rate of migration of 4.1% and more than 80%
18
19 of the inhabitants with ownership of their houses [20]. A map of the city and distribution of
20
21 the population is shown in Figure 2.
22

23
24
25 Gabon, located on the west coast of Central Africa, has an area of nearly 270,000
26
27 square kilometres (100,000 sq. mi) with a population estimated at 1.5 million. Its capital and
28
29 largest city is Libreville. In 2014, it is reported that 87% of the Gabonese population lived in
30
31 urban areas²⁸. The sixth largest city, Lambaréné, the capital of Moyen-Ogooué, is located 75
32
33 kilometers south of the equator, with a population of 25,257 in 2009. The majority of
34
35 Lambaréné residents live in semi-rural areas. About 42% of the Gabonese population is under
36
37 15 years of age²⁹. Similarly, Lambaréné's population is relatively young with about 50%
38
39 under 20 years of age.
40
41

42
43 The health services of Gabon are mostly public, but there are some private
44
45 institutions as well. With one of the best medical infrastructure in the region, almost 90% of
46
47 the population have access to health care services. Albert Schweitzer Hospital (ASH) is a
48
49 private institution which served as a study site for the passive fever surveillance study^{30 31}.
50
51 The study area in Lambaréné is shown in Figure 3.
52

53
54 Kenya, located in East Africa, lies on the equator, covering 581,309 km²
55
56 (224,445 sq. mi), with a population of approximately 45 million people in 2014 [2]. Kenya
57
58
59

1
2
3
4 generally has a warm and humid tropical climate, but is diverse ranging from the cooler
5
6 climate around the capital city, Nairobi, to a hot and dry climate inland, as well as a desert-
7
8 like climate in the north-eastern regions along the border with Somalia and Ethiopia ³². The
9
10 capital, Nairobi, is a regional commercial hub. The main industries include agriculture,
11
12 exporting tea and coffee, as well as the service industry.

13
14
15 Kenya is divided into 47 semi-autonomous counties. Mombasa is the country's
16
17 second largest city after Nairobi and is located on the east coast of the country [2].
18
19 Administratively, Mombasa is the capital of Mombasa County, what was formerly called
20
21 Coast Province. This overall Coast region covers over 80,000 km² in the south-eastern part of
22
23 Kenya, constituting about 15% of the country's land area, with a population of 3,325,307
24
25 residents.

26
27
28 The main driver of economy of Mombasa is tourism and trading industry. Mombasa
29
30 itself has a population of about 1.3 million with almost 50% of the population under 15 years
31
32 of age ²⁹. Increasingly, the population of the province lives in urban areas; at present about 45%
33
34 live in Mombasa and other urban centers. The long rains begins around April and the short
35
36 rains begins in October ³². Mean annual temperature ranges from 24°C to 27°C, but
37
38 maximum temperature averages over 30°C during the hottest months, January to April.

39
40
41 Figure 4 shows the area of Mvita subcounty of Mombasa, which was the catchment
42
43 area for the study in Kenya, with a catchment population of 74,735 residents. The map
44
45 indicates the three facilities involved in the study.

46 47 48 *Sample size*

49
50
51 Given the paucity of available age-specific dengue incidence data in the study
52
53 countries or nearby countries, it was difficult to obtain population-based incidence to make
54
55 assumptions when calculating sample sizes. The required catchment population for the
56
57
58
59
60

1
2
3
4 passive facility-based fever surveillance was roughly estimated based on the limited data
5
6 available in the literature. Annual incidence estimates were calculated based on available
7
8 prevalence estimates with the assumption that the outcome of interest has zero prevalence at
9
10 age zero, and that force of infection is constant. It was assumed that prevalence estimates
11
12 found for one particular age group would be adjusted as the annual incidence and used across
13
14 all ages.

15
16
17 Wichmann et al. calculated an expansion factor for children by comparing data from
18
19 three cohort studies to national surveillance data in Southeast Asia³³. For children in
20
21 Thailand, the age-specific expansion factors calculated were 11.85 for <5 years, 8.76 for 5-9
22
23 years, and 7.81 for 10-14 years³³. The results show that, even for Asia where better reporting
24
25 and surveillance systems are available, there is a considerable degree of underreporting. For
26
27 Africa, there may be more dengue cases under-ascertained (not seek care) and under-reported
28
29 (not reported even if a patient with dengue seek care as dengue is not one of the routinely
30
31 notifiable diseases in Africa), but such information on extent of underestimation of dengue
32
33 was not available^{34 35}. Also, the incidence estimates used in our sample size calculations
34
35 were not from population-based studies. While it would have been ideal to adjust the
36
37 incidence further for likely underestimation, the annual incidence used in sample size
38
39 calculations could not be adjusted for possible under-reporting due to the lack of data. The
40
41 sample sizes were calculated with 95% confidence levels and a margin of error at a fixed
42
43 significance level within 25% of the true proportion of incidence. This gives relative
44
45 precision of 75%, considering the gap in evidence for dengue incidence in the study areas.
46
47 The final sample sizes were calculated by assuming 20% non-response rate or loss to follow-
48
49 up. The required catchment population size for the fever surveillance study in Burkina Faso
50
51 was estimated to be 100,000, Gabon to be 77,000, and Kenya to be 70,000. In these
52
53 catchment populations, the number of enrolled subjects depends on the number of eligible
54
55
56
57
58
59
60

1
2
3
4 patients who seek care at the study facilities. How many eligible febrile episodes would
5
6 actually present at our study facilities was difficult to predict; but after assessment of the
7
8 volume of febrile patients at the facilities, a realistic upper limit for enrollment for a study
9
10 period of approximately 1.5 years was set at 3,000 subjects to offer enrollment to all
11
12 consenting eligible patients.

13
14
15 For the serological survey, the sample size was calculated similarly using the
16
17 prevalence proportion based on published literature. Seroprevalence of 0.304 for Burkina
18
19 Faso ¹⁵, 0.123 for Gabon ²¹, and 0.144 for Kenya ³⁶ were used. With the same confidence
20
21 levels and allowed margin of error, and assuming 10-30% (variable by site) non-response rate,
22
23 the sample size was calculated to be 3,000 participants at each site. Again, with the scarcity
24
25 of data from the selected countries, there were no other prevalence estimates reported or
26
27 estimates from different age groups. As prevalence is expected to increase with age, and
28
29 higher prevalence would give a smaller sample size, our calculations are likely to be
30
31 conservative.
32
33

34 35 36 37 *Study components*

38 39 40 41 Fever surveillance – design and methods

42
43
44 To determine burden due to symptomatic dengue in each of the three sites in Burkina
45
46 Faso, Gabon, and Kenya, passive facility-based fever surveillance was implemented in a
47
48 well-defined catchment area population. In Burkina Faso, the surveillance study was initiated
49
50 in December 2014 in five selected primary health care centres, locally called “Centre de
51
52 Santé et de Promotion Sociale” (CSPS), in the municipality of Ouagadougou, with a
53
54 catchment population of 105,000 residents. This project was implemented in collaboration
55
56 with Centre Muraz in Bobo-Dioulasso, EQUITE sante program (a collaborative program
57
58
59
60

1
2
3
4 between University of Montreal and Action-Gouvernance-Integration-Reinforcement, AGIR,
5 based in Ouagadougou, funded by Canadian Institute of Health Research), and DVI. In
6
7
8 Gabon, the surveillance study was initiated in the Albert Schweitzer Hospital serving a
9
10
11 catchment population of 130,000 residents in the Moyen-Ogooué and surroundings within
12
13 Lambaréné, in collaboration with CERMEL and Institute of Tropical Medicine in Tubingen,
14
15 Germany. In Kenya, the surveillance study was implemented at Ganjoni dispensary, Tudor
16
17 sub-county Hospital, and Coast Provincial General Hospital, serving a catchment population
18
19 of 70,000 residents in Mombasa, in collaboration with Kenya Medical Research Institute
20
21 (KEMRI) and Ministry of Health of Kenya.
22
23

24 As described in Figure 5, both outpatients and inpatients at the designated study
25
26 facilities, who meet inclusion criteria as mentioned earlier are tested for dengue, first with SD
27
28 Dengue Duo[®] RDT. Dengue confirmation is done by detection of dengue virus in serum
29
30 samples using PCR, as well as anti-dengue IgM and IgG antibodies in acute and convalescent
31
32 serum by ELISA (SD Dengue IgM & IgG capture ELISA[®] tests, Standard Diagnostics,
33
34 Yongin-Si, Korea)^{10 37}. Every consecutive patient meeting inclusion criteria is eligible for
35
36 enrolment during the study period. Infants < 1 year old were not included due to operational
37
38 limitations, such as difficulty of infantile bleeding.
39
40
41
42
43
44

45 In Ouagadougou, Burkina Faso, the fever surveillance initiated in December 2014
46
47 continued until February 2017 (approximately 2 years). In Lambaréné, Gabon, the fever
48
49 surveillance initiated in April 2015 continued until January 2017 (approximately 1.5 years).
50
51 In Mombasa, Kenya, the fever surveillance initiated in March 2016 will continue until June
52
53 2017.
54

55
56 Among subjects enrolled in the fever surveillance, those who are positive by dengue
57
58
59
60

1
2
3
4 rapid diagnostic test are offered further enrolment in the cost-of-illness survey, consisting of
5
6 interviews on the day of acute illness visit, day 10-14 from the first visit, and day 28, if
7
8 illness continues. The cost-of-illness survey questionnaire was designed to estimate the direct
9
10 medical, direct non-medical, and indirect costs associated with dengue-positive patients
11
12 identified at study facilities. This survey also estimates the cost of treating dengue at the
13
14 facility level. Data are gathered by linking patients' medical records concerning outpatient
15
16 visits, inpatient visits, and service consumption (e.g., diagnostic tests, medication, and other
17
18 services provided to patients). The cost-of-illness portion of the study will be described
19
20 separately.
21
22
23
24
25

26 Fever surveillance – laboratory testing

27
28
29 As shown in Figure. 6, in all three sites, acute samples are tested using a commercial
30
31 RDT for dengue NS1 and IgM/IgG (Dengue Duo[®], Standard Diagnostics, Yongin-Si, Korea).
32
33 Dengue Duo RDT is used on the day of acute illness visit at the site of patient presentation
34
35 (day 1). The acute and convalescent samples are subsequently tested at a local laboratory
36
37 using dengue IgM/IgG ELISA (SD Dengue IgM & IgG Capture ELISA[®], Standard
38
39 Diagnostics, Yongin-Si, Korea). The serum is separated and stored in 4 aliquots of about 500
40
41 µL for various lab tests, as indicated in consent documents.
42
43
44
45

46 After ELISA testing, samples will be shipped to IVI in Korea. Samples with positive
47
48 results by RDT or ELISA undergo further testing by RT-PCR at the Clinical Immunology
49
50 Laboratory of IVI. Four DENV serotype-specific real-time RT-PCR assays are used for
51
52 laboratory confirmation of dengue and serotyping³⁸. The DENV 1-4 RT-PCR assays are
53
54 carried out in 25µL reaction mixtures containing 5µL template RNA, TagMan[®] Fast Virus 1-
55
56
57
58
59
60

1
2
3
4 step mastermix (Applied Biosystems®), 0.9 µM of each primer, and 0.2 µM probe³⁸.
5
6

7 Amplification and detection are performed in a StepOne Plus real-time PCR system and the
8 baseline and threshold are determined using the auto-baseline and threshold feature in
9
10 StepOne Software v2.2.2 (Applied Biosystems®). Thermocycling parameters are as follows:
11
12 reverse transcription at 50 °C for 5 min, inactivation at 95 °C for 20 s, followed by 45 cycles
13
14 of fluorescence detection at 95 °C for 3 s, and annealing at 60 °C for 30 s³⁸. A specimen is
15
16 considered positive if target amplification was recorded within 40 cycles.
17
18
19
20
21
22

23 Serological survey – design and methods

24
25
26 While the facility-based fever surveillance studies provide estimates of the burden of
27
28 medically-attended dengue disease, evaluation of all DENV infections in a population –
29
30 including subclinical and mildly symptomatic infections, which impact immune status – is
31
32 needed to capture the overall impact of dengue. As part of the study package, population-
33
34 based serological surveys were conducted in the same catchment population used for the
35
36 fever surveillance. At each of the three sites in Africa, the serosurvey was conducted on a
37
38 cohort of approximately 3,000 randomly selected residents of urban and semi-urban parts of
39
40 Ouagadougou, Lambaréné, and Mombasa. Without individual-level census information on all
41
42 residents of Lambaréné and Mombasa, with help of community/village health workers,
43
44 randomization was done based on neighbourhoods (or defined areas for which the health
45
46 workers/volunteers are responsible) as cluster units. As the community/village health workers
47
48 are familiar with the villages and their residents, they are good entry points into the
49
50 communities. With these health workers, the field team screened houses in the selected
51
52 villages by knocking on doors of every 5~7 houses, depending on the household density per
53
54 neighbourhood. Also, demographic information collected in previous research projects
55
56
57
58
59
60

1
2
3
4 conducted in the same area was used as a guide, if available. In the case of the site in
5
6 Ouagadougou, HDSS data were available and the EQUITE SANTE, a CIHR funded research
7
8 program of University of Montreal had set up a geographic information system (GIS)
9
10 database system of houses in the study area. Using these data, households of potential
11
12 enrollees of the serosurvey were pre-selected randomly and household visits were made in
13
14 Ouagadougou. In the three sites, about 45% of the serosurvey samples were targeted to be
15
16 collected from children 1 - 14 years-of-age, and 55% were targeted to be collected from
17
18 adults between 15 and 55 years of age to reflect the age distribution of the general population
19
20 of the area. Household-based enrollment was offered to the head of the household until the
21
22 specific cap for the age-group was reached in Lambaréné and Mombasa.
23
24

25
26 Randomly-selected subjects 1-55 years of age underwent phlebotomy (5ml for
27
28 children and 7ml for adults) twice — during pre-transmission (before the rainy season) and
29
30 post-transmission (after the rainy season) at 6 month intervals. The sera were evaluated using
31
32 IgG indirect ELISA at baseline and after 6 months. The presence of dengue IgG antibodies at
33
34 6 month intervals will be used to estimate the level of occurrence of inapparent DENV
35
36 infection and to calculate the rate of infection in the catchment population. Flow cytometry-
37
38 based DENV neutralization assays will be applied to a subset of samples to assess for
39
40 presence of dengue neutralizing antibodies and seroconversion over the 6 month interval. In
41
42 addition to overall seroconversion, age-specific seroconversion estimates in the catchment
43
44 population, as well as the proportion of inapparent infections, are determined.
45
46
47
48
49
50

51 Serological survey – laboratory testing

52

53
54 From the samples collected in the serosurvey, about 200 μ L of serum are used and
55
56 tested at a local laboratory using dengue IgG ELISA (Panbio Dengue IgG Indirect ELISA®,
57
58
59
60

1
2
3
4 Alere North America, LLC, Florida, United States). After ELISA testing for dengue IgG at
5
6 the local labs, samples will be shipped to IVI. Given potential serological cross-reactivity
7
8 among flaviviruses³⁹, flow cytometry-based neutralization assays will be performed against
9
10 selected flaviviruses to include yellow fever virus, West Nile virus, Zika virus, and Japanese
11
12 Encephalitis virus at the Clinical Immunology Lab of the International Vaccine Institute (IVI),
13
14 Seoul, Korea^{40 41}. About 50 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in
15
16 Gabon and Kenya will be tested.
17

18
19
20 About 1,000 µL of serum is kept aside for this procedure. The flow cytometry-based
21
22 neutralization assays are performed in duplicate in 96-well cell culture plates with flat-bottom
23
24 wells, each containing DC-SIGN-expressing U937 cells⁴⁰. The amount of virus used in the
25
26 assay infects between 7 and 15% of the cells. Human immune sera are serially diluted and the
27
28 virus is pre-incubated with the sera for 1 h at 37°C⁴⁰. The cells are washed, and the virus and
29
30 serum mixture is added to the cells for 1 h at 37°C, and the cells are further incubated for 24
31
32 to 48 h at 37°C in 5% CO₂. The cells are fixed, permeabilized, and stained with fluoresce-
33
34 conjugated monoclonal antibody 4G2, which recognizes the flavivirus E protein⁴². FACScan
35
36 flow cytometer (Becton Dickinson, San Diego, CA) is used to analyze the cells⁴⁰. The serum
37
38 dilution that neutralized 50% of the viruses is calculated by nonlinear, dose-response
39
40 regression analysis with Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).
41
42

43
44 In addition, a Luminex-based multiplex immunoassay will be performed on a
45
46 randomly selected sub-sample to assess for IgG to different flaviviruses⁴³. About 200
47
48 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in Gabon will be tested.
49
50 Detection of IgG against ZIKV and each the four DENV serotypes was performed on patient
51
52 serum samples using an in-house microsphere-based multiplex immuno-assay (arbo-MIA) at
53
54 the Clinical Immunology Lab of IVI^{44 45}. The arbo-MIA is based on a mixture of
55
56 microspheres covalently coupled with either DENV-1, -2, -3, -4 or ZIKV recombinant
57
58
59

17

1
2
3
4 antigens (E protein domain III) produced in *Drosophila* S2 expression system. Briefly,
5
6 microsphere mixtures were sequentially incubated in the dark under constant shaking with a
7
8 1:400 dilution of patient serum samples, with 2 µg/mL anti-human IgG biotin-conjugated
9
10 antibody (Jackson ImmunoResearch, West Grove, PA) and with 2 µg/mL streptavidin-R-
11
12 phycoerythrin conjugate (Life technologies). After the final incubation, the median
13
14 fluorescence intensity (MFI) of each microsphere set was quantified using a BioPlex 200
15
16 instrument (Bio-Rad Laboratories, Hercules, CA). Samples were considered seropositive if
17
18 the ratio of MFI values obtained for the viral antigen to the control antigen was superior to
19
20 the defined cut-off. The cut-off of the MIA was determined for each viral antigen by ROC
21
22 curve analysis using well characterized sera.
23
24

25
26 In Lambaréné, the enrolment bleed, took place in November -December 2015 with
27
28 2nd blood collection in May 2016. In Ouagadougou, the enrolment bleed took place in May-
29
30 June 2015 with follow-up blood collections in December 2015, June 2016, and January 2017.
31
32 In Mombasa, enrolment bleed took place in May 2016 with the 2nd blood collection in
33
34 November 2016 – February 2017.
35
36

37 38 39 Healthcare Utilization Survey

40
41
42 As the passive fever surveillance is conducted at the study facilities, potential dengue
43
44 patients could be missed if they seek care elsewhere. To identify the proportion of fever and
45
46 dengue cases potentially missed by the passive surveillance system due to patients living in
47
48 the study area but seeking care outside of study facilities, a population-based healthcare
49
50 utilization survey was conducted in 400 randomly selected households from the study
51
52 catchment area to characterize their healthcare utilization patterns of the households when
53
54 they have (self-reported) febrile episodes among the family members. In addition to assessing
55
56
57
58
59
60

1
2
3
4 health-seeking behaviours of the residents, preferences in terms of health-seeking behavior
5
6 and respective reasons for their preferences were investigated. The questionnaire was
7
8 administered to 400 heads of households. Among 3,000 residents who participated in the
9
10 serosurvey, there were about 600 households. From these households, 400 heads of
11
12 households were randomly selected and offered enrolment in the health utilization survey.
13
14 Heads of households or a senior representative within the household were asked questions on
15
16 health seeking patterns of their family members. The surveys provide data to determine the
17
18 proportion of these cases missed by our passive fever surveillance system. Also, the surveys
19
20 document health seeking patterns, who would seek care at which facilities, who would make
21
22 health-seeking related decisions, and the reasons for their preferences.
23
24
25
26
27

28 *Study questionnaires*

29
30 For the fever surveillance study, questionnaires are administered at the acute illness visit and
31
32 the convalescent visit. The convalescent visit may take place at the health care facility (10-14
33
34 days later) or at the patient's home (15-21 days after the acute visit), according to patient
35
36 preference and availability. The questionnaires are completed by medical staff of the study
37
38 facilities, including demographic and clinical information (e.g., signs, symptoms, past
39
40 medical history, treatments prescribed, and diagnoses). The same staff also complete the
41
42 follow-up questionnaire at the convalescent visit within 21 days from the acute visit. Study
43
44 nurses complete surveillance enrolment log. Lab technicians complete the lab section (mostly
45
46 dengue-related diagnostics) and the forms are compiled by the study coordinator on site.
47
48
49

50 For the serosurvey component, questionnaires are administered at the household by trained
51
52 field team staff at each serosurvey visit. Study nurses complete the questionnaire after a brief
53
54 physical and medical examination. There are (a) follow-up visit(s) in about 6 months and the
55
56 same staff make the household visits to complete the follow-up questionnaire. Enrolment log
57
58
59

is maintained by our study coordinator on site.

Variables of the surveillance questionnaires

The variables collected are listed in table 1.

Table 1. List of variables collected in the passive fever surveillance data collection form

Topic	Description	Items
Basic information	Demographic and basic information about the patient and the treatment received	Type of treatment where patient is enrolled (IPD vs. OPD) Date of fever onset, duration of fever Current temperature Tourniquet test results Patient's address (district and village-level) Date of visit, date of birth, age, and sex Weight and height
General health condition	Current condition of the patient (self-report) and underlying diseases of the patient	How well the patient could handle daily activities Pre-existing conditions
Signs and symptoms during this illness	A set of sign and symptoms that may be related to fever and dengue (DF and DHF)	Rash, fatigue, headache, retro-orbital pain, neck/ear pain, sore throat, breathing difficulty, cough, expectoration, gastrointestinal signs (Nausea/vomiting, diarrhea, abdominal pain, etc.), hemorrhagic signs (nose/gum bleeding, ecchymosis, petechiae, etc.), signs of shock (cyanosis, capillary refill), arthralgia, myalgia, loss of appetite, jaundice, etc.
Medical History:	Previous dengue-related or other flavivirus infection as well as vaccination history (self-report)	Previous dengue infection and related hospitalization Previous infection to other commonly circulating arboviral infection in the area Yellow fever vaccination history
Laboratory findings	Records from the routine laboratory tests widely used in clinical fever/dengue patient management, as part of the hospital care procedure	Platelet count, hematocrit, haemoglobin, leukocytes, neutrophils, protein level, AST, ALT, urine test results, etc.

Clinical Diagnosis	Clinician's diagnosis with or without referring to the RDT	Diagnosis given by the physician based on clinical presentation after physical examination of the patient.
Dengue testing results	Results from the dengue tests, mainly RDTs for dengue as well as other commonly circulating arbovirus in the area	Dates of blood draw Test results of the RDT IgM/IgG capture ELISA results PCR results (if available)
Treatment	Medicine(s) prescribed and the starting and end dates	Antibiotics, paracetamol, ibuprofen, aspirin, and others that may be site-specifically prescribed
Outcome	Outcome of this particular visit	Hospitalized, returned home, or referral
Hospitalization	Information collected only among hospitalized patients in the surveillance to record other severe signs and progression of illness	Admission and discharge diagnoses Presence of haemorrhagic signs or shock syndrome
Hospital Charges	Expenses and hospital charges incurred by patient on the visit 1	Amount of the out of pocket payment by the patient or the family/or guardian Breakdown of the hospital charges (laboratory, medication, admission-related charges)
Final outcome	Outcome of the patient's illness at the 2 nd visit	Final diagnosis given for the patient outcome of illness Completion of study participation (early termination and the reason, etc.)

Planned statistical analysis

From the fever surveillance data, incidence of symptomatic dengue among patients that seek health care at the study facilities will be calculated. Age-specific incidence rates in all the children and adults will be determined by referring to the size and distribution of the general population of the study area at the time of surveillance as the denominator in calculation of the incidence of symptomatic dengue cases. Each person residing in the study area is assumed to contribute 12 months of person time to the denominator. Although the study areas all report a low migration rate, the in-migration is assumed to balance the out-

1
2
3
4 migration of the population during the study period. Age-specific incidence of symptomatic
5
6 dengue will be calculated by using age-specific denominators and the number of symptomatic
7
8 dengue cases in eligible individuals as the numerator.
9

10
11 Using the data collected in the Healthcare Utilization Survey, the proportion of
12
13 febrile cases missed by the passive surveillance system will be determined. Then using the
14
15 proportion, the numerator will be further adjusted in recognition of those missed fever cases
16
17 from the study area, which could have been dengue. Also, comparison will be made between
18
19 those that agreed to participate and those that declined participation among the eligible
20
21 potential enrollees. The enrollment log, which recorded basic information obtained during the
22
23 screening process of potential enrollees, will be reviewed. In addition to checking that our
24
25 sample of febrile cases is representative of febrile patients of the general population in the
26
27 catchment area, refusal rates will be determined based on information in the log. Then, the
28
29 refusal rates will be used to adjust the numerator.
30
31

32
33 SPSS software will be used for analysis of the fever surveillance data. Multivariable
34
35 logistic regression will be used to compare confirmed dengue patients versus non-dengue
36
37 febrile patients in terms of symptomatic presentation, based on signs and symptoms collected
38
39 from all patients with laboratory-confirmed dengue by serology and RT-PCR, adjusting for
40
41 possible confounders, such as age, days since onset of fever, primary vs. secondary infection,
42
43 inpatient vs. outpatient, etc. Differences in symptomatic complex of DF (and DHF, if data
44
45 allows) by age and serotype will be also determined using multivariable logistic regression.
46
47

48
49 As outpatient disease accounts for the greater part of dengue disease burden, clinical
50
51 profile of individuals with DENV infection will be characterized by the type of treatment
52
53 (hospitalized and outpatients), as well as by severity of the disease (severe vs. non-severe by
54
55 the 2009 WHO criteria)⁴⁶. Classification is determined after the course of illness is
56
57 completed (typically during the convalescent visit). Symptomatic dengue is classified as
58
59

22

1
2
3
4 outpatient or hospitalized. Progression of dengue is recorded in the CRF as DF, DHF I, DHF
5
6 II, DHF III or DHF IV and clinical patterns will be compared by the severity grade ^{46 47}.
7
8 These will be compared to results obtained from other DVI studies in Latin America
9
10 (Colombia) and Asia (Thailand, Vietnam, and Cambodia). Overall, comparisons will be made
11
12 across Burkina Faso, Gabon, and Kenya.
13

14
15 With the age-stratified sera that reflect the age distribution of the general population
16
17 of the country, the serological survey sampling strategy ensures sufficient subjects to obtain
18
19 precise age-specific estimates of sero-positivity and sero-conversion of the catchment area
20
21 population. The sero-conversion rate and change in the immune status will be determined by
22
23 age group during the study period. The age-stratified serosurvey data will also allow
24
25 calculation of the force of infection of dengue in the study population. After enrolment, there
26
27 were subjects who drop out in the follow-up bleeds about 6 months later. Basic demographic
28
29 information will be compared between those that completed participation and those with
30
31 incomplete participation to check whether our sample represents the catchment area
32
33 population. Comparisons will be made among Burkina Faso, Gabon and Kenya.
34
35
36
37
38
39
40

41 *Ethical considerations*

42
43 To minimize inconvenience of the study to patients, clinicians and nurses were
44
45 sensitized and trained regarding the study requirements and procedures in order for data
46
47 collection to be integrated into routine patient care. The clinicians and nurses selected for the
48
49 study receive coordinated support from study field staff throughout the study process. Written
50
51 informed consent, and assent for participants 7 (13 for Kenya) -17 years of age, were
52
53 obtained from patients by study staff. Study staff go through consent and assent documents
54
55 for short summary of the disease, detailed description of study procedure, and information on
56
57
58
59
60

1
2
3
4 reimbursement. Patient data are documented in the study designated office and only the study
5
6 staff have access to the data that had been de-identified without any personal identifiable
7
8 information. Data are exclusively handled in the study office and stored safely in a protected
9
10 database in the study office as well as the DVI main server.

11
12 The protocol for each study obtained ethical approvals from the Institutional Review
13
14 Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and
15
16 Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI
17
18 Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and
19
20 Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB
21
22 of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and
23
24 the National Health Ethical Committee of Burkina Faso.

25 26 27 28 29 30 Discussion

31
32
33 Dengue cases have been detected since 1960's in Africa and there has been
34
35 continued presence of the *Aedes* vectors in the continent ^{5 7}. However, very few dengue
36
37 studies have been conducted in Africa. Also, little evidence is from population-based studies
38
39 ⁶. Compared to the volume of evidence from SE Asia and the Americas, there is critical data
40
41 scarcity on dengue in Africa. Suspicion of substantial dengue burden in Africa is based on
42
43 limited reports of outbreaks and a handful of sero-prevalence studies testing different viruses
44
45 among samples that likely do not represent the general population. In the three countries
46
47 selected for our field studies, somewhat more data were available but were still very limited.
48
49 In Burkina Faso, a recent observational study conducted in 2013 reported that 8.7% of the
50
51 febrile patients showed positive results on dengue RDT ¹⁶. In Gabon, one study suggested
52
53 minimal DENV circulation in rural areas ²¹, while a recent study reported 12.3%
54
55 seroprevalence, by IgG antibodies against dengue, among toddlers 30 months of age in semi-
56
57
58
59
60

24

1
2
3
4 rural parts of Lambaréné ²⁰. In Kenya, about 13% of the individuals in Mombasa have been
5
6 reported evidence of past or current DENV infection by RT-PCR and IgM anti-dengue
7
8 ELISA after the 2013 outbreak ²⁶. Despite the limited scope and generalizability of these
9
10 studies, they suggest that there may be more dengue than previously appreciated due to
11
12 underestimation and misdiagnosis ^{25 26}.

13
14
15 These studies all indicate presence of dengue and some level of underlying sero-
16
17 prevalence in the countries of our field studies. However, often these studies are limited by
18
19 their retrospective design or sample collection (blood donors or sample collected from
20
21 surveys of other diseases) to demonstrate the true, population-based, burden of dengue. We
22
23 proposed to address this gap by population-based dengue surveillance and sero-prevalence
24
25 studies in West, (West-) Central, and East Africa.
26
27

28
29 The present studies at three sites in Africa will provide important information on
30
31 undocumented DENV circulation in Africa. Such data will help to strengthen the evidence
32
33 base for dengue burden in Africa. Better defined disease burden data based on our studies
34
35 could be used to assess the relative need for dengue prevention and control measures, such as
36
37 whether a dengue vaccine would be a cost-effective public health intervention for countries in
38
39 Africa. Clinical findings from our studies could also be used as a guide for dengue case
40
41 detection and case management.
42
43

44
45 The studies have some important limitations. We recognize variability of the dengue
46
47 epidemiology over time and by the region. Due to resource constraints, our studies are limited
48
49 in terms of time frames and geographically focused for measuring dengue illnesses and
50
51 infections. Therefore, it may limit generalizability of our data collected from our studies.
52

53
54 One potential source of bias in estimating the incidence of symptomatic dengue is
55
56 under-ascertainment due to the community residents with relevant symptoms seeking care
57
58 from other healthcare providers and facilities than the facility under surveillance. As the
59

1
2
3
4 study design remains passive surveillance, cases are ascertained only at our study facilities.
5
6 By estimating the proportion of febrile patients seeking care elsewhere, as well as refusal
7
8 rates among the potential enrollees that were screened for eligibility criteria, the degree of
9
10 fever patients missed by the study facility will be determined. Inverse probability weighting
11
12 will be used to account for these potential subjects missed by the surveillance as adjustments
13
14 in incidence calculation. Also, depending on the transmission volume of dengue or other co-
15
16 circulating diseases with onset of fever there may be patients that are diagnosed with other
17
18 diseases and ruled out of dengue. Furthermore, with respect to dengue diagnostics for our
19
20 serological surveys, there are other circulating flaviviruses in Africa leading to challenges in
21
22 identifying human antibodies that may be due to past dengue infections. While our testing
23
24 plan covers some of the common flaviviruses, there are others in circulation in Africa, such
25
26 as Banzai and Usutu viruses⁴⁸⁻⁵⁰. Due to resource limitations, our plans for laboratory testing
27
28 include yellow fever virus, West Nile virus, Zika virus, and Japanese Encephalitis virus as
29
30 well as DENV 1-4. As our serological surveys were geographically focal and limited to a
31
32 number of viruses, we recognize diagnostic limitations where we may possibly miss out on
33
34 true dengue-positive individuals. These factors may increase the likelihood of under-
35
36 reporting or over-reporting.
37
38
39
40
41

42 In addition, the sero-survey and healthcare utilization survey are conducted on a
43
44 randomized sub-sample of the catchment area population and there may be limited
45
46 generalizability of the data collected from these surveys. With unknown differences among
47
48 those that agree to participate and those that do not agree, the data may not be representative
49
50 of the general population of the study countries.
51
52
53
54

55 Conclusions
56
57
58
59
60

1
2
3
4 Data collection continues and study closure is planned in all three sites in April –
5
6 June 2017. Although not described in this paper, preliminary results indicate a substantial
7
8 level of dengue incidence and prevalence in each site. The data collected from our studies
9
10 will provide a more accurate assessment of the unknown dengue disease burden in Burkina
11
12 Faso, Gabon, and Kenya. These data can fill a gap in undocumented burden of dengue in the
13
14 region and, collectively, may be used to infer dengue burden in other areas of Western,
15
16 Central, and Eastern Africa. Countries in Africa may not consider introduction of a dengue
17
18 vaccine as the foremost priority in the near future due to many other competing public health
19
20 problems and limited resources as a major challenge. For cost-effective implementation of
21
22 public health interventions, accurate data on dengue burden from epidemiological studies
23
24 would be needed for policy makers to make evidence-based decisions on control and
25
26 prevention of dengue. Our studies will provide some much needed information based on
27
28 population-based research to assess dengue burden in Africa.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

List of abbreviations

GDAC - Global Dengue and *Aedes*-transmitted Diseases Consortium

IVI - International Vaccine Institute

DENV- dengue viruses

DVI - Dengue Vaccine Initiative

Ouaga-HDSS - health and demographic surveillance system

DHF - dengue hemorrhagic fever

CERMEL - Centre de Recherches Médicales de Lambaréné

ASH – Albert Schweitzer Hospital

CSPS - Centre de Santé et de Promotion Sociale

KEMRI - Kenya Medical Research Institute

SD – Standard Diagnostics

GIS = geographic information system

MFI - median fluorescence intensity

CRCHUM - Centre Hospitalier de l'Université de Montréal

Declarations

- Ethics approval and consent to participate

The protocol for each study obtained ethical approvals from the Institutional Review Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and the National Health Ethical Committee of Burkina Faso.

- Consent for publication

Not applicable

- Availability of data and material

Data sharing is not applicable to this article as no datasets were analyzed during the current study.

This manuscript does not include data from the studies described here in. This is a protocol paper. The datasets that are being generated for analysis as described in the current study are not yet publicly available as the studies are currently ongoing at the time of submission. They will be available from the corresponding author on reasonable request.

- Competing interests

The authors declare that they have no competing interests.

- Funding

The current study was supported by funds from the Bill and Melinda Gates Foundation (OPP 1053432). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

1
2
3
4 • Authors' contributions

5
6 JKL designed the study, is overseeing data collection, and was a major contributor in writing
7 the manuscript. MC co-designed the study, oversaw some parts of data collection, and
8 supported in writing of the manuscript. JSL was a contributor in designing of the study and
9 oversight of parts of data collection. KSL was a contributor in oversight of data collection.
10 SN supported in data collection. SKL supported in data collection. VR supported in designing
11 of the study and was a major contributor in finalization of the manuscript. JF was a
12 contributor in data collection. BL was a contributor in designing of the study and data
13 collection. SHM was a contributor in designing of the study and site establishment. ME was a
14 contributor in designing of the study. EA supported in data collection. NO supported in data
15 collection. AB supported in data collection. EB supported in data generation. SMN was a
16 contributor in designing of the study and site establishment. STA was a contributor in
17 designing of the study and site establishment. SY was a contributor in designing of the study
18 and site establishment. NA was a major contributor in providing oversight of the data
19 collection and finalization of the manuscript. IKY was a major contributor in designing of the
20 study and finalization of the manuscript.
21 All authors read and approved the final manuscript.
22
23
24

25
26
27 • Acknowledgements

28
29 We thank the doctors and laboratory staff of CSPS of Ouagadougou, ASH, Ganjoni
30 dispensary, Tudor sub-county Hospital, and Coast Provincial General Hospital, as well as at
31 Centre Muraz, CERMEL, and KEMRI. We thank collaborators at AGIR, IRD France, and
32 University of Montreal, and University of Tübingen. Lastly, we would like to thank the DVI
33 team and statisticians and administrative staff at the International Vaccine Institute for their
34 helpful comments during the preparation of this manuscript and support during the studies.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013;**496**(7446):504-7.
2. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. *Clin Epidemiol* 2013;**5**:299-309.
3. Chang M, Christophel E, Gopinath D, et al. Challenges and future perspective for dengue vector control in the Western Pacific Region, Regional Analysis. *Western Pacific Surveillance and Response Journal* 2011;**2**(2):9-16.
4. Eisen L, Beaty B, Morrison A, et al. Proactive Vector control strategies and improved monitoring and evaluation practices for dengue prevention. *J Med Entomol* 2009;**46**(6):1245-55.
5. Gubler D, Clark G. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* 1995;**1**(2):55-57. .
6. Amarasinghe A, Kuritsky J, Letson G, et al. Dengue virus infection in Africa. *Emerg Infect Dis* 2011;**17**(8):1349-54. .
7. Messina JP BO, Scott TW, Zou C, Pigott DM, Duda KA, Bhatt S, Katzelnick L, Howes RE, Battle KE, Simmons CP, Hay SI. Global spread of dengue virus types: mapping the 70 year history. *Trends Microbiol* 2014;**22**(3):138-46.
8. Fagbami A, Monath T, Fabiyi A. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. *Trans R Soc Trop Med Hyg* 1977;**71**(1):60-5.
9. Carey D, Causey O, Reddy S, et al. Dengue viruses from febrile patients in Nigeria, 1964-68. *Lancet* 1971;**1**(7690):105-6.
10. Beatty M, Stone A, Fitzsimons D, et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. *PLoS Negl Trop Dis* 2010;**4**(11):e890.
11. Were F. The dengue situation in Africa. *Paediatrics and Internatinoal Child Health* 2012;**32**(S1):18-21.
12. Sierra B, Triska P, Soares P, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. *PLoS Pathog* 2017;**13**(2):e1006220. .
13. Chacón-Duque J, Adhikari K, Avendaño E, et al. African genetic ancestry is associated with a protective effect on Dengue severity in colombian populations. *Infect Genet Evol* 2014;**27**:89-95. .
14. Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS neglected tropical diseases* 2012;**6**(8):e1760.
15. Collenberg E, Ouedraogo T, Ganame J, et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. *J Med Virol* 2006;**78**(5):683-92.
16. Ridde V, Agier I, Bonnet E, et al. Presence of three dengue serotypes in Ouagadougou (Burkina Faso): research and public health implications. *Infect Dis Poverty* 2016;**5**(23).
17. Caron M, Grard G, Paupy C, et al. First evidence of simultaneous circulation of three different dengue virus serotypes in Africa. *PloS one* 2013;**8**(10):e78030.
18. Leroy EM, Nkoghe D, Ollomo B, et al. Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007. *Emerging infectious diseases* 2009;**15**(4):591-3.

19. Caron M, Paupy C, Grard G, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012;**55**(6):e45-53.
20. Gabor J, Schwarz N, Esen M, et al. Dengue and chikungunya seroprevalence in Gabonese infants prior to major outbreaks in 2007 and 2010: A sero-epidemiological study. *Travel Med Infect Dis* 2016.
21. Pourrut X, Nkoghe D, Gonzalez JP, et al. No evidence of dengue virus circulation in rural Gabon. *Emerging infectious diseases* 2011;**17**(8):1568-9.
22. Andries A, Duong V, Ngan C, et al. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. *PLoS Negl Trop Dis* 2012;**6**(12):e1993.
23. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. *PLoS One* 2009;**4**(10):e7611. .
24. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med* 2011;**365**(20):1863-75. .
25. Ochieng C AP, Vittor AY, Nyoka R, Gikunju S, Wachira C, Waiboci L, Umuro M, Kim AA, Nderitu L, Juma B, Montgomery JM, Breiman RF, Fields B. Seroprevalence of Infections with Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya, 2007. *PLoS One* 2015;**10**(7).
26. Ellis EM, Neatherlin JC, Delorey M, et al. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. *PLoS Negl Trop Dis* 2015;**9**(4):e0003733.
27. United Nations Development Programme. Population, urban (% of population). In: *Reports HD*, ed.: UNDP, 2013.
28. United Nations. World Urbanization Prospects: The 2014 Revision, Highlights. In: *Department of Economic and Social Affairs PD*, ed. United Nations: United Nations, 2014.
29. Central Intelligence Agency. Age structure. *The world factbook* Central Intelligence Agency.
30. Ramharter M, Adegnika AA, Agnandji ST, et al. History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. *The Middle European Journal of Medicine, WIENER KLINISCHE WOCHENSCHRIFT* 2007;**119**(Suppl 3):8-12.
31. Schwarz NG, Gysels M, Pell C, et al. Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon. *Vaccine* 2009;**27**(2009):5371-75.
32. Kenya. Secondary Kenya. <https://en.wikipedia.org/w/index.php?title=Kenya&oldid=737329303>
33. Wichmann O, Yoon I, Vong S, et al. Dengue in Thailand and Cambodia: An assessment of the degree of underestimated disease burden based on reported cases. . *PLoS NTD* 2010.
34. Gibbons C, Mangen M, Plass D, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC public health* 2014;**14**(147).
35. European Centre for Disease Prevention and Control (ECDC). Data quality monitoring and surveillance system evaluation - A handbook of methods and applications. Stockholm: European Centre for Disease Prevention and Control (ECDC), 2014.

- 1
- 2
- 3
- 4 36. Mease L, Coldren R, Musila L, et al. Seroprevalence and distribution of arboviral
- 5 infections among rural Kenyan adults: a cross-sectional study. *Virology* 2011;**8**(371).
- 6 37. World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in
- 7 endemic areas. Geneva: World Health Organization, 2008.
- 8 38. Alm E, Lindegren G, Falk K, et al. One-step real-time RT-PCR assays for serotyping
- 9 dengue virus in clinical samples. *BMC Infect Dis* 2015;**15**(493).
- 10 39. Peeling R, Artsob H, Pelegrino J, et al. Evaluation of diagnostic tests: dengue. *Nature*
- 11 *Reviews Microbiology* 2010:S30-S37
- 12 40. Kraus A, Messer W, Haymore L, et al. Comparison of plaque- and flow cytometry-based
- 13 methods for measuring dengue virus neutralization. *J Clin Microbiol*
- 14 2007;**45**(11):3777-80.
- 15 41. de Alwis R, de Silva A. Measuring antibody neutralization of dengue virus (DENV) using
- 16 a flow cytometry-based technique. *Methods Mol Biol* 2014;**1138**:27-39.
- 17 42. Lambeth C, White L, Johnston R, et al. Flow cytometry-based assay for titrating dengue
- 18 virus. *J Clin Microbiol* 2005;**43**(7):3267-72.
- 19 43. Cabral-Castro M, Saramago Peralta R, Cavalcanti M, et al. A Luminex-based single DNA
- 20 fragment amplification assay as a practical tool for detecting and serotyping dengue
- 21 virus. *Journal of virological methods* 2016;**236**:18-24.
- 22 44. Balasuriya U, Shi P, Wong S, et al. Detection of antibodies to West Nile virus in equine
- 23 sera using microsphere immunoassay. *J Vet Diagn Invest* 2006;**18**(4):392-5.
- 24 45. Beck C, Desprès P, Paulous S, et al. A High-Performance Multiplex Immunoassay for
- 25 Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses. *Biomed Res*
- 26 *Int* 2015;**2015**(678084).
- 27 46. Hadinegoro SRS. The revised WHO dengue case classification: does the system need to
- 28 be modified? *Paediatr Int Child Health* 2012;**32**(S1):33-38.
- 29 47. Guilarde AO, Turchi MD, Siqueira Jr JB, et al. Dengue and Dengue Hemorrhagic Fever
- 30 among Adults: Clinical Outcomes Related to Viremia, Serotypes, and Antibody
- 31 Response. *The Journal of Infectious Diseases*; **197**(6): 817-24. .
- 32 48. Mossel E, Crabtree M, Mutebi J, et al. Arboviruses Isolated From Mosquitoes Collected
- 33 in Uganda, 2008-2012. *J Med Entomol* 2017;**54**(5):1403-09. .
- 34 49. Shope R, al. e. *The Flaviviruses: Detection, Diagnosis and Vaccine Development*:
- 35 Academic Press, 2003.
- 36 50. Nikolay B, Diallo M, Boye C, et al. Usutu virus in Africa. *Vector Borne Zoonotic Dis*
- 37 2011;**11**(11):1417-23.
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4 Fig. 1 Description of the study components, including passive facility-based fever
5 surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys
6
7
8
9

10
11 There are two arms in the study package, composed of four parts. In the health facility-based
12 arm of the study package, there are the passive facility-based fever surveillance and cost-of-
13 illness survey embedded within the surveillance. In the community arm of the study, there are
14 serological survey and healthcare utilization survey.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Fig. 2 Map of the study area in Ouagadougou, Burkina Faso

5
6 Fig. 3 Map of the study area in Lambaréné, Gabon

7
8
9 Fig. 4 Map of the study area in Mombasa, Kenya

10
11
12
13 Figures 2 – 4 show the map of the study area at each site in Burkina Faso, Gabon, and Kenya.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 5 Patient flow in the fever surveillance
5
6
7

8 Eligible febrile patients identified and enrolled as study subjects will follow these steps to
9
10 complete participation in the passive fever surveillance.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 6 Laboratory testing algorithm for dengue
5
6
7

8
9 Samples from subjects of the passive fever surveillance would follow these steps of the
10
11 testing algorithm for confirmation of dengue.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1 Description of study components, including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Fig. 2 Map of the study area in Ouagadougou, Burkina Faso

A map of the city and distribution of the population in Ouagadougou, Burkina Faso


140x198mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




A map of the city and distribution of the population in Lambaréné, Gabon

140x198mm (300 x 300 DPI)



A map of the city and distribution of the population in Mombasa, Kenya

140x198mm (300 x 300 DPI)



* A small number of those samples that are negative on ELISA or NS1 are tested with PCR to exclude false negative results of the ELISA.

Patient flow in the fever surveillance - Eligible febrile patients identified and enrolled as study subjects will follow these steps to complete participation in the passive fever surveillance.

140x198mm (300 x 300 DPI)




Fig. 6 Laboratory testing algorithm for dengue

* Dengue Duo® test is performed on enrolled febrile patients to identify dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey.

**Selected samples, including those that were found positive by IgM and NS1 on Dengue Duo® as well as those positive by IgM and IgG capture ELISA, will be tested with RT-PCR.

Laboratory testing algorithm for dengue: Samples from subjects of the passive fever surveillance would follow these steps of the testing algorithm for confirmation of dengue.

140x198mm (300 x 300 DPI)

BMJ Open

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies: protocol of field studies of the Dengue Vaccine Initiative

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017673.R3
Article Type:	Protocol
Date Submitted by the Author:	25-Sep-2017
Complete List of Authors:	<p>Lim, Jacqueline; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health</p> <p>Carabali, Mabel; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium</p> <p>Lee, Jung-Seok; International Vaccine Institute, Development and Delivery</p> <p>Lee, Kang Sung ; International Vaccine Institute, Development and Delivery</p> <p>Namkung, Suk; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium</p> <p>Lim, Si-Ki; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium</p> <p>Ridde, Valéry; Université de Montréal Ecole de Santé Publique, ESPUM; Université de Montréal, Département de médecine sociale et préventive</p> <p>Fernandes, Jose; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer</p> <p>Lell, Bertrand; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer</p> <p>Matendehero, Sultani ; Ministry of Health, Kenya, Communicable Disease Prevention and Control</p> <p>Esen, Meral; University of Tübingen, Institute of Tropical Medicine</p> <p>Andia, Esther; Kenya Medical Research Institute, Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)</p> <p>Oyembo, Noah; Kenya Medical Research Institute, Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)</p> <p>Barro, Ahmed; Action-Gouvernance-Integration-Reinforcement, Program Equité</p> <p>Bonnet, Emmanuel ; Institut de recherche pour le développement</p> <p>Njenga, Sammy; Kenya Medical Research Institute, Eastern & Southern Africa Centre of International Parasite Control (ESACIPAC)</p> <p>Agnandji, Selidji ; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer</p> <p>Yaro, Seydou; Centre MURAZ</p> <p>Alexander, Neal; London School of Hygiene and Tropical Medicine Faculty of Epidemiology and Population Health</p> <p>Yoon, In Kyu; International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium</p>
Primary Subject Heading:	Infectious diseases

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Infectious diseases, Epidemiology, Global health, Public health
Keywords:	dengue, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES, Tropical medicine < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

For peer review only

Evaluating dengue burden in Africa in passive fever surveillance and sero-prevalence studies:
protocol of field studies of the Dengue Vaccine Initiative

Jacqueline K. Lim^{1 11*}, Mabel Carabali¹, Jung-Seok Lee², Kang Sung Lee², Suk Namkung¹,
SI-Ki Lim¹, Valery Ridde³, Jose Fernandes⁴, Bertrand Lell⁴, Sultani Hadley Matendecheo⁵,
Meral Esen⁶, Esther Andia⁷, Noah Oyembo⁷, Ahmed Barro⁸, Emmanuel Bonnet⁹, Sammy M.
Njenga⁷, Selidji Todagbe Agnandji⁴, Seydou Yaro¹⁰, Neal Alexander¹¹, In Kyu Yoon¹

¹International Vaccine Institute, Global Dengue and Aedes-transmitted Diseases Consortium, Seoul, Korea, Republic of; ²International Vaccine Institute, Development and Delivery, Seoul, Korea, Republic of; ³Montreal School of Public Health (ESPUM), Montreal, QC, Canada; ⁴Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer, B.P.242, Lambaréné, Gabon; ⁵Communicable Disease Prevention and Control, Ministry of Health, Nairobi, Kenya; ⁶Institute of Tropical Medicine, University of Tübingen, Germany; ⁷Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; ⁸Action-Gouvernance-Integration-Reinforcement (AGIR), Program Equité, Ouagadougou, Burkina Faso; ⁹Institut de Recherche pour le Développement (IRD), Paris, France; ¹⁰Centre Muraz, Bobo-Dioulasso, Burkina Faso; ¹¹Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine

*Corresponding author

Jacqueline K. Lim^{1*}, MPH

Research Scientist

Global Dengue and Aedes-transmitted Diseases Consortium (GDAC)

International Vaccine Institute (IVI)

SNU Research Park, Gwankak-ro 1

Gwanak-gu, Seoul, Korea 151-191

T: +82-2-881-1340 (Dir) / +82-2-872-2801 (ext. 340)

Email: kalim@ivi.int

37 pages

Word count of the text: 6,516 (not counting the Abstract and table 1)

Word count of the abstract: 319

Figures and tables: 6 figures and 1 table

Abstract

Introduction.

Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardized methods were launched in three locations in Africa.

Methods and Analysis.

In 2014-17, the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; to obtain comparable incidence data on dengue and assess its burden through standardized hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys, and healthcare utilization surveys. All three sites conducted case detection using standardized procedures with uniform laboratory assays to diagnose dengue. Healthcare utilization surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between dengue and non-dengue patients using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3,000 randomly selected residents at each site at 6-month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test.

Ethics and Dissemination.

The protocol for each study obtained ethical approvals from the Institutional Review Boards of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions. By standardizing methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals by the end of 2017.

Strengths of this study

- There have not been population-based studies conducted with a multi-disciplinary approach (i.e. surveillance, healthcare utilization, and sero-survey in one catchment area population). Data from the passive surveillance will be used to calculate annual incidences of dengue and data from the serosurvey will estimate the force of infection and prevalence.
- The studies were conducted in three locations in Africa, based on standardized methods and laboratory algorithm. Thus, comparison by site would be possible.

Limitations of this study

- 1
2
3
4 - This is not a cohort study. The passive facility-based surveillance may lead to under-
5 estimation of the burden of dengue fever by measuring incidence based on only those
6 that sought care at our study facilities.
7
8 - There may be limited generalizability of our study results to other dengue-endemic
9 parts of Africa.
10

11
12 Keywords: dengue; Africa; seroepidemiologic Studies; incidence
13

14 Running head: Evaluating dengue burden in Africa: DVI field studies
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Dengue fever, a mosquito-borne flavivirus infection caused by four related but antigenically distinct dengue viruses (DENVs, serotypes 1–4), is a major and rapidly increasing global public health problem. Recent studies have estimated an annual incidence of 50–100 million symptomatic infections globally¹. Dengue is a high burden disease that disproportionately affects countries in the tropics and subtropics, many of which have limited health care resources². Although one dengue vaccine has been recently licensed in several endemic countries, the vaccine has restricted age and epidemiological indications. Other prevention and control measures such as vector control are suboptimal as stand-alone interventions^{3,4}, and no drugs for treatment are currently available.

Like in Asia and the Americas, epidemics of dengue were reported from Africa in the late 19th and early 20th centuries^{5,6}. Specifically for Africa, there are records of multiple dengue case reports between 1964 and 1968 with DENV 2 in Nigeria⁷. Data from several studies conducted in the 1960–70s in Nigeria supported a substantially high level of immunity in adults as well as children^{8,9}. In 2011, Amarasinghe et al. conducted a comprehensive review of literature on dengue in Africa and described that dengue cases have been reported in 34 countries in Africa, with most of these countries also having *Aedes* mosquitoes⁶. However, prior studies which suggested the presence of dengue in Africa were limited by their retrospective design or sample collection (blood donors or sample collected from surveys of other diseases), and often from travellers, with a small number of reported autochthonous cases, to demonstrate the true, population-based, burden of dengue. Also, while many dengue endemic countries in Asia and Latin America have mandatory reporting of dengue cases to public health authorities, and national surveillance systems in place to monitor incidence patterns¹⁰, most African countries lack such established reporting

1
2
3
4 mechanisms and only sporadic outbreaks and individual case reports have been documented.
5
6 In addition, the frequently non-specific clinical presentation of dengue may be difficult to
7
8 distinguish from the myriad other infectious diseases present in Africa, since dengue
9
10 diagnostic assays are not widely available. Thus, the burden of dengue remains largely
11
12 unknown in Africa^{6 11}. Without such dengue burden data, informed decision-making about
13
14 prevention and control measures, including dengue vaccine introduction, in Africa are not
15
16 possible.
17
18

19
20 Limited by surveillance capacity hindering continuous reporting in the region, there
21
22 had not been frequent and systematic reporting of dengue in Africa. African ancestry is
23
24 known to be protective against severe dengue and the candidate genes were recently
25
26 identified in a Cuban patient^{12 13}. Bhatt et al.'s modelling of the global dengue burden
27
28 suggests high burden in Africa in terms of equal numbers of infections (both apparent and
29
30 inapparent) as in Latin America¹. There are new findings about dengue in Africa, but there is
31
32 still much unknown about the magnitude of the dengue problem in the continent. To improve
33
34 estimates of population-based dengue disease burden in Africa and validate whether the
35
36 undocumented burden of dengue is as high in Africa as in the Americas with empirical data,
37
38 the Dengue Vaccine Initiative (DVI) initiated field studies at three sites in West, West-
39
40 Central, and East Africa in Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa,
41
42 Kenya; respectively. In each of the three sites, a standardized package of study components,
43
44 including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-
45
46 illness surveys, and serological surveys (Fig 1), was initiated between December 2014 and
47
48 March 2016.
49
50
51

52
53
54
55 Methods

Site selection

Study sites were selected, in part, based on their likelihood of supporting DENV transmission. To select sites, we considered dengue outbreaks and cases reports in the literature, available seroprevalence studies, as well as country-specific dengue risk maps of the probability of DENV transmission and the level of evidence of dengue presence, reporting the uncertainty of the consensus estimates of dengue in Africa^{7 14}. In addition, adequate research infrastructure to implement the studies was taken into account. Finally, inclusion of different regions of Africa was also a factor in site selection. Thus, Ouagadougou, Burkina Faso; Lambaréné, Gabon; and Mombasa, Kenya; were selected, respectively, to measure the burden of dengue in selected sites from West, (West-) Central, and East Africa.

In Burkina Faso, the first reported dengue outbreak occurred in Ouagadougou in 1982 due to DENV-2⁶. Serological prevalence of dengue antibodies among pregnant women and blood donors was found to be 26.3% in a rural setting (Nouna village) and 36.5% in an urban setting (Ouagadougou) in 2006¹⁵. More recently, an observational study conducted by Ridde et al. among febrile patients consulting at selected study facilities in 2013-14 showed 8.7 % (33/379) to be positive by dengue RDT; and 15 of 60 samples tested by RT-PCR to be dengue positive¹⁶. With evidence for the presence of dengue, along with a strong health and demographic surveillance system (Ouaga-HDSS) which could be used to describe the demographic characteristics of the catchment area, a field study was initiated in Ouagadougou, Burkina Faso in December 2014.

In Gabon, cases of dengue hemorrhagic fever (DHF) caused by up to three different DENV serotypes have been reported, and dengue seroprevalence has been found to be between 5 and 20%¹⁷⁻¹⁹. Results of a recently published study demonstrated seroprevalence of 12.3% among toddlers approximately 30 months of age in semi-rural Lambaréné between 2007 and 2010²⁰. However, a different study in 2005-2008 suggested minimal DENV

1
2
3
4 transmission in rural areas of Gabon²¹. This latter study examined antibodies against dengue
5
6 in individuals from randomly selected villages representing about 10% of all Gabonese
7
8 villages. Blood samples were tested by anti-DENV IgG and IgM capture ELISA and found to
9
10 have only minimal IgG (0.5%) and IgM (0.5%) seroprevalence. Based on these low
11
12 prevalences, the authors concluded that there was no active circulation of DENV in rural
13
14 Gabon. However, the low seroprevalence may have been affected by low sensitivities of the
15
16 tests used, leading to a high rate of false negative, and/or selection bias in the blood sample
17
18 pool among the selected villagers²². Seroprevalence estimates in the 2007/2010 study may
19
20 have also been impacted by the possibility of false-positive results due to IgG cross-reactivity
21
22 among flaviviruses²¹. Nevertheless, given the possibility of DENV circulation in Gabon, a
23
24 field study was initiated in Lambaréné in March 2015 in a community with a catchment
25
26 population of about 77,000 residents, using the clinical research infrastructure of the Centre
27
28 de Recherches Medicales de Lambaréné (CERMEL), benefiting from experienced research
29
30 staff who conducted a large Phase 3 malaria vaccine trial^{23 24}.

31
32
33 In Kenya, more evidence is available for the presence of dengue based on local data.
34
35 Dengue was the most common viral pathogen in retrospectively tested blood specimens from
36
37 HIV-negative survey samples from the 2007 Kenya AIDS Indicator Survey. Antibody testing
38
39 for dengue as well as chikungunya and Rift Valley fever was performed by IgG ELISA using
40
41 either commercial kits or CDC assays; 12.5% were found to be dengue positive²⁵. Similarly,
42
43 a household survey found 13% of individuals from 701 households in Mombasa had
44
45 serological evidence of either past or current DENV infection²⁶. These data suggest that
46
47 there is more dengue in Kenya than indicated by public health reporting, possibly due to
48
49 misdiagnosis^{25 26}. A field study was initiated in Mombasa, Kenya in March 2016.

50 51 52 53 54 55 56 57 *Study participants*

1
2
3
4
5 For the passive facility-based fever surveillance, individuals who met the following criteria
6
7 were eligible for study enrollment:
8

- 9 1. Age 1- 55 years old;
- 10 11 2. Resident of the catchment area covered by healthcare facilities participating in the
12 study, without plans to move out of the catchment area within 12 months;
- 13 14 3. Signed informed consent, and assent for those aged between 7 and 18 years; and
- 15 16 17 4. Patients presenting with current fever (axillary temperature $\geq 37.5^{\circ}$ C) or history of
18 fever for ≤ 7 days duration without localizing signs (fever caused by a localized
19 infection as well as fever with a known and confirmed etiology other than dengue,
20 such as malaria confirmed by malaria RDT- listed in the patient identification SOP).
21
22
23
24
25
26
27
28
29

30 For the serological survey, criteria 1-3 were applied. For the healthcare utilization
31 survey, household interviews were conducted among the heads or representatives of the
32 household invited from each family participating in the serosurvey.
33
34
35
36
37
38
39

40 *Study area and population*

41 Burkina Faso, located in West Africa, has a population of 14,017,462. The country is
42 mainly rural with about 29% of the population reported to be living in urban areas in 2014.
43 However, Burkina Faso is urbanizing rapidly and is positioned as the country with the fourth
44 fastest urbanization in the last 25 years^{27,28}. The capital, Ouagadougou, has a population of
45 2,741,128. The majority of the population live in urban settings. About 45% of the population
46 are under 15 years of age²⁹. The city is divided into 12 districts and 52 sectors. Ouagadougou
47 is the country's largest city and the cultural and economic center. The city is part of the
48 Soudano-Sahelian area, with a rainfall of about 800 mm per year. The rainy season is from
49
50
51
52
53
54
55
56
57
58
59

1
2
3
4 May to October, with a mean temperature of 28 °C (82 °F). The cold season runs from
5
6 December to January, with a minimum average temperature of 16 °C (61 °F). During the hot
7
8 season, which runs from March to May, the temperature can reach as high as 43 °C (109 °F).
9

10
11 The Health and Demographic Surveillance System is in place in Ouagadougou.
12
13 Ouaga-HDSS monitors a population of 81,717 residents; according to this surveillance
14
15 system, the city population is very stable with a rate of migration of 4.1% and more than 80%
16
17 of the inhabitants with ownership of their houses [20]. A map of the city and distribution of
18
19 the population is shown in Figure 2.
20
21

22
23 Gabon, located on the west coast of Central Africa, has an area of nearly 270,000
24
25 square kilometres (100,000 sq. mi) with a population estimated at 1.5 million. Its capital and
26
27 largest city is Libreville. In 2014, it is reported that 87% of the Gabonese population lived in
28
29 urban areas ²⁸. The sixth largest city, Lambaréné, the capital of Moyen-Ogooué province, is
30
31 located 75 kilometers south of the equator, with a population of 25,257 in 2009. The majority
32
33 of Lambaréné residents live in semi-rural areas. About 42% of the Gabonese population is
34
35 under 15 years of age ²⁹. Similarly, Lambaréné's population is relatively young with about 50%
36
37 under 20 years of age.
38
39

40
41 The health services of Gabon are mostly public, but there are some private
42
43 institutions as well. With one of the best medical infrastructure in the region, almost 90% of
44
45 the population have access to health care services. Albert Schweitzer Hospital (ASH) is a
46
47 private institution which served as a study site for the passive fever surveillance study ^{30 31}.
48
49 The study area in Lambaréné is shown in Figure 3.
50

51
52 Kenya, located in East Africa, lies on the equator, covering 581,309 km²
53
54 (224,445 sq. mi), with a population of approximately 45 million people in 2014 [2]. Kenya
55
56 generally has a warm and humid tropical climate but is diverse, ranging from the cooler
57
58
59
60

1
2
3
4 climate around the capital city, Nairobi, to a hot and dry climate inland, as well as a desert-
5
6 like climate in the north-eastern regions along the border with Somalia and Ethiopia ³². The
7
8 capital, Nairobi, is a regional commercial hub. The main industries include agriculture,
9
10 exporting tea and coffee, as well as the service industry.

11
12 Kenya is divided into 47 semi-autonomous counties. Mombasa is the country's
13
14 second largest city after Nairobi and is located on the east coast of the country [2].
15
16 Administratively, Mombasa is the capital of Mombasa County, which was formerly called
17
18 Coast Province. This overall Coast region covers over 80,000 km² in the south-eastern part of
19
20 Kenya, constituting about 15% of the country's land area, with a population of 3,325,307
21
22 residents.

23
24
25 The main economic driver of Mombasa is tourism and trading industry. Mombasa
26
27 itself has a population of about 1.3 million with almost 50% of the population under 15 years
28
29 of age ²⁹. Increasingly, the population of the province lives in urban areas; at present about 45%
30
31 live in Mombasa and other urban centers. The “long rains” period begins around April and
32
33 the “short rains” period begins in October ³². Mean annual temperature ranges from 24°C to
34
35 27°C, but maximum temperature averages over 30°C during the hottest months, January to
36
37 April.

38
39
40 Figure 4 shows the area of Mvita subcounty of Mombasa, which was the catchment
41
42 area for the study in Kenya, with a catchment population of 74,735 residents. The map
43
44 indicates the three facilities involved in the study.
45
46
47

48 49 50 *Sample size*

51
52 Given the paucity of available age-specific dengue incidence data in the study
53
54 countries or nearby countries, it was difficult to obtain population-based incidence to make
55
56 assumptions when calculating sample sizes. The required catchment population for the
57
58
59
60

1
2
3
4 passive facility-based fever surveillance was roughly estimated based on the limited data
5
6 available in the literature. Annual incidence estimates were calculated based on available
7
8 prevalence estimates with the assumption that the outcome of interest has zero prevalence at
9
10 age zero, and that force of infection is constant. It was assumed that prevalence estimates
11
12 found for one particular age group would be adjusted as the annual incidence and used across
13
14 all ages.

15
16
17 Wichmann et al. calculated an expansion factor for children by comparing data from
18
19 three cohort studies to national surveillance data in Southeast Asia³³. For children in
20
21 Thailand, the age-specific expansion factors calculated were 11.85 for <5 years, 8.76 for 5-9
22
23 years, and 7.81 for 10-14 years³³. The results show that, even for Asia where better reporting
24
25 and surveillance systems are available, there is a considerable degree of underreporting. For
26
27 Africa, there may be more dengue cases under-ascertained (not seeking care) and under-
28
29 reported (not reported even if a patient with dengue seeks care, given that dengue is not one
30
31 of the routinely notifiable diseases in Africa), but such information on the extent of
32
33 underestimation of dengue was not available^{34 35}. Also, the incidence estimates used in our
34
35 sample size calculations were not from population-based studies. While it would have been
36
37 ideal to adjust the incidence further for likely underestimation, the annual incidence used in
38
39 sample size calculations could not be adjusted for possible under-reporting due to the lack of
40
41 data. The sample sizes were calculated with 95% confidence levels and a margin of error at a
42
43 fixed significance level within 25% of the true proportion of incidence. This gives relative
44
45 precision of 75%, considering the gap in evidence for dengue incidence in the study areas.
46
47
48 The final sample sizes were calculated by assuming 20% non-response rate or loss to follow-
49
50 up. The required catchment population size for the fever surveillance study in Burkina Faso
51
52 was estimated to be 100,000, Gabon to be 77,000, and Kenya to be 70,000. In these
53
54 catchment populations, the number of enrolled subjects depends on the number of eligible
55
56
57
58
59
60

1
2
3
4 patients who seek care at the study facilities. How many eligible febrile episodes would
5
6 actually present at our study facilities was difficult to predict; but after assessment of the
7
8 volume of febrile patients at the facilities, a realistic upper limit for enrollment for a study
9
10 period of approximately 1.5 years was set at 3,000 subjects to offer enrollment to all
11
12 consenting eligible patients.

13
14
15 For the serological survey, the sample size was calculated similarly using the
16
17 prevalence proportion based on published literature. Seroprevalence of 0.304 for Burkina
18
19 Faso ¹⁵, 0.123 for Gabon ²¹, and 0.144 for Kenya ³⁶ were used. With the same confidence
20
21 levels and allowed margin of error, and assuming 10-30% (variable by site) non-response rate,
22
23 the sample size was calculated to be 3,000 participants at each site. Again, with the scarcity
24
25 of data from the selected countries, there were no other prevalence estimates reported or
26
27 estimates from different age groups. As prevalence is expected to increase with age, and
28
29 higher prevalence would give a smaller sample size, our calculations are likely to be
30
31 conservative.
32
33

34 35 36 37 *Study components*

38 39 40 Fever surveillance – design and methods

41
42
43 To determine burden due to symptomatic dengue in each of the three sites in Burkina
44
45 Faso, Gabon, and Kenya, passive facility-based fever surveillance was implemented in a
46
47 well-defined catchment area population. In Burkina Faso, the surveillance study was initiated
48
49 in December 2014 in five selected primary health care centres, locally called “Centre de
50
51 Santé et de Promotion Sociale” (CSPS), in the municipality of Ouagadougou, with a
52
53 catchment population of 105,000 residents. This project was implemented in collaboration
54
55 with Centre Muraz in Bobo-Dioulasso, EQUITE sante program (a collaborative program
56
57
58
59
60

1
2
3
4 between University of Montreal and Action-Gouvernance-Integration-Reinforcement, AGIR,
5 based in Ouagadougou, funded by the Canadian Institute of Health Research), and DVI. In
6 Gabon, the surveillance study was initiated in the Albert Schweitzer Hospital serving a
7 catchment population of 130,000 residents in the Moyen-Ogooué and surroundings within
8 Lambaréné, in collaboration with CERMEL and Institute of Tropical Medicine in Tübingen,
9 Germany. In Kenya, the surveillance study was implemented at Ganjoni dispensary, Tudor
10 sub-county Hospital, and Coast Provincial General Hospital, serving a catchment population
11 of 70,000 residents in Mombasa, in collaboration with Kenya Medical Research Institute
12 (KEMRI) and Ministry of Health of Kenya.

13
14
15
16
17
18
19
20
21
22
23
24 As described in Figure 5, both outpatients and inpatients at the designated study
25 facilities, who meet inclusion criteria as mentioned earlier are tested for dengue, first with SD
26 Dengue Duo[®] RDT. Dengue confirmation is done by detection of dengue virus in serum
27 samples using PCR, as well as anti-dengue IgM and IgG antibodies in acute and convalescent
28 serum by ELISA (SD Dengue IgM & IgG capture ELISA[®] tests, Standard Diagnostics,
29 Yongin-Si, Korea)^{10 37}. Every consecutive patient meeting inclusion criteria is eligible for
30 enrolment during the study period. Infants < 1 year old were not included due to operational
31 limitations, such as difficulty of infantile bleeding.

32
33
34
35
36
37
38
39
40
41
42
43
44
45 In Ouagadougou, Burkina Faso, the fever surveillance was initiated in December
46 2014 and continued until February 2017 (approximately 2 years). In Lambaréné, Gabon, the
47 fever surveillance was initiated in April 2015 and continued until January 2017
48 (approximately 1.5 years). In Mombasa, Kenya, the fever surveillance was initiated in March
49 2016 and continued until June 2017.

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Among subjects enrolled in the fever surveillance, those who are positive by dengue

1
2
3
4 rapid diagnostic test are offered further enrolment in the cost-of-illness survey, consisting of
5
6 interviews on the day of acute illness visit, day 10-14 from the first visit, and day 28, if
7
8 illness continues. The cost-of-illness survey questionnaire was designed to estimate the direct
9
10 medical, direct non-medical, and indirect costs associated with dengue-positive patients
11
12 identified at study facilities. This survey also estimates the cost of treating dengue at the
13
14 facility level. Data are gathered by linking patients' medical records concerning outpatient
15
16 visits, inpatient visits, and service consumption (e.g., diagnostic tests, medication, and other
17
18 services provided to patients). The cost-of-illness portion of the study will be described
19
20 separately.
21
22
23

24 25 26 Fever surveillance – laboratory testing 27

28
29 As shown in Figure 6, in all three sites, acute samples are tested using a commercial
30
31 RDT for dengue NS1 and IgM/IgG (Dengue Duo[®], Standard Diagnostics, Yongin-Si, Korea).
32
33 Dengue Duo RDT is used on the day of acute illness visit at the site of patient presentation
34
35 (day 1). The acute and convalescent samples are subsequently tested at a local laboratory
36
37 using dengue IgM/IgG ELISA (SD Dengue IgM & IgG Capture ELISA[®], Standard
38
39 Diagnostics, Yongin-Si, Korea). The serum is separated and stored in 4 aliquots of about 500
40
41 µL for various laboratory tests, as indicated in consent documents.
42
43
44
45

46 After ELISA testing, samples will be shipped to the International Vaccine Institute
47
48 (IVI) in Korea. Samples with positive results by RDT or ELISA undergo further testing by
49
50 RT-PCR at the Clinical Immunology Laboratory of IVI. Four DENV serotype-specific real-
51
52 time RT-PCR assays are used for laboratory confirmation of dengue, and serotyping³⁸. The
53
54 DENV 1-4 RT-PCR assays are carried out in 25µL reaction mixtures containing 5µL
55
56
57
58
59
60

1
2
3
4 template RNA, TagMan® Fast Virus 1-step mastermix (Applied Biosystems®), 0.9 µM of
5
6
7 each primer, and 0.2 µM probe³⁸. Amplification and detection are performed in a StepOne
8
9
10 Plus real-time PCR system, and the baseline and threshold are determined using the auto-
11
12 baseline and threshold feature in StepOne Software v2.2.2 (Applied Biosystems®).
13
14 Thermocycling parameters are as follows: reverse transcription at 50 °C for 5 min,
15
16 inactivation at 95 °C for 20 s, followed by 45 cycles of fluorescence detection at 95 °C for 3 s,
17
18 and annealing at 60 °C for 30 s³⁸. A specimen is considered positive if target amplification is
19
20 recorded within 40 cycles.
21
22
23
24
25

26 Serological survey – design and methods

27
28
29 While the facility-based fever surveillance studies provide estimates of the burden of
30
31 medically-attended dengue disease, evaluation of all DENV infections in a population –
32
33 including subclinical and mildly symptomatic infections, which impact immune status – is
34
35 needed to capture the overall impact of dengue. As part of the study package, population-
36
37 based serological surveys were conducted in the same catchment population used for the
38
39 fever surveillance. At each of the three sites in Africa, the serosurvey was conducted on a
40
41 cohort of approximately 3,000 randomly selected residents of urban and semi-urban parts of
42
43 Ouagadougou, Lambaréné, and Mombasa. Without individual-level census information on all
44
45 residents of Lambaréné and Mombasa, with help of community/village health workers,
46
47 randomization was done based on neighbourhoods (or defined areas for which the health
48
49 workers/volunteers are responsible) as cluster units. As the community/village health workers
50
51 are familiar with the villages and their residents, they are good entry points into the
52
53 communities. With these health workers, the field team screened houses in the selected
54
55
56
57
58
59
60

1
2
3
4 villages by knocking on doors of every 5~7 houses, depending on the household density per
5
6 neighbourhood. Also, demographic information collected in previous research projects
7
8 conducted in the same area was used as a guide, if available. In the case of the site in
9
10 Ouagadougou, HDSS data were available and the EQUITE SANTE, a CIHR funded research
11
12 program of the University of Montreal, had set up a geographic information system (GIS)
13
14 database of houses in the study area. Using these data, households of potential enrollees of
15
16 the serosurvey were pre-selected randomly and household visits were made in Ouagadougou.
17
18 In the three sites, about 45% of the serosurvey samples were targeted to be collected from
19
20 children 1 - 14 years-of-age, and 55% were targeted to be collected from adults between 15
21
22 and 55 years of age to reflect the age distribution of the general population of the area.
23
24 Household-based enrollment was offered to the head of the household until the specific cap
25
26 for the age-group was reached in Lambaréné and Mombasa.
27
28
29

30
31 Randomly-selected subjects 1-55 years of age underwent phlebotomy (5ml for
32
33 children and 7ml for adults) twice — before the rainy season and after the rainy season, at
34
35 approximately 6-month intervals. The sera were evaluated using IgG indirect ELISA at
36
37 baseline and after 6 months. The presence of dengue IgG antibodies at 6-month intervals will
38
39 be used to estimate the level of occurrence of inapparent DENV infection and to calculate the
40
41 rate of infection in the catchment population. Flow cytometry-based DENV neutralization
42
43 assays will be applied to a subset of samples to assess for presence of dengue neutralizing
44
45 antibodies and seroconversion over the 6-month interval. In addition to overall
46
47 seroconversion, age-specific seroconversion estimates in the catchment population, as well as
48
49 the proportion of inapparent infections, will be determined.
50
51
52
53
54
55
56
57
58
59
60

Serological survey – laboratory testing

From the samples collected in the serosurvey, about 200 μ L of serum are used and tested at a local laboratory using dengue IgG ELISA (Panbio Dengue IgG Indirect ELISA[®], Alere North America, LLC, Florida, United States). After ELISA testing for dengue IgG at the local laboratories, samples will be shipped to IVI. Given potential serological cross-reactivity among flaviviruses³⁹, flow cytometry-based neutralization assays will be performed against selected flaviviruses to include yellow fever virus, West Nile virus, Zika virus, and Japanese Encephalitis virus at the Clinical Immunology Lab of IVI^{40,41}. About 50 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in Gabon and Kenya will be tested.

About 1,000 μ L of serum is allotted for this procedure. The flow cytometry-based neutralization assays are performed in duplicate in 96-well cell culture plates with flat-bottom wells, each containing DC-SIGN-expressing U937 cells⁴⁰. The amount of virus used in the assay infects between 7 and 15% of the cells. Human immune sera are serially diluted and the virus is pre-incubated with the sera for 1 h at 37°C⁴⁰. The cells are washed, and the virus and serum mixture is added to the cells for 1 h at 37°C, and the cells are further incubated for 24 to 48 h at 37°C in 5% CO₂. The cells are fixed, permeabilized, and stained with fluorescein-conjugated monoclonal antibody 4G2, which recognizes the flavivirus E protein⁴². FACScan flow cytometer (Becton Dickinson, San Diego, CA) is used to analyze the cells⁴⁰. The serum dilution that neutralizes 50% of the viruses is calculated by nonlinear, dose-response regression analysis with Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).

In addition, a Luminex-based multiplex immunoassay will be performed on a randomly selected sub-sample to assess for IgG to different flaviviruses⁴³. About 200

1
2
3
4 samples per bleed for 4 bleeds in Burkina Faso and 2 bleeds in Gabon will be tested.
5
6 Detection of IgG against ZIKV and each of the four DENV serotypes will be performed on
7
8 patient serum samples using an in-house microsphere-based multiplex immuno-assay (arbo-
9
10 MIA) at the Clinical Immunology Lab of IVI^{44,45}. The arbo-MIA is based on a mixture of
11
12 microspheres covalently coupled with either DENV-1, -2, -3, -4 or ZIKV recombinant
13
14 antigens (E protein domain III) produced in Drosophila S2 expression system. Briefly,
15
16 microsphere mixtures were sequentially incubated in the dark under constant shaking with a
17
18 1:400 dilution of patient serum samples, with 2 µg/mL anti-human IgG biotin-conjugated
19
20 antibody (Jackson ImmunoResearch, West Grove, PA) and with 2 µg/mL streptavidin-R-
21
22 phycoerythrin conjugate (Life technologies). After the final incubation, the median
23
24 fluorescence intensity (MFI) of each microsphere set is quantified using a BioPlex 200
25
26 instrument (Bio-Rad Laboratories, Hercules, CA). Samples are considered seropositive if the
27
28 ratio of MFI values obtained for the viral antigen to the control antigen is superior to the
29
30 defined cut-off. The cut-off of the MIA is determined for each viral antigen by ROC curve
31
32 analysis using well characterized sera.
33
34
35
36

37
38 In Lambaréné, the enrolment bleed took place in November -December 2015, while
39
40 the 2nd blood collection occurred in May 2016. In Ouagadougou, the enrolment bleed took
41
42 place in May-June 2015 with follow-up blood collections in December 2015, June 2016, and
43
44 January 2017. In Mombasa, the enrolment bleed took place in May 2016 with the 2nd blood
45
46 collection in November 2016 – February 2017.
47
48
49
50

51 Healthcare Utilization Survey

52
53
54 As the passive fever surveillance is conducted at study facilities, potential dengue
55
56 patients could be missed if they seek care elsewhere. To identify the proportion of fever and
57
58
59
60

1
2
3
4 dengue cases potentially missed by the passive surveillance system due to patients living in
5
6 the study area but seeking care outside of study facilities, a population-based healthcare
7
8 utilization survey was conducted in 400 randomly selected households from the study
9
10 catchment area to characterize the healthcare utilization patterns of the households when they
11
12 have (self-reported) febrile episodes among the family members. In addition to assessing
13
14 health-seeking behaviours of the residents, preferences in terms of health-seeking behavior
15
16 and respective reasons for their preferences were investigated. The questionnaire was
17
18 administered to 400 heads of households. Among 3,000 residents who participated in the
19
20 serosurvey, there were about 600 households. From these households, 400 heads of
21
22 households were randomly selected and offered enrolment in the health utilization survey.
23
24 Heads of households or a senior representative within the household were asked questions on
25
26 health seeking patterns of their family members.
27
28
29
30
31
32

33 *Study questionnaires*

34
35 For the fever surveillance study, questionnaires are administered at the acute illness visit and
36
37 the convalescent visit. The convalescent visit may take place at the health care facility (10-14
38
39 days later) or at the patient's home (15-21 days after the acute visit), according to patient
40
41 preference and availability. The questionnaires are completed by medical staff of the study
42
43 facilities, including demographic and clinical information (e.g., signs, symptoms, past
44
45 medical history, treatments prescribed, and diagnoses). The same staff also complete the
46
47 follow-up questionnaire at the convalescent visit within 21 days from the acute visit. Study
48
49 nurses complete surveillance enrolment log. Lab technicians complete the lab section (mostly
50
51 dengue-related diagnostics) and the forms are compiled by the study coordinator on site.
52
53
54

55 For the serosurvey component, questionnaires are administered at the household by trained
56
57 field team staff at each serosurvey visit. Study nurses complete the questionnaire after a brief
58
59

physical and medical examination. At the follow-up visit(s) in about 6 months, the same staff make the household visits to complete the follow-up questionnaire. Enrolment log is maintained by the study coordinator on site.

Variables of the surveillance questionnaires

The variables collected are listed in table 1.

Table 1. List of variables collected in the passive fever surveillance data collection form

Topic	Description	Items
Basic information	Demographic and basic information about the patient and the treatment received	Type of treatment where patient is enrolled (IPD vs. OPD) Date of fever onset, duration of fever Current temperature Tourniquet test results Patient's address (district and village-level) Date of visit, date of birth, age, and sex Weight and height
General health condition	Current condition of the patient (self-report) and underlying diseases of the patient	How well the patient could handle daily activities Pre-existing conditions
Signs and symptoms during this illness	A set of sign and symptoms that may be related to fever and dengue (DF and DHF)	Rash, fatigue, headache, retro-orbital pain, neck/ear pain, sore throat, breathing difficulty, cough, expectoration, gastrointestinal signs (Nausea/vomiting, diarrhea, abdominal pain, etc.), hemorrhagic signs (nose/gum bleeding, ecchymosis, petechiae, etc.), signs of shock (cyanosis, capillary refill), arthralgia, myalgia, loss of appetite, jaundice, etc.
Medical History:	Previous dengue-related or other flavivirus infection as well as vaccination history (self-report)	Previous dengue infection and related hospitalization Previous infection to other commonly circulating arboviral infection in the area Yellow fever vaccination history
Laboratory findings	Records from the routine laboratory tests widely used in	Platelet count, hematocrit, haemoglobin, leukocytes, neutrophils,

	clinical fever/dengue patient management, as part of the hospital care procedure	protein level, AST, ALT, urine test results, etc.
Clinical Diagnosis	Clinician's diagnosis with or without referring to the RDT	Diagnosis given by the physician based on clinical presentation after physical examination of the patient.
Dengue testing results	Results from the dengue tests, mainly RDTs for dengue as well as other commonly circulating arbovirus in the area	Dates of blood draw Test results of the RDT IgM/IgG capture ELISA results PCR results (if available)
Treatment	Medicine(s) prescribed and the starting and end dates	Antibiotics, paracetamol, ibuprofen, aspirin, and others that may be site-specifically prescribed
Outcome	Outcome of this particular visit	Hospitalized, returned home, or referral
Hospitalization	Information collected only among hospitalized patients in the surveillance to record other severe signs and progression of illness	Admission and discharge diagnoses Presence of haemorrhagic signs or shock syndrome
Hospital Charges	Expenses and hospital charges incurred by patient on the visit 1	Amount of the out of pocket payment by the patient or the family/or guardian Breakdown of the hospital charges (laboratory, medication, admission-related charges)
Final outcome	Outcome of the patient's illness at the 2 nd visit	Final diagnosis given for the patient outcome of illness Completion of study participation (early termination and the reason, etc.)

Planned statistical analysis

From the fever surveillance data, incidence of symptomatic dengue among patients that seek health care at the study facilities will be calculated. Age-specific incidence rates in all the children and adults will be determined by referring to the size and distribution of the general population of the study area at the time of surveillance as the denominator in calculation of the incidence of symptomatic dengue cases. Each person residing in the study area is assumed to contribute 12 months of person time to the denominator. Although the

1
2
3
4 study areas all report a low migration rate, the in-migration is assumed to balance the out-
5
6 migration of the population during the study period. Age-specific incidence of symptomatic
7
8 dengue will be calculated by using age-specific denominators and the number of symptomatic
9
10 dengue cases in eligible individuals as the numerator.
11

12
13 Using the data collected in the Healthcare Utilization Survey, the proportion of
14
15 febrile cases missed by the passive surveillance system will be determined. Then using the
16
17 proportion, the numerator will be further adjusted in recognition of those missed fever cases
18
19 from the study area, which could have been dengue. Also, comparison will be made between
20
21 those that agreed to participate and those that declined participation among the eligible
22
23 potential enrollees. The enrollment log, which records basic information obtained during the
24
25 screening process of potential enrollees, will be reviewed. In addition to checking that our
26
27 sample of febrile cases is representative of febrile patients of the general population in the
28
29 catchment area, refusal rates will be determined based on information in the log. Then, the
30
31 refusal rates will be used to adjust the numerator.
32
33

34
35 SPSS software will be used for analysis of the fever surveillance data. Multivariable
36
37 logistic regression will be used to compare confirmed dengue patients versus non-dengue
38
39 febrile patients in terms of symptomatic presentation, based on signs and symptoms collected
40
41 from all patients with laboratory-confirmed dengue by serology and RT-PCR, adjusting for
42
43 possible confounders, such as age, days since onset of fever, primary vs. secondary infection,
44
45 inpatient vs. outpatient, etc. Differences in symptomatic complex of DF (and DHF, if data
46
47 allows) by age and serotype will be also determined using multivariable logistic regression.
48
49

50
51 As outpatient disease accounts for the greater part of dengue disease burden, clinical
52
53 profile of individuals with DENV infection will be characterized by the type of treatment
54
55 (hospitalized and outpatients), as well as by severity of the disease (severe vs. non-severe by
56
57 the 2009 WHO criteria)⁴⁶. Classification is determined after the course of illness is
58
59

22

1
2
3
4 completed (typically during the convalescent visit). Symptomatic dengue is classified as
5
6 outpatient or hospitalized. Progression of dengue is recorded as DF, DHF I, DHF II, DHF III
7
8 or DHF IV, and clinical patterns will be compared by the severity grade^{46 47}. These will be
9
10 compared to results obtained from other DVI studies in Latin America (Colombia) and Asia
11
12 (Thailand, Vietnam, and Cambodia). Overall, comparisons will be made across Burkina Faso,
13
14 Gabon, and Kenya.

15
16
17 With the age-stratified sera that reflect the age distribution of the general population
18
19 of the country, the serological survey sampling strategy ensures sufficient subjects to obtain
20
21 precise age-specific estimates of sero-positivity and sero-conversion of the catchment area
22
23 population. The sero-conversion rate and change in the immune status will be determined by
24
25 age group during the study period. The age-stratified serosurvey data will also allow
26
27 calculation of the force of infection of dengue in the study population. After enrolment, there
28
29 are subjects who drop out in the follow-up bleeds about 6 months later. Basic demographic
30
31 information will be compared between those that completed participation and those with
32
33 incomplete participation to check whether study subjects represent the catchment area
34
35 population. Comparisons will be made among Burkina Faso, Gabon and Kenya.
36
37
38
39
40
41
42

43 *Ethical considerations*

44
45 To minimize inconvenience of the study to patients, clinicians and nurses were
46
47 sensitized and trained regarding the study requirements and procedures in order for data
48
49 collection to be integrated into routine patient care. The clinicians and nurses selected for the
50
51 study receive coordinated support from study field staff throughout the study process. Written
52
53 informed consent, and assent for participants 7 (13 for Kenya) -17 years of age, were
54
55 obtained from patients by study staff. Study staff go through consent and assent documents
56
57
58
59
60

1
2
3
4 for short summary of the disease, detailed description of study procedures, and information
5
6 on reimbursement. Patient data are documented in the study designated office; only the study
7
8 staff have access to the data that are de-identified. Data are exclusively handled in the study
9
10 office and stored safely in a protected database in the study office as well as on the DVI main
11
12 server.
13

14
15 The protocol for each study obtained ethical approvals from the Institutional Review
16
17 Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and
18
19 Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI
20
21 Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and
22
23 Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB
24
25 of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and
26
27 the National Health Ethical Committee of Burkina Faso.
28
29
30
31

32 Discussion

33
34
35 Dengue cases have been detected since the 1960's in Africa, and there has been
36
37 continued presence of *Aedes* vectors in the continent^{5,7}. However, very few dengue studies
38
39 have been conducted in Africa, and little evidence is based on population-based studies⁶.
40
41 Compared to the volume of evidence from SE Asia and the Americas, there is critical data
42
43 scarcity on dengue in Africa. Suspicion of substantial dengue burden in Africa is based on
44
45 limited reports of outbreaks and a handful of sero-prevalence studies testing different viruses
46
47 among samples that likely do not represent the general population. In the three countries
48
49 selected for our field studies, somewhat more data are available, but are still very limited. In
50
51 Burkina Faso, a recent observational study conducted in 2013 reported that 8.7% of the
52
53 febrile patients showed positive results on dengue RDT¹⁶. In Gabon, one study suggested
54
55 minimal DENV circulation in rural areas²¹, while another study reported 12.3%
56
57
58
59
60

1
2
3
4 seroprevalence, by IgG antibodies against dengue, among toddlers 30 months of age in semi-
5 rural parts of Lambaréné²⁰. In Kenya, about 13% of the individuals in Mombasa have been
6 reported to have evidence of past or current DENV infection by RT-PCR and IgM anti-
7 dengue ELISA after the 2013 outbreak²⁶. Despite the limited scope and generalizability of
8 these studies, they suggest that there may be more dengue than previously appreciated due to
9 underestimation and misdiagnosis^{25,26}.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

These studies suggest the presence of dengue and some level of underlying sero-
prevalence in the countries of our field studies. However, often these studies are limited by
their retrospective design or sample collection (blood donors or sample collected from
surveys of other diseases) to demonstrate the true, population-based, burden of dengue. We
proposed to address this gap by population-based dengue surveillance and sero-prevalence
studies in West, (West-) Central, and East Africa.

The present studies at three sites in Africa will provide important information on
undocumented DENV circulation in Africa. Such data will help to strengthen the evidence
base for dengue burden in Africa. Better defined disease burden data based on our studies
could be used to assess the relative need for dengue prevention and control measures, such as
whether a dengue vaccine would be a cost-effective public health intervention for countries in
Africa. Clinical findings from our studies could also be used as a guide for dengue case
detection and case management.

The studies have some important limitations. We recognize variability of dengue
epidemiology over time and by region. Due to resource constraints, our studies are limited in
terms of time frames and geographical extent. These constraints may limit the generalizability
of our studies.

One potential source of bias in estimating the incidence of symptomatic dengue is
under-ascertainment due to the community residents with relevant symptoms seeking care

1
2
3
4 from other healthcare providers and facilities than the study facilities. As the study design
5 remains passive surveillance, cases are ascertained only at our study facilities. By estimating
6 the proportion of febrile patients seeking care elsewhere, as well as refusal rates among the
7 potential enrollees that were screened for eligibility criteria, the degree of febrile patients
8 missed by the study can be determined. Inverse probability weighting will be used to account
9 for these potential subjects missed by the surveillance as adjustments in incidence calculation.
10 Also, depending on the transmission volume of dengue or other co-circulating diseases with
11 onset of fever, there may be patients that are diagnosed with other diseases and ruled out for
12 dengue. Furthermore, with respect to dengue diagnostics for our serological surveys, there are
13 other circulating flaviviruses in Africa leading to challenges in identifying antibodies to past
14 dengue infections. While our testing plan assesses for some flaviviruses, others known to
15 circulate in Africa, such as Banzi and Usutu viruses, are not part of the testing plan⁴⁸⁻⁵⁰. Due
16 to resource limitations, serological testing will be limited to yellow fever virus, West Nile
17 virus, Zika virus, and Japanese Encephalitis virus as well as DENV 1-4. Therefore, in some
18 cases, it may be difficult to determine prior exposure to DENV versus other flaviviruses
19 based on serological data. This cross-reactivity may lead to over-estimation of dengue force
20 of infection
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 In addition, the sero-survey and healthcare utilization survey are conducted on a
43 randomized sub-sample of the catchment area population and there may be limited
44 generalizability of the data collected from these surveys. With unknown differences among
45 those that agree to participate and those that do not agree, the data may not be representative
46 of the general population of the study countries.
47
48
49
50
51

52
53
54
55 Conclusions
56
57
58
59
60

1
2
3
4 The data collected from our studies will contribute to the assessment of the unknown
5 dengue disease burden in Burkina Faso, Gabon, and Kenya. These data can fill a gap in
6 undocumented burden of dengue in the region and, collectively, may be used to infer dengue
7 burden in other areas of Western, Central, and Eastern Africa. Countries in Africa may not
8 consider introduction of a dengue vaccine as a priority in the near future due to many other
9 competing public health problems and limited resources. For cost-effective implementation
10 of public health interventions, accurate data on dengue burden from epidemiological studies
11 would be needed for policy makers to make evidence-based decisions on control and
12 prevention of dengue. Our studies will provide some much needed information based on
13 population-based research to assess dengue burden in Africa.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

List of abbreviations

GDAC - Global Dengue and *Aedes*-transmitted Diseases Consortium

IVI - International Vaccine Institute

DENV- dengue viruses

DVI - Dengue Vaccine Initiative

Ouaga-HDSS - health and demographic surveillance system

DHF - dengue hemorrhagic fever

CERMEL - Centre de Recherches Médicales de Lambaréné

ASH – Albert Schweitzer Hospital

CSPS - Centre de Santé et de Promotion Sociale

KEMRI - Kenya Medical Research Institute

SD – Standard Diagnostics

GIS = geographic information system

MFI - median fluorescence intensity

CRCHUM - Centre Hospitalier de l'Université de Montréal

Declarations

- Ethics approval and consent to participate

The protocol for each study obtained ethical approvals from the Institutional Review Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and Tropical Medicine, and the Ethics Committee of host country institutions, including KEMRI Scientific and Ethical Review Unit in Kenya, Gabon National Ethics Committee and Institutional Ethics Committee, Scientific Review Board of CERMEL in Gabon, and the IRB of Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal, and the National Health Ethical Committee of Burkina Faso.

- Consent for publication

Not applicable

- Availability of data and material

Data sharing is not applicable to this article as no datasets were analyzed during the current study.

This manuscript does not include data from the studies described here in. This is a protocol paper. The datasets that are being generated for analysis as described in the current study are not yet publicly available as the studies are currently ongoing at the time of submission. They will be available from the corresponding author on reasonable request.

- Competing interests

The authors declare that they have no competing interests.

- Funding

The current study was supported by funds from the Bill and Melinda Gates Foundation (OPP 1053432). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

NA receives support from the United Kingdom Medical Research Council (MRC) and Department for International Development (DFID) (MR/K012126/1). VR holds a CIHR-funded Research Chair in Applied Public Health (CPP-137901).

1
2
3
4 • Authors' contributions

5
6 JKL designed the study, is overseeing data collection, and was a major contributor in writing
7 the manuscript. MC co-designed the study, oversaw some parts of data collection, and
8 supported in writing of the manuscript. JSL was a contributor in designing of the study and
9 oversight of parts of data collection. KSL was a contributor in oversight of data collection.
10 SN supported in data collection. SKL supported in data collection. VR supported in designing
11 of the study and was a major contributor in finalization of the manuscript. JF was a
12 contributor in data collection. BL was a contributor in designing of the study and data
13 collection. SHM was a contributor in designing of the study and site establishment. ME was a
14 contributor in designing of the study. EA supported in data collection. NO supported in data
15 collection. AB supported in data collection. EB supported in data generation. SMN was a
16 contributor in designing of the study and site establishment. STA was a contributor in
17 designing of the study and site establishment. SY was a contributor in designing of the study
18 and site establishment. NA was a major contributor in providing oversight of the data
19 collection and finalization of the manuscript. IKY was a major contributor in designing of the
20 study and finalization of the manuscript.
21 All authors read and approved the final manuscript.
22
23
24

25
26
27 • Acknowledgements

28
29 We thank the doctors and laboratory staff of CSPS of Ouagadougou, ASH, Ganjoni
30 dispensary, Tudor sub-county Hospital, and Coast Provincial General Hospital, as well as at
31 Centre Muraz, CERMEL, and KEMRI. We thank collaborators at AGIR, IRD France, and
32 University of Montreal, and University of Tubingen. Lastly, we would like to thank the DVI
33 team and statisticians and administrative staff at the International Vaccine Institute for their
34 helpful comments during the preparation of this manuscript and support during the studies.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013;**496**(7446):504-7.
2. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. *Clin Epidemiol* 2013;**5**:299-309.
3. Chang M, Christophel E, Gopinath D, et al. Challenges and future perspective for dengue vector control in the Western Pacific Region, Regional Analysis. *Western Pacific Surveillance and Response Journal* 2011;**2**(2):9-16.
4. Eisen L, Beaty B, Morrison A, et al. Proactive Vector control strategies and improved monitoring and evaluation practices for dengue prevention. *J Med Entomol* 2009;**46**(6):1245-55.
5. Gubler D, Clark G. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* 1995;**1**(2):55-57. .
6. Amarasinghe A, Kuritsky J, Letson G, et al. Dengue virus infection in Africa. *Emerg Infect Dis* 2011;**17**(8):1349-54. .
7. Messina J, Brady O, Scott T, et al. Global spread of dengue virus types: mapping the 70 year history. *Trends Microbiol* 2014;**22**(3):138-46.
8. Fagbami A, Monath T, Fabiyi A. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. *Trans R Soc Trop Med Hyg* 1977;**71**(1):60-5.
9. Carey D, Causey O, Reddy S, et al. Dengue viruses from febrile patients in Nigeria, 1964-68. *Lancet* 1971;**1**(7690):105-6.
10. Beatty M, Stone A, Fitzsimons D, et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. *PLoS Negl Trop Dis* 2010;**4**(11):e890.
11. Were F. The dengue situation in Africa. *Paediatrics and Internatinoal Child Health* 2012;**32**(S1):18-21.
12. Sierra B, Triska P, Soares P, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. *PLoS Pathog* 2017;**13**(2):e1006220. .
13. Chacón-Duque J, Adhikari K, Avendaño E, et al. African genetic ancestry is associated with a protective effect on Dengue severity in colombian populations. *Infect Genet Evol* 2014;**27**:89-95. .
14. Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. *PLoS neglected tropical diseases* 2012;**6**(8):e1760.
15. Collenberg E, Ouedraogo T, Ganame J, et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. *J Med Virol* 2006;**78**(5):683-92.
16. Ridde V, Agier I, Bonnet E, et al. Presence of three dengue serotypes in Ouagadougou (Burkina Faso): research and public health implications. *Infect Dis Poverty* 2016;**5**(23).
17. Caron M, Grard G, Paupy C, et al. First evidence of simultaneous circulation of three different dengue virus serotypes in Africa. *PloS one* 2013;**8**(10):e78030.
18. Leroy EM, Nkoghe D, Ollomo B, et al. Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007. *Emerging infectious diseases* 2009;**15**(4):591-3.
19. Caron M, Paupy C, Grard G, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito

- coinfections in Gabon, central Africa. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012;**55**(6):e45-53.
20. Gabor J, Schwarz N, Esen M, et al. Dengue and chikungunya seroprevalence in Gabonese infants prior to major outbreaks in 2007 and 2010: A sero-epidemiological study. *Travel Med Infect Dis* 2016.
21. Pourrut X, Nkoghe D, Gonzalez JP, et al. No evidence of dengue virus circulation in rural Gabon. *Emerging infectious diseases* 2011;**17**(8):1568-9.
22. Andries A, Duong V, Ngan C, et al. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. *PLoS Negl Trop Dis* 2012;**6**(12):e1993.
23. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. *PLoS One* 2009;**4**(10):e7611. .
24. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med* 2011;**365**(20):1863-75. .
25. Ochieng C AP, Vittor AY, Nyoka R, Gikunju S, Wachira C, Waiboci L, Umuro M, Kim AA, Nderitu L, Juma B, Montgomery JM, Breiman RF, Fields B. Seroprevalence of Infections with Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya, 2007. *PLoS One* 2015;**10**(7).
26. Ellis EM, Neatherlin JC, Delorey M, et al. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya, 2013. *PLoS Negl Trop Dis* 2015;**9**(4):e0003733.
27. United Nations Development Programme. Population, urban (% of population). In: Reports HD, ed.: UNDP, 2013.
28. United Nations. World Urbanization Prospects: The 2014 Revision, Highlights. In: Department of Economic and Social Affairs PD, ed. United Nations: United Nations, 2014.
29. Central Intelligence Agency. Age structure. The world factbook Central Intelligence Agency.
30. Ramharther M, Adegnika AA, Agnandji ST, et al. History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. *The Middle European Journal of Medicine, WIENER KLINISCHE WOCHENSCHRIFT* 2007;**119**(Suppl 3):8-12.
31. Schwarz NG, Gysels M, Pell C, et al. Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon. *Vaccine* 2009;**27**(2009):5371-75.
32. Kenya. Secondary Kenya. <https://en.wikipedia.org/w/index.php?title=Kenya&oldid=737329303>
33. Wichmann O, Yoon I, Vong S, et al. Dengue in Thailand and Cambodia: An assessment of the degree of underestimated disease burden based on reported cases. . *PLoS NTD* 2010.
34. Gibbons C, Mangen M, Plass D, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC public health* 2014;**14**(147).
35. European Centre for Disease Prevention and Control (ECDC). Data quality monitoring and surveillance system evaluation - A handbook of methods and applications. Stockholm: European Centre for Disease Prevention and Control (ECDC), 2014.
36. Mease L, Coldren R, Musila L, et al. Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study. *Virol J* 2011;**8**(371).

37. World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Geneva: World Health Organization, 2008.
38. Alm E, Lindegren G, Falk K, et al. One-step real-time RT-PCR assays for serotyping dengue virus in clinical samples. *BMC Infect Dis* 2015;**15**(493).
39. Peeling R, Artsob H, Pelegrino J, et al. Evaluation of diagnostic tests: dengue. *Nature Reviews Microbiology* 2010:S30-S37
40. Kraus A, Messer W, Haymore L, et al. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. *J Clin Microbiol* 2007;**45**(11):3777-80.
41. de Alwis R, de Silva A. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. *Methods Mol Biol* 2014;**1138**:27-39.
42. Lambeth C, White L, Johnston R, et al. Flow cytometry-based assay for titrating dengue virus. *J Clin Microbiol* 2005;**43**(7):3267-72.
43. Cabral-Castro M, Saramago Peralta R, Cavalcanti M, et al. A Luminex-based single DNA fragment amplification assay as a practical tool for detecting and serotyping dengue virus. *Journal of virological methods* 2016;**236**:18-24.
44. Balasuriya U, Shi P, Wong S, et al. Detection of antibodies to West Nile virus in equine sera using microsphere immunoassay. *J Vet Diagn Invest* 2006;**18**(4):392-5.
45. Beck C, Desprès P, Paulous S, et al. A High-Performance Multiplex Immunoassay for Serodiagnosis of Flavivirus-Associated Neurological Diseases in Horses. *Biomed Res Int* 2015;**2015**(678084).
46. Hadinegoro SRS. The revised WHO dengue case classification: does the system need to be modified? *Paediatr Int Child Health* 2012;**32**(S1):33-38.
47. Guilarde AO, Turchi MD, Siqueira Jr JB, et al. Dengue and Dengue Hemorrhagic Fever among Adults: Clinical Outcomes Related to Viremia, Serotypes, and Antibody Response. *The Journal of Infectious Diseases*; **197**(6): 817-24. .
48. Mossel E, Crabtree M, Mutebi J, et al. Arboviruses Isolated From Mosquitoes Collected in Uganda, 2008-2012. *J Med Entomol* 2017;**54**(5):1403-09. .
49. Shope R, al. e. *The Flaviviruses: Detection, Diagnosis and Vaccine Development*: Academic Press, 2003.
50. Nikolay B, Diallo M, Boye C, et al. Usutu virus in Africa. *Vector Borne Zoonotic Dis* 2011;**11**(11):1417-23.

1
2
3
4 Fig. 1 Description of the study components, including passive facility-based fever
5 surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys
6
7
8

9
10
11 There are two arms in the study package, composed of four parts. In the health facility-based
12 arm of the study package, there are the passive facility-based fever surveillance and cost-of-
13 illness survey embedded within the surveillance. In the community arm of the study, there are
14 serological survey and healthcare utilization survey.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Fig. 2 Map of the study area in Ouagadougou, Burkina Faso

5
6 Fig. 3 Map of the study area in Lambaréné, Gabon

7
8
9 Fig. 4 Map of the study area in Mombasa, Kenya

10
11
12
13 Figures 2 – 4 show the map of the study area at each site in Burkina Faso, Gabon, and Kenya.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 5 Patient flow in the fever surveillance
5
6
7

8 Eligible febrile patients identified and enrolled as study subjects will follow these steps to
9
10 complete participation in the passive fever surveillance.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Fig. 6 Laboratory testing algorithm for dengue
5
6
7

8
9 Samples from subjects of the passive fever surveillance would follow these steps of the
10
11 testing algorithm for confirmation of dengue.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Fig. 1 Description of study components, including passive facility-based fever surveillance, healthcare utilization surveys, cost-of-illness surveys, and serological surveys

210x297mm (300 x 300 DPI)




A map of the study area in Ouagadougou, Burkina Faso

165x145mm (300 x 300 DPI)

only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



A map of the study area in Lambarene, Gabon

151x145mm (300 x 300 DPI)

only




A map of the study area in Mombasa, Kenya

166x147mm (300 x 300 DPI)

only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



* A small number of those samples that are negative on ELISA or NS1 are tested with PCR to exclude false negative results of the ELISA.

Patient flow in the fever surveillance - Eligible febrile patients identified and enrolled as study subjects will follow these steps to complete participation in the passive fever surveillance.

140x198mm (300 x 300 DPI)




Fig. 6 Laboratory testing algorithm for dengue

* Dengue Duo® test is performed on enrolled febrile patients to identify dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey.

**Selected samples, including those that were found positive by IgM and NS1 on Dengue Duo® as well as those positive by IgM and IgG capture ELISA, will be tested with RT-PCR.

Laboratory testing algorithm for dengue: Samples from subjects of the passive fever surveillance would follow these steps of the testing algorithm for confirmation of dengue.

140x198mm (300 x 300 DPI)